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Implementation of evidence-based medicine is often suboptimal. The objectives of this thesis 
are to explore the delivery of evidence-based medicine and outcomes in patients with ischaemic 
heart disease (IHD) and atrial fibrillation (AF). 
METHODS 
Retrospective observational cohort studies were conducted using linked anonymised data from 
the secure anonymised information linkage (SAIL) databank. Patients included (i) those 
undergoing percutaneous coronary intervention, (ii) patients prescribed vitamin K antagonist 
(VKA) for AF, and (iii) patients with AF who had undergone successful PCI. 
RESULTS 
Amongst patients directed to take clopidogrel for one-year post-PCI, discontinuation was far 
lower (~6%) than in previous studies where the treatment duration was not known. Despite 
this, early discontinuation and/or bleeding was associated with an increased risk of adverse 
events.  
In a national cohort of PCI patients, we observed a low rate of achievement of 
international guideline target lipid levels (<25%) and low prescribing of intensive lipid 
lowering therapy amongst those not at target. Females and patients who had undergone elective 
PCI were least likely to have their lipid levels documented and be at target. 
In patients prescribed VKA for AF guideline defined poor anticoagulation control was 
common and associated with significantly higher bleeding event rates, independent of common 
comorbidities that are recognised as risk factors for stroke and bleeding. 
In patients with AF who had undergone PCI outcomes were poor: approximately 1 in 
5 had either a stroke, acute coronary syndrome (ACS) or died in the year follow-up. Bleeding 
events were also common and associated with a five, three and four-fold increased risk of 
stroke, ACS, and death. 
CONCLUSION 
This thesis has characterised the nature of multiple therapeutic gaps and associated adverse 
outcomes with common clinical conditions. Thus, identifying opportunities to improve 




I declare that the work presented in this thesis has not previously been accepted in substance 
for any degree and is not being concurrently submitted in candidature for any other degree. 
Daniel Harris 5th August 2021 
This thesis is the result of my own investigations, except where otherwise stated and that other 
sources are acknowledged by footnotes giving explicit references and that a bibliography is 
appended. 
Daniel Harris 5th August 2021 
I give consent for this thesis, if accepted to be made available online in the University’s Open 
Access Repository and for inter-library loan, and for the title and summary to be made available 
to outside organisations. 
Daniel Harris 5th August 2021 
I declare that that the University’s ethical procedures have been followed and, where 
appropriate, that ethical approval has been granted. 





Over the past five years there are many colleagues, friends and family that have provided 
support, guidance, inspiration and much more. I am deeply indebted.  
 
My deepest gratitude to my supervisors, and friends - Professor Julian Halcox and Professor 
Mike Gravenor. I couldn’t have had better! You’ve made these tough years fun. 
 
A special thanks to Dr Arron Lacey, who very patiently taught me how to code, provided vital 
contributions to the manuscripts, support and enthusiasm over these years, and for answering 
every late-night request for help! Many thanks to Ashley Akbari and Fatemeh Torabi for all 
the excellent advice, trouble shooting, contributions and friendship.  
 
Thank you to Dr James Barry for igniting this Ph.D. and to Professor Dave Smith, Dr Geraint 
Jenkins, Dr Daniel O’Baid and Professor Alex Chase for the many hours of questioning you’ve 
put up with, contributions to the manuscripts and the knowledge you’ve given freely. 
 
I am most grateful to Professor Steve Bain, Mark Simpson and Gemma Hughes for agreeing 
to fund and support this research programme, and the extended research team including Anne-
Clare Owen and Tina Morgan. Without your support this wouldn’t have happened.  
 
 iv 
The SAIL team including Daniel Mallory, Daniel Thayer, Dr Ting Wang, Caroline Brooks and 
Geoff Murley for the support and contributions to the SWORDS and SABRE studies. 
 
Thanks to John Fitzgerald for his IT expertise and support with the discharge prescribing data 
and Douglas Neil for expertise with graphics. 
 
Thanks to Prof Lyons and his team who welcomed me to the Data science Building. 
 
A special thanks to my oldest friend Mr Kevin Williams whose coaching, guidance and 
friendship continued past the squash court! 
 
Finally, my sincere gratitude to my family who have sacrificed so much. My wife Sarah, who 
has allowed me to pursue this ambition; escape the chores, often just escape, who has kept me 
going throughout this Ph.D. and so much more. To my children Isabelle and Emily, I’m sorry 
that this has taken so much time. And to my parents, I am forever grateful for their sacrifices, 








PUBLICATIONS AND ABSTRACTS PRESENTED DURING THE PERIOD OF THIS PH.D. 
At the time of submission of this thesis, papers from chapters 2,3 & 4 were published, chapter 
5 was in review and chapter 6 was in the process of submission. The references to the published 
manuscripts are as follows: 
 
1. Harris DE, Lacey A, Akbari A, et al. Early Discontinuation of P2Y12 antagonists  and 
Adverse Clinical Events Post–Percutaneous Coronary Intervention: A Hospital and Primary 
Care Linked Cohort. J Am Heart Assoc 2019; 8: e012812. 2019/10/29. DOI: 
10.1161/JAHA.119.012812. 
 
2. Harris DE, Thayer D, Wang T, et al. An observational study of INR control according 
to NICE criteria in patients with non-valvular atrial fibrillation-The SAIL Warfarin Out of 
Range Descriptors Study (SWORDS). Eur Heart J Cardiovasc Pharmacother 2019 
2019/11/27. DOI: 10.1093/ehjcvp/pvz071. 
 
3. Harris DE, Lacey A, Akbari A, et al. Achievement of European guideline-
recommended lipid levels post-percutaneous coronary intervention: A population-level 




 The following abstracts have also been presented at international conferences: 
• Early discontinuation of P2Y12 antagonists and adverse outcomes post percutaneous 
coronary intervention. Presented at American College of Cardiology Conference 2018, 
Orlando. JAAC (March 2018); 71, 11 
• Early discontinuation of P2Y12 antagonists and adverse outcomes post percutaneous 
coronary intervention. Presented at Europrevent 2018, Ljubljana. European Journal of 
Preventive Cardiology (May 2018); 25, suppl_1  
• Discontinuation of statins and adverse clinical outcomes post percutaneous coronary 
intervention. Presented at American Heart association conference 2018, Chicago. 
Circulation. 2018; 138, suppl_1:14994 
• Evaluation of the Effectiveness of Warfarin Anticoagulation in Welsh Patients with 
Non-Valvular Atrial Fibrillation: The Sail Warfarin Out of Range Descriptors Study 
(SWORDS). Presented at American Heart association conference 2018, Chicago. 
Circulation. 2018; 138, suppl_1:14903 
• Bleeding events associated with NICE defined poor INR control. An observational 
study of patients prescribed warfarin for non-valvular atrial fibrillation in the Welsh 
population. Presented at European Heart & Stroke Conference 2020, Barcelona. 
• An observational Study of INR Control and Bleeding Events, According to European 
Society of cardiology (ESC) Guidelines, in Non-Valvular Atrial Fibrillation (NVAF) 
patients stratified by Male and Female Sex. Presented at the International Society on 
Thrombosis and Haemostasis Congress 2020 Milan. Res Pract Thromb Haemost. 




In addition the following publication and abstracts has arisen from this Ph.D: 
• Thayer D, Rees A, Kennedy J, et al. Measuring follow-up time in routinely-collected 
health datasets: Challenges and solutions. PLoS One 2020; 15: e0228545. 2020/02/11. 
DOI: 10.1371/journal.pone.0228545 
• Machine learning approaches for prediction of 1-year risk of major bleeding events in 
anticoagulated atrial fibrillation patients in Wales. Presented at European Heart & 
Stroke Conference 2020, Barcelona. 
• A longitudinal study of anticoagulant prescribing in patients with Atrial Fibrillation in 




Glossary ................................................................................................................................................ xx 
Chapter 1. ................................................................................................................................. 1 
Thesis introduction .................................................................................................................................. 1 
Cardiovascular disease ............................................................................................................................ 1 
Ischaemic heart disease ........................................................................................................................... 1 
Mechanisms of platelet activation and sites of action for antiplatelet therapy ........................................................ 4 
Coronary angiography ............................................................................................................................................. 7 
Revascularisation by percutaneous coronary intervention and antiplatelet therapy ................................................ 8 
Revascularisation with coronary artery bypass grafts ........................................................................................... 14 
Conservative medical management ....................................................................................................................... 14 
Management of dyslipidaemia in the secondary prevention of coronary heart disease ........................................ 15 
Atrial fibrillation ................................................................................................................................... 19 
Management strategy for Atrial fibrillation ........................................................................................................... 21 
Mechanism of thrombosis in atrial fibrillation ...................................................................................................... 21 
Antithrombotic therapy for the prevention of stroke and systemic embolism in atrial fibrillation ....................... 23 
Clinical risk scores for stroke and bleeding risk in patients with Atrial fibrillation .............................................. 26 
Atrial fibrillation in patients undergoing percutaneous coronary intervention ..................................... 29 
Using real-world data to identify and describe gaps in the delivery of the evidenced based medicine 33 
Objectives of Chapter 2 ......................................................................................................................................... 33 
Objectives of Chapter 3 ......................................................................................................................................... 33 
Objectives of Chapter 4 ......................................................................................................................................... 34 
Objectives of Chapter 5 ......................................................................................................................................... 34 
Objectives of Chapter 6 ......................................................................................................................................... 35 
Objectives of Chapter 7 ......................................................................................................................................... 35 
Methods ................................................................................................................................................. 36 
Secure Anonymised Information Linkage databank ............................................................................................. 36 
Governance, ethics and approvals ......................................................................................................................... 37 
Processing of data within this thesis ...................................................................................................................... 37 
 x 
Coronary intervention dataset ................................................................................................................................ 38 
Discharge prescribing data .................................................................................................................................... 38 
Anonymisation of person data ............................................................................................................................... 39 
Processing discharge prescribing dataset within SAIL ......................................................................................... 40 
Patient Episode database for Wales and hospital coding standards ...................................................................... 43 
Classification of Interventions and Procedures ..................................................................................................... 46 
Creating hospital datasets ...................................................................................................................................... 46 
Welsh Longitudinal General Practice dataset ........................................................................................................ 48 
Patient outcomes, co-morbidities and prescriptions .............................................................................................. 49 
Internal validation .................................................................................................................................................. 50 
Contributions ......................................................................................................................................... 53 
References ............................................................................................................................................. 54 
Chapter 2. ............................................................................................................................... 68 
Early discontinuation of P2Y12 antagonists and adverse clinical events post 
percutaneous coronary intervention – a hospital & primary care linked cohort ............ 68 
Abstract ................................................................................................................................................. 69 
Background ........................................................................................................................................... 70 
Methods ................................................................................................................................................. 71 
Datasets and linkage .............................................................................................................................................. 71 
Index event data ..................................................................................................................................................... 72 
P2Y12 antagonist prescribing and discontinuation ................................................................................................. 73 
Statistical Analyses ................................................................................................................................................ 73 
Results  .................................................................................................................................................. 75 
Study Population .................................................................................................................................................... 75 
Clopidogrel discontinuation ................................................................................................................................... 77 
Death and major Cardiovascular events ................................................................................................................ 79 
Discussion ............................................................................................................................................. 83 
Strengths and limitations of this study ................................................................................................................... 86 
 xi 
Conclusion ............................................................................................................................................ 88 
References ............................................................................................................................................. 89 
Supplementary material ........................................................................................................................ 92 
Major bleeding events ............................................................................................................................................ 92 
Primary end point codes ........................................................................................................................................ 93 
Individual outcomes of MI, ischemic stroke, coronary revascularization and death ............................................ 96 
Chapter 3 ................................................................................................................................ 99 
Achievement of European guideline-recommended lipid levels post-percutaneous 
coronary intervention: a population-level observational study ......................................... 99 
Abstract ............................................................................................................................................... 100 
Background ......................................................................................................................................... 101 
Methods ............................................................................................................................................... 102 
Lipid levels and prescriptions for lipid modifying therapy ................................................................................. 103 
Statistical analysis ................................................................................................................................................ 104 
Results 106 
LDL- C levels ...................................................................................................................................................... 108 
Non-HDL-C levels ............................................................................................................................................... 111 
TG Levels ............................................................................................................................................................ 111 
Discussion ........................................................................................................................................... 113 
Strengths and limitations ..................................................................................................................................... 116 
Conclusion .......................................................................................................................................... 118 
References ........................................................................................................................................... 119 
Supplementary material ...................................................................................................................... 123 
Chapter 4. ............................................................................................................................. 129 
An observational study of INR control according to NICE criteria in patients with non-
valvular atrial fibrillation. The SAIL Warfarin Out of Range Descriptors Study 
(SWORDS) ............................................................................................................................ 129 
 xii 
Abstract ............................................................................................................................................... 130 
Background ......................................................................................................................................... 131 
Method 133 
Study design and data sources ............................................................................................................................. 133 
Medical history, demographic information and prescriptions ............................................................................. 134 
Calculation of individual Time in Therapeutic Range (TTR) and identification of low and high INRs ............. 134 
Statistical methods ............................................................................................................................................... 135 
Missing data ......................................................................................................................................................... 136 
Results 137 
Multivariable modelling ...................................................................................................................................... 140 
Discussion ........................................................................................................................................... 145 
Strengths and limitations of this study ................................................................................................................. 148 
Conclusion .......................................................................................................................................... 150 
References ........................................................................................................................................... 151 
Supplementary material ...................................................................................................................... 155 
Chapter 5 .............................................................................................................................. 160 
Bleeding events associated with poor INR control in a national cohort prescribed 
warfarin for non-valvular atrial fibrillation. The SAIL AF bleeding Risk Evaluation 
(SABRE) study ..................................................................................................................... 160 
Abstract ............................................................................................................................................... 161 
Introduction ......................................................................................................................................... 162 
Methods ............................................................................................................................................... 163 
Cohort selection ................................................................................................................................................... 163 
Temporal calculation of INR control ................................................................................................................... 164 
Bleeding events .................................................................................................................................................... 165 
Medical history, demographic information, and prescriptions ............................................................................ 165 
Statistical methods ............................................................................................................................................... 166 
Missing data ......................................................................................................................................................... 166 
 xiii 
Results  ................................................................................................................................................ 167 
Estimates of the effect of INR control on risk of bleed ....................................................................................... 173 
Bleeding event rate .............................................................................................................................................. 174 
Bleeding related to individual organ systems ...................................................................................................... 174 
Discussion ........................................................................................................................................... 176 
Conclusion .......................................................................................................................................... 180 
Supplementary information ................................................................................................................. 185 
Temporal INR Control ......................................................................................................................................... 185 
Examples of Exclusion Criteria ........................................................................................................................... 186 
Secondary analyses: breakdown by type of bleed ............................................................................................... 200 
Chapter 6 .............................................................................................................................. 205 
Wales Atrial Fibrillation and Recurrent Events after PCI (WARP) .............................. 205 
Introduction ......................................................................................................................................... 206 
Method 207 
Medical history, demographic information and prescriptions ............................................................................. 207 
Antithrombotic prescribing and classification ..................................................................................................... 208 
Statistical analyses ............................................................................................................................................... 209 
Primary end points ............................................................................................................................................... 209 
Results 210 
Relationships between thromboembolic risk and adverse outcomes .................................................................. 214 
Relationships between antithrombotic regimen, thromboembolic risk and adverse outcomes ........................... 214 
Multivariable modelling ...................................................................................................................................... 217 
Discussion ........................................................................................................................................... 218 
Conclusion .......................................................................................................................................... 223 
References ........................................................................................................................................... 224 
Supplementary material ...................................................................................................................... 228 
Chapter 7. ............................................................................................................................. 236 
 
 xiv 
LIST OF TABLES 
Table 1.1 Adjusted stroke rate based in CHA2DS2-VASc score ............................................. 27 
Table 1.2 Adjusted bleed rate in HAS-BLED score ............................................................... 28 
Table 2.1 Demographics and medical history of patients by discharge prescribing intention of 
P2Y12 Inhibitors. ...................................................................................................................... 76 
Table 2.2 Multivariable Cox proportional hazard model of characteristics associated with 
clopidogrel discontinuation ...................................................................................................... 80 
Table 2.3 Multivariable Cox proportional hazard model of characteristics associated with 
adverse clinical outcomes ........................................................................................................ 82 
Supplementary table 2.1 ICD-10 Codes for major bleeding events ...................................... 92 
Supplementary table 2.2 ICD10 codes for major adverse outcomes .................................... 93 
Supplementary table 2.3 OPCS codes (versions 4.5 to 4.8) for major adverse outcomes .... 94 
Supplementary table 2.4. Demographics and medical history of patients included and 
excluded in the analysis ........................................................................................................... 95 
Supplementary table 2.5. Multivariable Cox proportional hazard model of characteristics 
associated with the independent adverse outcomes of MI, ischemic stroke, coronary 
revascularization or death ........................................................................................................ 97 
Supplementary table 2.6. Individual event rate* for Stroke, MI, coronary revascularization 
and death according to presence of clopidogrel discontinuation and/or bleed ........................ 98 
Supplementary table 2.7. Multivariable Cox proportional hazard model of characteristics 
associated with bleeding events during follow up ................................................................... 98 
Table 3.1. Cohort characteristic and comparison between those with and without a documented 
lipid profile in the first-year post-discharge -post-PCI .......................................................... 107 
Supplementary table 3.1 Multivariable binary regression analysis of variables associated with 
the absence of a documented lipid profile during follow up. ................................................ 123 
Supplementary table 3.2. Multivariable binary regression analysis of variables associated 
with LDL-C ≥1.4mmol/L ....................................................................................................... 124 
Supplementary table 3.3 Multivariable binary regression analysis of variables associated with 
non-HDL-C ≥2.2mmol/L ....................................................................................................... 125 
 xv 
Supplementary table 3.4 Multivariable binary regression analysis of variables associated with 
triglycerides ≥1.5mmol/L ...................................................................................................... 126 
Table 4.1 Cohort demographics and medical history. ........................................................... 138 
Table 4.2 Multivariable logistic regression model of INR control verses deprivation index and 
CHA2DS2-VASc score ........................................................................................................... 143 
Table 4.3 Multivariable regression models of patient characteristics verses INR control. ... 144 
Supplementary table 4.1 Diagnostic codes ......................................................................... 157 
Supplementary table 4.2 Cohort characteristics and comparisons to patients with INR 
readings that were not available and those with insufficient INR readings for inclusion ..... 157 
Supplementary table 4.3 Comparisons between those with deprivation index data present and 
missing from the final cohort ................................................................................................. 158 
Supplementary table 4.4 Multivariable regression models of patient characteristics verses 
INR control using BIC and Lasso models. ............................................................................ 159 
Table 5.1 Cohort baseline characteristics; including pair-wise comparisons of baseline 
characteristics of subgroups with and without bleeding events during follow up. ... 169 
Table 5.2 Multivariable Cox-regression model for hazard of major bleeding events determined 
by poor INR control (according to NICE, ESC/US and a modified-ESC/US criteria). ........ 170 
Table 5.3 Multivariable Cox-regression model for hazard of major bleeding events determined 
by poor INR control (according to NICE, ESC/US and a modified-ESC/US criteria). ........ 172 
Table 5.4. Multivariable Cox-regression model for hazard of major bleeding events determined 
by poor INR control (according to NICE definition). ............................................................ 175 
Supplementary table 5.1a Read codes for bleeding events from WLGP data. ................... 190 
Supplementary table 5.1b ICD-10 codes for bleeding events from PEDW. ....................... 194 
Supplementary table 5.2 Cohort characteristics and comparisons to patients with inadequate 
number of INR readings to calculate INR control prior to a bleed and those with inadequate 
number of INR results to calculate INR control across any period during the study. ........... 197 
Supplementary table 5.3. Comparisons between those with deprivation index present and 
missing from the final cohort. ................................................................................................ 198 
Supplementary table 5.4 Bleeding event rate according to INR guideline criteria. ............ 199 
 xvi 
Supplementary table 5.5 Multivariable Cox-regression model for hazard of bleeding events 
determined by poor INR control (according ESC/US definition of poor INR control 
(TTR<70%)). ......................................................................................................................... 200 
Supplementary table 5.6 Multivariable Cox-regression model for hazard of major bleeding 
events determined by poor INR control (according the modified ESC/US definition of poor 
INR control (TTR<70% or low or high INRs)). .................................................................... 201 
Supplementary table 5.7 Bleeding event rate within organ systems according to periods of 
NICE guideline criteria for INR control. ............................................................................... 202 
Supplementary table 5.8 Bleeding event rate within organ systems according to periods of 
ESC/US guideline criteria for INR control. ........................................................................... 203 
Supplementary table 5.9 Bleeding event rate within organ systems according to periods of a 
modified ESC/US guideline criteria INR control. ................................................................. 204 
Table 6.1 Baseline characteristics of cohort by antithrombotic regimen .............................. 212 
Table 6.2 Adverse event rates during the first year follow up post-PCI ............................... 214 
Table 6.3 Multivariable Cox-proportional hazard models of characteristics associated with 
adverse outcomes ................................................................................................................... 216 
Supplementary table 6.1 ICD10 codes for major adverse outcomes .................................. 228 
Supplementary table 6.2 Combinations of antithrombotic therapy. .................................... 230 
Supplementary table 6.3 Kaplan Meier estimates of patient outcome in the year post discharge
 ................................................................................................................................................ 230 
Supplementary table 6.4 Multivariable Cox-proportional hazard models of characteristics 
associated with adverse outcomes using stepwise AIC criteria ............................................. 231 
Supplementary table 6.5 Comparison of BIC and SPSS selection criteria for multivariable 
Cox regression models for adverse outcomes ........................................................................ 232 
Supplementary table 6.6 Cohort characteristics between those included prescribed DAPT, 




LIST OF FIGURES 
Figure 1.1 Lesion types of atherosclerosis and a proposed sequence of their development. .... 2 
Figure 1.2 Plaque rupture and healing. ..................................................................................... 4 
Figure 1.3 Platelet targets of antiplatelet therapy. .................................................................... 6 
Figure 1.4 Algorithm for DAPT in patients with coronary artery disease. ............................. 13 
Figure 1.5 Electrical impulses in ‘normal’ sinus rhythm and in atrial fibrillation. ................. 20 
Figure 1.6 Phases of coagulation processes leading to formation of fibrin clot. .................... 22 
Figure 1.7 Coagulation cascade and site of inhibition for warfarin and DOAC. .................... 23 
Figure 1.8 Management algorithm for AF patients presenting with elective PCI or ACS 
undergoing PCI. ....................................................................................................................... 32 
Figure 1.9 Example of anonymisation of datasets for transfer and use within SAIL. ............ 40 
Figure 1.10 SQL query displaying the frequency of drug names and highlighting the spelling 
& misspelling ng of clopidogrel. ............................................................................................. 41 
Figure 1.11 SQL showing different durations for clopidogrel ................................................ 41 
Figure 1.12 SQL used to ‘clean’ and structure the prescribing data ....................................... 42 
Figure 1.13 Schematic of classifications of spells and superspells during is single period of 
care between multiple hospitals ............................................................................................... 45 
Figure 1.14 SQL for creating hospital tables .......................................................................... 47 
Figure 1.15 SQL code to identify start date and end date of each hospital admission ........... 48 
Figure 1.16 SQL code and results of searching hospital datasets for the word ‘failure’ ........ 51 
Figure 1.17 SQL code and results showing the frequency of ICD-10 codes during a hospital 
admission for a PCI .................................................................................................................. 52 
Figure 2.1 Study population cohort selection ......................................................................... 75 
Figure 2.2 Discontinuation of clopidogrel post PCI in those recommended to continue for one 
year ........................................................................................................................................... 78 
Figure 2.3. Characteristics associated with clopidogrel discontinuation within one year of 
discharge during follow up using univariable cox proportional hazards model ...................... 79 
 xviii 
Figure 2.4. Characteristics associated with death or major cardiovascular adverse events .... 81 
Figure 3.1 Time to first post-discharge lipid profile ............................................................. 106 
Figure 3.2 Post discharge lipid results .................................................................................. 109 
Figure 3.3 Prescribed lipid lowering therapy in patients at or above (a) 2019 & (b) 2016 
ESC/EAS guideline LDL-C targets. ...................................................................................... 110 
Figure 3.4 Lowest Triglyceride recorded between 28 and 365 days in 10,592 patients ....... 112 
Figure 3.5 Number of patients and lipid lowering therapy according to Triglyceride levels.
 ................................................................................................................................................ 112 
Supplementary figure 3.1 Study population cohort selection. ............................................ 127 
Supplementary Figure 3.2 Number of patients and lipid lowering therapy according to non-
HDL-C level. .......................................................................................................................... 128 
Figure 4.1 Inclusion criteria for study cohort ....................................................................... 137 
Figure 4.2 Number of patients with poor INR control according to NICE criteria. ............. 140 
Figure 4.3 Characteristics associated with poor INR control. .............................................. 141 
Figure 4.4 INR control verses thromboembolic risk ............................................................. 142 
Supplementary Figure 4.1 Change in INR control across the study period ........................ 155 
Supplementary Figure 4.2 Number of patients with TTR<70% or have low or high INRs 
using the NICE low and high criteria. ................................................................................... 156 
Figure 5.1 Inclusion criteria for study cohort ....................................................................... 168 
Figure 5.2 Number of bleeds by organ system during periods of INR calculation. ............. 171 
Supplementary figure 5.1 TTR Temporal Window Identification Algorithm .................... 185 
Supplementary figure 5.2a INR inclusion criteria .............................................................. 186 
Supplementary figure 5.2b INR exclusion criteria ............................................................. 187 
Supplementary figure 5.2c INR exclusion criteria continued ............................................. 187 
Supplementary figure 5.2d INR exclusion criteria continued ............................................. 188 
Supplementary figure 5.3 Number of bleeds* across the entire study period, including periods 
outside of INR calculation. .................................................................................................... 189 
 xix 
Figure 6.1 Study population cohort selection. ...................................................................... 211 
Figure 6.2 Kaplan-Meier estimate of the risk of (a) stroke, (b) ACS, (c) death and (d) combined 
outcome of stroke, ACS or death, and (e) bleeding event during the first 365 days post 
discharge, stratified by antithrombotic regimen. ................................................................... 215 
Supplementary figure 6.1 Kaplan-Meier estimates of the risk of (a&b) stroke, (c&d) ACS, 
(e&f) death and (g&h) combnined outcome of stroke, ACS or death, and (i&j) bleeding event 
during the first 365 days post discharge, stratified by antithrombotic regimen and CHA2DS2-






This encompasses a range of conditions including unstable angina, 
non-ST-segment-elevation myocardial infarction (NSTEMI) and ST-
segment-elevation myocardial infarction (STEMI) that are due to a 
sudden reduction of blood flow to the heart, usually due to rupture of 
an atherosclerotic plaque that promotes formation of a clot in one of 
the coronary arteries. 
Anticoagulants A group of drugs that reduce the activity of one or more factors 
involved in the coagulation of blood and prolong the clotting time. 
Oral anticoagulants include Vitamin K antagonists (VKA) and the 
direct oral anticoagulants (DOACS). These are commonly prescribed 
to reduce the risk of clots developing in atrial fibrillation and also 
following deep vein thrombosis and pulmonary embolism.  
Antiplatelet  A group of drugs including aspirin and P2Y12 antagonists that decrease 
platelet aggregation and thrombus formation. 
Atrial fibrillation 
(AF) 
Atrial fibrillation is an irregular and often rapid heart rate that can 
increase the risk of strokes, heart failure and other heart-related 
complications. During atrial fibrillation, the heart's two upper 
chambers (the atria) beat chaotically and without contractile function, 
out of coordination with the two lower chambers (the ventricles) of the 
heart which beat irregularly. 
Cardiovascular 
disease (CVD) 
A group of disorders of the heart and vasculature, including 
hypertension; ischaemic heart disease (IHD); cerebrovascular disease 
(stroke); peripheral vascular disease (PVD); arrhythmias; rheumatic 




Coronary artery bypass grafting is a surgical procedure to restore 
normal blood flow to the heart, by connecting venous or arterial grafts 
from the aorta or internal mammary artery to the native coronary 
arteries beyond their region(s) of blockage. 
  
 xxi 
Cox-regression  Cox regression is a statistical method for investigating the effect of 
several variables upon the time a specified event takes to happen, in 
order to identify those variables that are independently associated with 




A generic term for a group of oral anticoagulants that inhibit 
coagulation factor Xa or thrombin activity. In the United Kingdom the 
following are available: apixaban, edoxaban and rivaroxaban (anti-
factor Xa) and dabigatran (a direct thrombin inhibitor).  
Dual antiplatelet 
therapy (DAPT) 
A combination of antiplatelet agents including aspirin and a P2Y12 
inhibitor/antagonist prescribed to reduce the risk or recurrent coronary 
ischaemic events post ACS. Also initiated at the time of coronary stent 
deployment to reduce the risk stent thrombosis and restenosis.  
Ischaemic heart 
disease (IHD) 
A pathological process characterised by development +/- 
destabilisation of atherosclerotic plaque in the coronary arteries. Also 
referred to as coronary heart disease. 
In stent restenosis 
(ISR) 




A statistical tool for determining the relative contributions of different 





Also referred to as non-ST-elevation myocardial infarction 
(NSTEMI). This is characterised by episodes of chest pain at rest or 
with minimal exertion, which increase in frequency or severity, often 
with dynamic ECG changes and release of biomarkers reflecting 
myocardial injury. This is usually caused by destabilisation or rupture 
of an atherosclerotic plaque.  
P2Y12 inhibitors P2Y12 inhibitors (also referred to P2Y12 antagonists) are antiplatelet 
agents including clopidogrel, prasugrel and ticagrelor. These are 
commonly prescribed to reduce the risk of thrombosis following acute 




This is a non-surgical procedure that uses a catheter (a thin flexible 
tube) to place and inflate a thin balloon, usually followed by 
placement of a small tubular structure called a stent, to open up blood 





Peripheral vascular disease is a common term used to refer to 
atherosclerotic peripheral arterial disease. This is a condition where a 
build-up of fatty deposits in the arteries restricts blood supply. This 
may occur in any artery outside of the heart and brain but most 





STEMI results from complete and prolonged occlusion of an 
epicardial coronary blood vessel, usually due to destabilisation of an 
atherosclerotic plaque, triggering the development of a clot which 
completely blocks the vessel. This rapidly shuts off the blood supply 
to the heart muscle supplied by the artery, which starts to die unless 
blood flow can be restored promptly. STEMI is defined based on ECG 
criteria, characterised by acute, regional elevation of the ST-segments 
or development of a new left bundle branch block pattern on the 12 
lead ECG. 
Stent thrombosis Stent thrombosis is defined as a thrombotic (clot-related) occlusion of 
a coronary stent. Stent thrombosis is a major complication associated 
with stent placement in percutaneous coronary intervention (PCI). 
Univariable 
analysis 
Univariable analysis is a simple statistical technique for analysing the 
strength of the relationship between a single variable (predictor) to an 
individual outcome or event. 
Unstable angina 
(UA) 
Sometimes referred to as acute coronary syndromes ‘ACS’. UA is 
defined as myocardial ischaemia at rest or minimal exertion in the 




Chapter one  1 
CHAPTER 1. 
THESIS INTRODUCTION 
This thesis examines the evidence-based management of two areas of cardiovascular disease 
(CVD); the management of ischaemic heart disease (IHD) focussing on the period post-
percutaneous coronary intervention (PCI), and secondly the antithrombotic management for 
the prevention of stroke in patients with atrial fibrillation (AF). 
CARDIOVASCULAR DISEASE 
CVD is a group of disorders of the heart and vasculature, including hypertension; IHD; 
cerebrovascular disease; peripheral vascular disease (PVD); arrhythmias; rheumatic and 
congenital heart disease, and cardiomyopathies. CVD is the single most common cause of 
death in the UK and worldwide, and in countries of all income groups.1, 2 In the UK, mortality 
from CVD has been decreasing (1980-2013), despite an increase in hospital admission and 
little change in prevalence.3 The decrease in mortality has largely been attributed to 
improvement in the management of individuals (including secondary prevention, heart failure 
treatment, management of the acute myocardial infarction, and hypertension), and 
improvement at a population level by reduction in smoking, improvement in blood pressure 
and cholesterol.4 
ISCHAEMIC HEART DISEASE 
IHD is a pathological process characterised by the accumulation of atherosclerotic plaque in 
the epicardial coronary arteries (figure 1.1). This chronic disease may have stable periods and 
can be modified by changes to lifestyle, pharmacotherapy, and invasive interventions. 
However, most often this disease is progressive and plaque growth can obstruct and occlude 
coronary arteries leading to myocardial ischaemia presenting clinically as angina.5 6 Abrupt 
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thrombotic occlusion of a high-risk coronary plaque can result in the most serious clinical 
manifestations of coronary artery disease, i.e. unstable angina (UA), acute myocardial 
infarction (AMI) (either as a non-ST-elevation acute coronary syndrome [NSTE-ACS] or ST-
elevation-[STEMI]) and sudden death.5 
 
Figure 1.1 Lesion types of atherosclerosis and a proposed sequence of their development.  
A, thickening characterized by smooth muscle cell accumulation within the intima. B, Intimal xanthoma 
corresponding to the accumulation of foam cell macrophages within the intima. Pathological intimal thickening 
in C denotes the accumulation of extracellular lipid pools in the absence of apparent necrosis. D, Fibroatheroma 
indicating the presence of a necrotic core. The necrotic core and surrounding tissue may eventually be calcified, 
which forms fibrocalcific plaque shown in E. 
From Bentzon JF. et al Mechanisms of plaque formation and rupture. Circ Res 2014; 114: 1852-1866.7 
 
 
Atherosclerotic lesions develop from a complex interplay between circulating factors, cell 
types and repeated exposure to systemic and local injury.8 High blood concentration of 
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apolipoprotein B (ApoB) containing lipoproteins, of which low-density lipoprotein (LDL) 
usually is the most prevalent form, is the most common cause of atherosclerosis. However, the 
disease is multifactorial and atherosclerotic plaques can develop at even modest levels of 
circulating LDL. Smoking, diabetes, hypertension, male-sex, and genetic susceptibility also 
contribute to the disease. 
In the initial stages of atherosclerosis, LDL particles accumulates in the arterial intima 
and are then modified by processes of oxidation and aggregation. These modified lipoproteins 
act as stimulators of the immune system inducing endothelial cells and smooth muscle cells to 
express adhesion molecules that interact with receptors on monocytes and stimulate their 
homing, migration, and differentiation into macrophages and dendritic cells (figure 1.1a).7  
Macrophages and dendritic cells take up lipids from the insudating lipoproteins and 
become foam cells (figure 1.1b).7, 9 Xanthomas or ‘fatty streaks’ then develop from 
accumulating several layers of foam cells. While many xanthomas do not progress any further, 
some develop lipid pools below the layer of foam cells (figure 1.1c). Ongoing invasion of 
macrophages with progressive lipid accumulation and inflammation leads to cellular necrosis 
(figure1.1d). This results in pools of free cholesterol, cellular debris, along with lipid 
accumulation and inflammatory cells known as necrotic cores (also referred to as ‘lipid rich 
cores’). Angiogenesis provides oxygen and nutrients for the expanding plaque but leads to 
further infiltration of immune and atherogenic lipoproteins. The plaque neovessels are fragile 
and may rupture leading to extravasation of erythrocytes and plasma protein. Intraplaque 
bleeds expands the plaque core and causes inflammation and is a common trigger for plaque 
rupture. Continued plaque growth results in a formation of a thin fibrous plaque susceptible to 
rupture (figure 1.1e and 1.2). 
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The development of atherosclerotic plaques and the resulting progressive obstruction 
may lead to stable angina. However, an ACS is nearly always the result of plaque rupture and 
thrombus formation.  
 
Figure 1.2 Plaque rupture and healing. 
Rupture of a thin-cap fibroatheroma with nonfatal thrombus and subsequent healing with fibrous tissue formation 
and constrictive remodelling. 
From Bentzon JF. et al Mechanisms of plaque formation and rupture. Circ Res 2014; 114: 1852-1866.7 
 
 
MECHANISMS OF PLATELET ACTIVATION AND SITES OF ACTION FOR ANTIPLATELET THERAPY 
Although platelets can adhere to intact endothelium, and participate in the progression of 
atherosclerosis, plaque rupture and exposure of the thrombogenic substrates to circulating 
platelets stimulates platelet attachment to the exposed subendothelium and platelet activation 
leading to aggregates and local thrombus formation. Activated platelets cause a positive 
feedback loop amplifying the response to the original stimulus and activation of the coagulation 
cascade leading to the formation of fibrin and a solid clot.8 
Platelet adherence to the ruptured endothelium is rapidly enabled by the platelet specific 
adhesion-signalling system, consisting of glycoprotein (GP)Ib-IX-V that binds von 
Willerbrand factor (vWF) and collagen. Engagement of this signalling system leads to rapid 
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platelet activation and morphological changes in platelet shape and plasma membrane as well 
as degranulation that promotes coagulation including activation of factor Xa and thrombin. 
In activated platelets, release of the agonist, adenosine diphosphate (ADP), and 
activation of the cyclooxygenase pathway leads to production and release of thromboxane A2 
(TxA2). This reinforces platelet activation by autocrine stimulation of G-protein–coupled 
receptors for ADP (P2Y1 and P2Y12) or TxA2.10 Thus, activation via primary platelet 
receptors, GPIb-IX-V/GPVI, or secondary receptors for ADP, TxA2 or, thrombin leads to 
activation of the platelet integrin, αIIbβ3 (GPIIb/IIIa) that binds fibrinogen or vWF and 
mediates platelet aggregation.  
Understanding of the processes involved in platelet activation, platelet aggregation and 
activation of the coagulation cascade leading to the development of thrombi has allowed us to 
exploit this system, using multiple antithrombotic agents binding at key receptors to reduce the 
normal thrombotic response, aid revascularisation and reduce further thrombotic episodes 
(figure 1.3). 
Aspirin inhibits prostaglandin(PG) -endoperoxidase synthase (PTGS1; also known as 
cyclooxygenase 1), preventing the production of PGs, particularly in platelets, inhibiting the 
TxA2 production.10 The P2Y12 receptor antagonists (clopidogrel, prasugrel and ticagrelor) 
prevents the binding ADP and subsequent platelet activation. Abciximab, tirofiban and 
eptifibatide bind directly to the GPIIb/IIIa receptors on activated platelets preventing the 
binding of fibrinogen and von Willebrand factor.11 
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Figure 1.3 Platelet targets of antiplatelet therapy.  
Schematic showing platelet surface receptors and signalling pathways leading to platelet activation and activation 
of the integrin, αIIbβ3, which binds fibrinogen or Von Willebrand factor and mediates platelet aggregation. 
Targets of currently available (shaded boxes) and novel drugs in development or in clinical trial (white boxes) are 
indicated. COX indicates cyclooxygenase; GP, glycoprotein; and TxA2, thromboxane A2. 
From Metharom P et al. Current state and novel approaches of antiplatelet therapy. Arteriosclerosis, Thrombosis, 
and Vascular Biology. 2015; 35:1327–1338.10 
 
 
In patients presenting with an ACS activation of the coagulation system and release of clotting 
factors produce small amounts of thrombin, that is amplified by activated platelets. 
Management of patients with an ACS relies on combinations of antithrombotic therapy to arrest 
platelet activity and thrombin production.12 Dual antiplatelet therapy (DAPT), consisting of 
aspirin and a P2Y12 antagonist is the cornerstone of treatment. Anticoagulation with a 
herparinoid is indicated during the acute phase until revascularisation or chest pain has 
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rescinded. For patients undergoing invasive revascularisation intravenous GPIIb/IIIa inhibitors 
may also be administered to further inhibit platelet activity in very high-risk patients. 
 
CORONARY ANGIOGRAPHY 
Coronary angiography provides the gold standard in defining the degree of severity of 
atherosclerotic coronary disease. Angiography involves insertion of a catheter into either the 
femoral or radial artery that is guided to the coronary arteries. Local injection of contrast dye 
and use of X ray imaging facilitates the visualisation of the coronary arteries allowing 
characterisation of the nature of the disease which is necessary to inform revascularisation 
strategies. 
 While there are no absolute contraindications to coronary angiography, neither is the 
procedure risk free. Bleeding is estimated to occur in ~2%, although most are minor, 
haematoma and retroperitoneal bleeds occurs in ~0.2% of cases13; the incidence of death is ~ 
0.05% for diagnostic procedures14; risk of stroke is 0.05-0.1% in those undergoing diagnostic 
angiography increasing to 0.18% - 0.4% in those proceeding to intervention15, acute kidney 
injury occurs in ~1.7% of cases and allergic reactions to contrast media in ~1% of patients. 
Risk of complications are higher amongst older patients, diabetics, those with renal 
insufficiency and the morbidly obese. Patients with severe ischaemic heart disease, reduced 
ejection fraction, recent stroke or MI, or a propensity to bleeding are at particularly increased 
risk of cardiac and vascular complications. 
 The transfemoral approach provides easier access, allows repeated puncturing, less 
radiation time and less contrast media.16 In comparison transradial catheterisation reduces 
bleeding, haematoma formation, facilitates earlier discharge, is patient preferred and is also 
lower cost. Studies amongst ACS patients randomly assigned to either transradial or 
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transfemoral approach have demonstrated lower bleeding with transradial (1.6 vs 2.3%; 
relative risk (RR) 0.67, 95% confidence interval (CI) 0.49-0.92, P=0.009) and improved 
mortality (1.6 vs 2.2%; RR 0.72, 95%CI 0.53-0.99, P=0.045) compared with transfemoral 
access.16  
 
REVASCULARISATION BY PERCUTANEOUS CORONARY INTERVENTION AND ANTIPLATELET 
THERAPY 
Coronary revascularisation by percutaneous coronary intervention (PCI) is now the dominant 
revascularisation strategy for patients presenting with STEMI across Europe.17 It is also an 
established mode of revascularisation in patients with NSTE-ACS and may also be indicated 
in flow-limiting coronary stenosis in patients with stable coronary artery disease (SCAD) to 
reduce myocardial ischaemia, amongst patients who remain symptomatic despite medical 
therapy.17 PCI may involve aspiration of a thrombus; administration of thrombolytic drugs 
direct to the thrombus, balloon angioplasty or most commonly, insertion of a stent.  
Balloon angioplasty was the earliest form of PCI but was limited by unpredictable 
vessel closure and high rate of restenosis at the site of the treated lesion due to vessel recoil, 
plaque prolapse and constrictive remodelling. The implantation of metal stents overcame many 
of these early issues with balloon angioplasty. The additional mechanical strength resulting in 
increased luminal diameter helped prevent vessel recoil and remodelling. However, there were 
two important limitations with these early stents. The first, stent thrombosis (ST) was reported 
to have occurred in approximately 25% of cases within 14 days of stent implantation despite 
judicial use of heparin, thrombolytics and/or anticoagulation.18  
The second limitation, in-stent restenosis (ISR) is defined as a reduction in lumen 
diameter after PCI determined by an excessive tissue proliferation in the stented artery 
Chapter one  9 
‘neointimal proliferation’, or by new-occurring atherosclerotic process called 
‘neoatherosclerosis’.19 Risk factors for restenosis include diabetes, smoking, reduce left 
ventricular function, age gender and previous by-pass surgery.19  
Drug eluting stents and improvements in stents design including thinner struts and more 
biocompatible polymer coatings as well as stents that are fully bioresorbable have reduced the 
occurrence of ISR.  
Stent thrombosis, although rare (<2% in the first year) has a major clinical impact with 
mortality as high as 45%.20 There are a number of mechanisms leading to stent thrombosis 
including patient, pharmacological, procedural, lesion and device factors, as well as platelet 
and coagulation factors.  
Patients presenting with ACS, diabetics, smokers, those with severely depressed left 
ventricular function and chronic kidney disease are at increased risk of stent thrombosis.21 High 
post-intervention platelet reactivity, thrombocytosis, hypercoagulable state and antiplatelet 
resistance should also be considered,22, 23 but early discontinuation of antiplatelet therapy is the 
leading cause of stent thrombosis.21  
The use of drug-eluting-stents (DES) has shown to be more effective in reducing stent 
thrombosis and restenosis over bare metal stents (BMS) and the newer generation of DES may 
also be more effective at reducing stent thrombosis over the first-generation DES.24, 25  
Regardless of stent type, the insertion of a stents(s) mandates a period of dual 
antiplatelet therapy (DAPT), most commonly a combination of aspirin and P2Y12 inhibitor 
therapy (clopidogrel, prasugrel or ticagrelor). The use of DAPT in the setting of PCI has been 
an established strategy since the Intracoronary Stenting and Antithrombotic Regimen (ISAR) 
trial published in 1996.26 In this trial patients were randomised to receive either antiplatelet 
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therapy (ticlodipine plus aspirin) or anticoagulant therapy (intravenous heparin, 
phenprocoumon, and aspirin). The primary end point was a composite of cardiovascular death, 
MI, aortocoronary bypass surgery, or repeat angioplasty occurred in 1.6% of those in the 
antiplatelet arm and 6.2% in the anticoagulant arm (RR 0.25, 95%CI 0.06-0.77).   
Since the ISAR trial, P2Y12 inhibitor therapy has been refined; firstly, to safer therapy 
(from ticlodipine to clopidogrel) and more recently to more potent/consistent and predictable 
therapy (clopidogrel to prasugrel or ticagrelor),27-31 particularly amongst patients with ACS. 
However, improved antiplatelet effect with prasugrel and ticagrelor over clopidogrel, comes 
with a cost of increased major and fatal bleeding. In the TRITON-TIMI 38 trial (Trial to assess 
Improvement in Therapeutic Outcomes by optimising platelet inhibition with prasugrel 
Thrombolysis in Myocardial Infarction 38), 13,608 patients with moderate to high risk ACS 
undergoing PCI were randomised to prasugrel or clopidogrel.31 The primary endpoint of CV 
death, nonfatal MI or nonfatal stroke occurred in 12.1% of patients receiving clopidogrel and 
9.9% receiving prasugrel (HR 0.81, 95%CI 0.73-0.90; P<0.001), however, major bleeding 
occurred in 2.4% receiving prasugrel and 1.8% of patients receiving clopidogrel (HR 1.32, 
95%CI 1.03-1.68; P=0.03). 
In the PLATO (PLATelet inhibition and patient Outcomes) trial 18,624 patients with 
an ACS were randomised to clopidogrel or ticagrelor.32 The primary endpoint of CV death, 
MI, or stroke occurred in 9.8% receiving ticagrelor compared to 11.7% receiving clopidogrel 
(HR 0.84, 95%CI 0.77-0.92; P <0.001). In patients not undergoing coronary artery bypass 
grafting, bleeding events were 4.5% in those receiving ticagrelor and 3.8% in those receiving 
clopidogrel (P=.03).  
 Research has also focused on the optimal duration of therapy.33-37 The necessity to 
study longer durations (beyond one year) of DAPT first arose due to the risk of late stent 
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thrombosis occurring after first-generation drug-eluting stent implantation. However, the rate 
of stent thrombosis amongst the new-generation DES is low at 0.5%, (95%CI 0.3-0.7 per 100 
person-years).38 Therefore, the ongoing risk of bleeding associated with prolonged DAPT does 
not justify the absolute benefit in preventing stent thrombosis, although there may be additional 
benefit from reducing development of thrombosis in non-stented arteries as well as providing 
systemic benefit from reducing stroke and peripheral artery occlusion. 
 
More recent research has focused on the systemic benefits from DAPT on reduction of 
cerebrovascular and peripheral vascular events and on the use of ‘triple therapy’ with low dose 
direct oral anticoagulants (DOACs) in patients with atrial fibrillation (AF) and without.39-45 
However, the addition of oral anticoagulants to antiplatelet therapy for the longer term 
prevention of ischaemic events (in patients without other indication for anticoagulation) post 
ACS has been limited by the excess in bleeding events.46  
 
The Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) RCT 
investigated a range of doses of apixaban (2.5mg twice daily, 10mg once daily, 10mg twice 
daily and 20mg once daily) in 1715 patients with a recent ACS. Nearly all patients received 
aspirin and 76% clopidogrel. The primary endpoint was major or clinically relevant bleeding 
and secondary endpoint was the composite of CV death, MI severe recurrent ischaemia, or 
stroke. The two higher dose apixaban arms were discontinued early due to excess bleeding. 
There was a trend towards lower rates of ischaemic events (compared to placebo) in the 
remaining treatment arms but with a more pronounced increase in bleeding. 
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In the ATLAS ACS 2-TIMI 51 trial 15,526 patients with a recent ACS were randomised 
to receive 2.5mg or 5mg twice daily rivaroxaban or placebo.39 93% of patients were prescribed 
a P2Y12 inhibitor in addition to aspirin. The lower dose (one quarter of the stroke prevention 
dose in AF) was associated with a decrease in CV mortality (2.7% vs 4.1%, P=0.002) but not 
the higher dose. Both doses were associated with an increase in non-fatal bleeding. 
 
Current guidelines recommend for a minimum of one year of DAPT for patients 
presenting with an ACS undergoing stenting at low risk of bleeding, reduced to six months 
amongst those at higher risk of bleeding (figure 1.4).47, 48 Amongst those with stable CAD 
undergoing PCI with stenting at low risk of bleeding the minimum duration of DAPT is 6 
months, decreasing to 3 months amongst those at higher risk of bleeding.  
 
In practice, the duration of DAPT may be dependent on a number of clinical 
characteristics. Duration may be shorter than guidelines to accommodate the need for future 
surgery; or to take account of risk factors for bleeding or poor adherence; the need to initiate 
or maintain anticoagulation for AF, valvular disease or thromboembolism; or as a result of 
limited evidence from RCTs in specific subgroups such as the elderly, or those with advanced 
kidney or liver disease. Duration of DAPT may also continue beyond the one year ‘standard’ 
where patients have had multiple revascularisation events, extensive length of stenting or 
extensive atherosclerotic disease, or have comorbidities such as diabetes and peripheral 
vascular disease. 
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Figure 1.4 Algorithm for DAPT in patients with coronary artery disease. 
ACS indicates acute coronary syndrome; BMS: bare-metal stent; BRS: bioresorbable vascular scaffold; DCB: 
drug-coated balloon; DES: drug-eluting stent; PCI: percutaneous coronary intervention; stable CAD: stable 
coronary artery disease. Colour-coding refers to the ESC classes of recommendations (green = Class I; yellow = 
Class IIA; orange = Class IIb). 
From Valgimigli et al. Eur Heart J. 2018; 39, 213-254.47 
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REVASCULARISATION WITH CORONARY ARTERY BYPASS GRAFTS  
While this thesis focusses on the evidenced based management of patients post PCI as opposed 
to medically managed or those undergoing coronary artery bypass grafting (CABG), for 
completeness it is worth mentioning a few words on these alternatives. 
 CABG is a surgical procedure to restore normal blood flow to the heart. The procedure 
may involve either diverting the left internal mammary artery to the left anterior descending 
branch of the left coronary artery or harvesting the saphenous vein from the leg and attaching 
one end to the aorta and the other immediately after the obstruction.  
The main advantages of PCI revascularisation compared to CABG include rapid 
reperfusion, rapid recovery with less post-operative complications, better patient comfort and 
lower cost. However, CABG may be preferable over PCI in diabetics, patients with reduced 
LV function (EF<35%), contraindications to DAPT, recurrent diffuse in-stent stenosis and 
those requiring indication for concomitant cardiac surgery.49 
 
CONSERVATIVE MEDICAL MANAGEMENT 
While PCI is the preferred method of reperfusion for many patients with STEMI or NSTEMI, 
procedure related complications may limit the feasibility of PCI in the elderly, frail, patients 
with chronic kidney disease, and left ventricular heart failure. Furthermore, in patients with a 
tendency to bleed, non-compliant with medicines or require urgent surgery, avoiding PCI with 
stents and the commitment to a period of DAPT may be preferable. Discontinuing or reducing 
antiplatelet therapy in patients who are either medically managed or who have undergone 
CABG is a risk but much less of a risk than in patients who have recently been stented who 
may experience stent thrombosis. 
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In the situation where neither PCI or CABG is feasible then an multi-disciplinary team 
approach consisting of interventional and non-interventional cardiologist may decide the best 
treatment approach.  
In patient with an ACS where medical management is the preferred option, DAPT for 
one year is recommended in those not at high risk of bleeding, reduced to six months in patients 
with a high risk of bleeding.27  
 
MANAGEMENT OF DYSLIPIDAEMIA IN THE SECONDARY PREVENTION OF CORONARY HEART 
DISEASE 
As previous discussed, ApoB containing lipoproteins play an important role in atherosclerosis. 
A concordance of information from RCTs, epidemiological studies and Mendelian 
randomisation studies have consistently demonstrated a log-linear relationship between LDL-
C plasma concentration, prolonged exposure to higher LDL-C overtime and increased risk of 
atherosclerotic CVD.50-53 
The reduction in LDL-C and other ApoB lipoproteins including very low density 
(VLDL), intermediate density (IDL), lipoprotein (a) Lp(a) and triglyceride (TG) is a recognised 
clinical target for both primary and secondary CVD risk management. Again, the concordance 
of information from RCTs, basic science and observational studies confirms that the greater 
the absolute reduction in LDL-C the greater the CV risk reduction.54,55, 56 
Statins are the first line treatment for both the primary and secondary management of 
CVD risk.57 The predominant effect of statins is through reduction in LDL-C, with a lesser 
effect on TG. Statins have also a number of suggested pleiotropic effects including anti-
inflammatory and antioxidant effects that may be beneficial in the prevention of CVD. The 
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degree of LDL-C reduction differs between statins and dose. A high-intensity statin regimen is 
defined by the European Society of Cardiology/European atherosclerosis Society (ESC/EAS) 
as the dose of statin that, on average, reduces LDL-C by ≥50%. This includes doses for 
atorvastatin ≥40mg and rosuvastatin≥20mg per day. 
Statins are amongst the most extensively studied medical treatments of all time. The 
majority of the land-mark statin trials compared either statin vs control or intensive vs less 
intensive statin treatment rather than a treat to target approach.58-61 This gave rise to the 
proposition of a “fire and forget” approach as a strategy of prescribing lipid lowering 
treatment.62 However, when the mean achieved LDL-C from these trials are mapped against 
cardiovascular outcomes, there is a clear trend to lowering CV events with lower LDL-C. A 
meta-analysis that included >170,000 patients from 26 RCTs of a statin vs control or more 
intensive vs less intensive regimen, concluded that for each 1mmol/L reduction in LDL-C there 
was ~ 22% reduction in the major vascular events (a combined endpoint of MI, death from 
IHD, or stroke or coronary revascularisation) over 5 years.56  
Despite the impressive benefits of statin therapy, in practice the response to treatment 
can be variable,63 and intolerance is reported in 10-20% of patients (largely due to reported 
muscle pain and myalgia) although in contrast, in RCTs of statin vs placebo there has been 
little difference, if any in the reporting in muscle symptoms between statin and control 
groups.64 
The benefits of lipid lowering on CV outcomes is not limited to statin therapy. 
Ezetimibe inhibits cholesterol uptake from the intestine which reduces the amount of 
cholesterol delivered to the liver. In response, the liver reacts by upgrading LDL-recptor 
expression, leading to reduction in circulating LDL-C in the blood. Clinical trials with 
ezetimibe have shown a moderate reduction in LDL-C (~15-22%),65 when added to statin 
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therapy there is an additional ~15% greater reduction in LDL-C.66 Clinical trials testing this 
approach have reported only a moderate 2% absolute risk reduction in clinical outcomes 
(HR=0,94, 95%CI 0.89-0.99, P=0.016) over seven years, commensurate with the moderate 
additional lowering of LDL-C.67 
The more recently introduced anti-proprotein convertase substilisin/kexin type 9 
(PCSK9) monoclonal antibodies (mAbs) have been shown to provide much more substantial 
lowering of LDL-C. The PCSK9 protein plays an important role in cholesterol homeostasis, 
mainly by reducing recycling of LDL receptors to the surface of hepatocytes. The mAbs 
evolocumab and alirocumab target the PCSK9 protein resulting in an increase surface 
expression of LDL receptors that subsequently results in decreased circulating LDL-C levels.  
Clinical studies of the PCSK9 antagonists, either alone or in combination with statins, 
and/or other lipid lowering agents results in a substantial reduction in LDL-C (~60%). Two 
clinical trials have examined cardiovascular outcomes with these agents: the Further 
Cardiovascular Outcomes Research with PCSK9 inhibition in subjects with Elevated Risk 
(FOURIER)68 and the Evaluations of cardiovascular Outcomes After an Acute Coronary 
Syndrome During Treatment with Alirocumab (ODYSSEY outcomes).69 Both these trials 
recruited patients with a history of a ASCVD (ODYSSEY also included recent ACS within 1 
to 12 months), prescribed maximally-tolerated statin therapy with an LDL-C ≥1.8mmol/L. 
Patients in both trials were randomised to the respective PCSK9 or placebo with follow up of 
2.2 (FOURIER) and 2.8 (ODYSSEY)years. The benefits ranged from 15-20% reduction in the 
primary endpoints of adverse CV outcomes. 
Fibrates have only a marginal, <20% reduction in LDL-C but are estimated to reduce 
TG levels by ~50%. The overall benefit on CV mortality is much less robust than statins, except 
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in subsets of the population with atherogenic dyslipidaemia (high TG levels and low HDL-
C).70 
The further lowering of LDL-C and improved CV outcomes with these non-statin 
agents has enforced the message of the importance of LDL-C lowering to treatment goals over 
a fire and forget approach. The latest (2019) ESC/EAS guidelines now recommended that 
LDL-C reduction of ≥50% from baseline and a LDL-C goal of <1.4mmol/L [<55mg/dL] in 
very high CVD risk patients, (reduced from <1.8mmol/L [70g/dL], in the 2016 guidelines) and 
<1.0mmol/L [<40mg/dL] in patients with recurrent atherosclerotic cardiovascular events 
within the previous 2 years.57, 71 
Guidelines have also incorporated ezetimibe and PCSK9 inhibitors to be used in a step 
wise approach for patients at high risk (or above) of CV events who are not at target (or 
intolerant) with statin therapy.57 
Additional therapeutic targets have been identified in recent years. The REDUCE-IT 
trial tested icosapent ethyl in patients established cardiovascular disease or with diabetes and 
other risk factors, prescribed statin therapy with  a fasting TG level of 1.5-5.6mmol/L.72 Over 
a median 4.9 year follow up the primary endpoint of cardiovascular death, nonfatal MI, 
nonfatal stroke, coronary revascularisation, or unstable angina occurred in 17.2% of patients 
in the icosapent ethyl group, compared with 22.0% in the placebo group.  
Furthermore, recent real-world studies in patients with known ASCVD and controlled 
LDL-C, have observed that patients with even moderately raised TG levels are at an increased 
risk of ASCVD, affirming hypertriglyceridaemia as an additional therapeutic risk factor.73  
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ESC guidelines now recommend considering prescribing N-3 fatty acids (N-3) in 




In a normal sinus rhythm electrical impulse originating in the sinoatrial node (SA node) of the 
right atrium sends an electrical impulse through the right and left atria, causing them to contract 
and force blood through to the respective ventricles (figure 1.5). The electrical impulse travels 
to the atrioventricular (AV node) which provides an electrical bridge to the ventricles allowing 
them to contract and pump blood out of the heart in a synchronised manner.74  
In AF electrical impulses are disorderly, with many impulses beginning and spreading 
at the same time through the atria, competing to travel through the AV node. The AV node 
limits these impulses traveling through the ventricles, but many get through resulting in 
irregular and rapid ventricular contractility and heartbeat. 
Dysregulation in heart rhythm from SA control can result in the heart rate being unable 
to adjust its rate effectively to normal stresses and demands of the body. Increase in resting 
heart rate and exaggerated heart rate response to exercise can result in shorter diastolic filling 
time, reducing cardiac output. This is further affected by irregular ventricular response. Loss 
of atrial contractile function can lead to diastolic dysfunction and atrial remodelling.75 
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The prevalence of AF is estimated to be between 2-3%.76, 77 Prevalence increases with age and 
in patients with hypertension, diabetes, heart failure, IHD, valvular heart disease, obesity or 
chronic kidney disease.78, 79 AF is independently associated with an increase in all-cause 
mortality,80-82 quintuples the risk of stroke83 and accounts for approximately 20% of all 
ischaemic strokes. Strokes due to AF tend to be more severe and associated with a higher 
mortality.80, 81, 84, 85  
AF also increases the risk of systemic embolic events (SEE). The frequency of these 
extracranial events is less well documented in both real-world studies and RCTs of 
anticoagulant in AF. Pooled data from four large RCTs of anticoagulation in AF estimate the 
risk of SEE at 0.24 per 100 patient years compared with 1.92/100 patient years for cerebral 
embolism.86 The majority of these SEE occurred in the lower extremities (54%), 31% 
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mesenteric and 10% in the upper extremities. Despite these relatively rarer events, morbidity 
and mortality is high with 60% requiring endovascular or surgical intervention and 25% 
mortality within 30days. 
 
MANAGEMENT STRATEGY FOR ATRIAL FIBRILLATION 
Outside of the management of patients who present acutely and haemodynamically unstable 
the management of AF involves (i) identification and correction of precipitating risk factors 
such as hypertension, thyrotoxicosis or hyperthyroidism, infection, excess alcohol 
consumption or amphetamine and other illicit drug use; (ii) assessing and managing the risk of 
stroke; (iii) assessing heart rate and considering rate control therapy and (iv) considering 
rhythm management for symptomatic improvement.87  
 
MECHANISM OF THROMBOSIS IN ATRIAL FIBRILLATION 
Thrombogenesis in AF is multifactorial: blood stasis, endothelial dysfunction and clotting 
activation (figure 1.6) are factors thought to contribute to thromobosis.88, 89 The most common 
site of intra-atrial thrombus formation is the left atrial appendage (LAA) (a long narrow pocket) 
is predisposed to blood stasis. Dilated atria, impaired contractility, and changes in the left atrial 
appendage occur as a result of AF give rise to abnormalities in blood flow and stasis in the left 
atria. Damage to the endothelium increases production of von Willebrand factor (a 
glycoprotein that act as a bridging molecule at sites of vascular damage and promotes platelet 
aggregation). Abnormal haemostasis and coagulation are also noted in patients with AF.  
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Figure 1.6 Phases of coagulation processes leading to formation of fibrin clot. 
Three overlapping phases are involved in the cell surface-based coagulation. The initiation phase starts with 
vascular injury, tissue factor (TF)-expressing cells are exposed to coagulation factors in the vessel lumen, 
initiating thrombosis. Platelets are activated and recruited to the site of injury. TF/FVIIA complexes activates 
coagulation factors IX, IXa, X and Xa generating small amounts of thrombin. The amplification phase results in 
signalling further platelet activation and aggregation, Thrombin on the surface of platelets activates FV, FVIII 
and FXI. In the propagation phase, binding of FVIIIa with FIXa, and FVa with FXa on platelet surfaces accelerates 
the production of FXa and thrombin. During propagation sufficient thrombin is generated for the clotting of 
soluble fibrinogen to form a fibrin meshwork. 
From De Caterina R et al. General mechanisms of coagulation and targets of anticoagulants. Thrombosis and 
Haemostasis. 2013; 109: 569-579.90 
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ANTITHROMBOTIC THERAPY FOR THE PREVENTION OF STROKE AND SYSTEMIC EMBOLISM IN 
ATRIAL FIBRILLATION 
The oral anticoagulants (OAC) include the vitamin-K antagonists (VKA) (most commonly 
warfarin) and direct oral anticoagulants (DOAC). Both groups are highly effective at 
preventing ischaemic strokes in AF 91-96, but differ significantly in their mechanism of 
inhibition within the clotting cascade (figure 1.7), prescribing and monitoring requirements. 
 
 
Figure 1.7 Coagulation cascade and site of inhibition for warfarin and DOAC. 
 
Vitamin K is essential to the production of several coagulation factors including factors II, VII, 
IX and X, as well as regulatory factors protein S and C. VKAs competitively inhibits vitamin 
K epoxide reductase complex 1, an essential enzyme for activating Vitamin K.  
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VKAs have been successful in reducing the risk of stroke97, with a meta-analysis of 29 
trials including 28,044 patients concluding dose adjusted warfarin conferred an approximate 
two-thirds reduction in stroke.91 Despite their effectiveness, there are a number of practical 
limitations to the use of VKAs including the high intra and inter-patient variability in response 
and the requirement to monitor and dose adjust according to the International Normalised Ratio 
(INR). Guidelines recommend maintaining an INR between 2 to 3.87, 98, 99 Increased INR is 
associated with increasing risk of bleeding while subtherapeutic INR increases the risk of 
stroke and systemic embolism. The net clinical benefit of warfarin is associated with the 
proportion of time that INR values are maintained within the therapeutic range, referred to as 
the time in therapeutic range (TTR).100, 101 TTR> 70% is associated with the greatest reduction 
in stroke and least bleeding events102 while TTR<50% offers no greater stroke protection than 
no therapy.100 
In earlier placebo controlled trials, aspirin was reported to offer a 42% reduction in 
stroke and systemic embolism events (6.3% vs 3.6% per year).103 However, further studies and 
a meta-analysis of seven trials comparing aspirin and placebo in patients with AF with 
additional risk factors for stroke concluded that the stroke risk reduction with aspirin was a 
more modest and non-significant 20% reduction.91  
In comparison with VKAs, aspirin provides far less reduction in stroke but confers as 
high a bleeding risk as OAC.104 The Birmingham Atrial Fibrillation Treatment of the Aged 
study (BAFTA) randomised patients ≥75 years with AF to either warfarin (target INR 2-3) or 
aspirin 75mg once daily (published 2007). Mean follow up was 2.7years, the yearly risk of the 
primary-endpoint of fatal or disabling stroke, intracranial haemorrhage, or clinically significant 
arterial embolism in warfarin group occurred in 1.8% vs 3.8% for the aspirin group; absolute 
yearly risk reduction 2%, 95% CI 0·7–3·2. The yearly risk of extracranial haemorrhage was 
1.4% warfarin vs 1.6% (aspirin); absolute risk reduction 0.2%, 95%CI -0.7 - 1.2%. 
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The ACTIVE-W trial tested combination antiplatelet therapy (aspirin plus clopidogrel 
versus warfarin in patients with AF. However, this trial was stopped early because of clear 
evidence of superiority of OAC in reducing vascular events (stroke, SEE, MI or vascular death) 
and a lower risk of major bleeding with OAC.105  
Despite the above trials showing superiority of VKAs, aspirin continued to be 
prescribed in AF, in part due to the recognition of the unsuitability of warfarin for many 
patients, intensive monitoring requirements, extensive interactions with other medicines and 
food and, importantly patient refusal of this treatment.106 
The DOACs include the factor Xa inhibitors apixaban, edoxaban and rivaroxaban and 
the direct thrombin inhibitor dabigatran. In comparison to VKAs, the DOACs are prescribed 
at fixed doses, require infrequent monitoring and dose adjustment based only on weight, age 
and renal function.  
In 2011 the AVERROES RCT tested apixaban vs aspirin in 5599 patients in whom 
VKA therapy was unsuitable.104 The trial was stopped early due to superiority of apixaban; the 
primary outcome of stroke or systemic embolism was 1.6% per year in the apixaban group and 
2.7% per year in the aspirin arm (HR with apixaban, 0.45; 95%CI, 0.32-0.62, P<0.001). There 
was no significant difference in major bleeding events (1.4 vs 1.2%, P=0.57). 
In 2012 the ESC updated their AF guidance with the withdrawal of aspirin for stroke 
prevention in AF107, followed by the National Institute for Health and Care Excellence (NICE) 
doing so in 2014.108 International guidelines now recommend OAC in all patients with AF 
except those as the lowest risk of ischaemic stroke where the risk of bleeding may exceed the 
net benefit from reduction in stroke.87, 109  
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Trials comparing each of the DOACs vs warfarin showed a decrease in overall bleeding 
events with DOACs93, 95, 96, 110 with some also showing a reduction in stroke or systemic 
embolism93, 96 and a reduction in mortality.93 
 
CLINICAL RISK SCORES FOR STROKE AND BLEEDING RISK IN PATIENTS WITH ATRIAL 
FIBRILLATION 
The risk of stroke or systemic embolism amongst patients with AF is dependent on various 
clinical and echocardiographic features. Understanding the individual’s stroke risk is necessary 
to inform decisions on anticoagulation, which can be a delicate balance between decreasing 
stroke risk and increasing the risk of bleeding.  
 Several risk stratification tools based on small population observational studies have 
been available111, 112, however, the CHA2DS2-VASc score developed using data from large 
registries and surveys, provides a simple and validated method of calculating annual stroke risk 
for which decisions on prescribing anticoagulation can be based.113  
The risk of stroke in patients with AF using the CHA2DS2-VASc score is calculated as: 
(Congestive heart failure, 1point; hypertension, 1 point; age 65-74, 1 point, age≥75, 2 points, 
diabetes, 1 point; prior stroke or TIA, 2 points and vascular disease [prior MI, peripheral 
vascular disease or aortic plaque], 1point). As the CHA2DS2-VASc score increases so does the 
adjusted annual risk of stroke (table1.1). International guidelines recommend considering 
prescribing OAC in patients with a risk score of ≥1 in males and ≥2 in females.87, 109  
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Table 1.1 Adjusted stroke rate based in CHA2DS2-VASc score 











*for CHA2DS2-VASc score ≥7 there was insufficient power to accurately 
calculate the stroke rate.  
Adapted from Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk 
stratification for predicting stroke and thromboembolism in atrial 
fibrillation using a novel risk factor-based approach: the euro heart survey 
on atrial fibrillation. Chest 2010; 137: 263-272. 
 
The benefits of stroke prevention with OAC needs to be carefully balanced with the increase 
risk of bleeding. Risk factor scores have been predominantly developed based in patients 
prescribed VKA including the HAS-BLED (hypertension [uncontrolled, >160mmHg systolic], 
1 point; abnormal renal/liver function, 1 point each; history of stroke, 1point; bleeding history 
or predisposition, 1point; labile INR, 1 point; 1 Age >65years, 1 point; drugs/alcohol 
(antiplatelet agents, non-steroidal anti-inflammatory agents) 1 point each (table 1.2).114 The 
HAS-BLED score was developed from the data from a cohort of 3,978 patients prescribed 
VKA and enrolled in the Euro Heart Survey on AF (a European registry). The predictive 
accuracy in the cohort (C statistic 0.72) was consistent when applied across multiple subgroups. 
The HAS-BLED score has since been incorporated into international guidelines on AF 
management.87, 109 
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Stroke and bleeding risk factors can overlap. However, where the stroke risk calculated 
from the CHA2DS2-VASc can only increase, the bleeding risk calculated with the HAS-BLED 
score is partially modifiable and is intended to be used to identify and manage risk factors for 
bleeding. In patients with a high bleeding risk, it is recommended that bleeding risk factors be 
identified and managed, rather than withholding OAC where possible.87 
 
Table 1.2 Adjusted bleed rate in HAS-BLED score  
HAS-BLED score Adjusted bleed rate 
(%/year) 





Adapted from Lip GY, Nieuwlaat R, Pisters R, et al. Refining 
clinical risk stratification for predicting stroke and thromboembolism in 
atrial fibrillation using a novel risk factor-based approach: the euro heart 
survey on atrial fibrillation. Chest 2010; 137: 263-272. 
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ATRIAL FIBRILLATION IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY 
INTERVENTION 
IHD is a risk factor for developing AF and similarly hypertension, increasing age and left 
ventricular dysfunction are shared risk factors for both IHD and AF. Approximately 10% of 
patients undergoing PCI have AF, although estimates vary from 6-12%.115-117 Furthermore, 
new-onset AF has been reported to occur in ~6-8% of patients within 7days of PCI.118, 119 
The presence of AF in patients undergoing PCI represents a clinical challenge. DAPT 
is recommended to prevent in-stent thrombosis and coronary artery occlusion in patients 
undergoing PCI for both ACS and elective stenting.27, 48 In patients with AF, OAC been shown 
to be superior to the combination of aspirin and clopidogrel in preventing vascular events 
(stroke, systemic embolism, myocardial infarction(MI) and death).120 The combination of 
DAPT plus OAC, referred to as triple antithrombotic therapy (TAT) may provide both coronary 
and cerebral protection but increases the risk of bleeding.121-123  
Despite this relatively common clinical dilemma, prospective trials, real-world 
observational studies and registry data investigating optimal antithrombotic therapy in AF 
patients undergoing PCI have been sparse. The What is the Optimal Antiplatelet and 
Anticoagulant Therapy in Patients with Oral Anticoagulation and Coronary Stenting (WOEST) 
trial was the first prospective randomised trial to test the use of clopidogrel alone with OAC 
versus TAT in patients undergoing PCI where there was an additional indication for OAC.123 
In this small trial of 573 patient with follow up for one year there were fewer bleeds in the 
OAC+AP group 19.4% vs 44.4% in the TAT group (HR 0.36, 95% CI 0.26-0.50, P<0.0001), 
although the reduction in bleeding was particularly confined to minimal and minor bleeding 
events, with a non-statically significant reduction in major bleeding. There was no increase in 
thrombotic events, including MI, target vessel revascularisation and stroke. However, this 
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small open label study had a number of limitations, including low numbers to assess differences 
in thrombotic outcomes, procedural antithrombotic therapy was not described, and the trial 
included patients with indication for OAC other than AF. Despite these limitations this study 
was the first prospective study to assess TAT vs OAC+AP antithrombotic therapy in patients 
undergoing PCI with indications for OAC. 
Studies utilising Danish registry data have analysed the risk of MI/coronary death, 
ischaemic stroke, and bleeding according to multiple antithrombotic therapy regimens in 
patients with AF hospitalised with MI and /or undergoing PCI between 2001-2009.124 
Compared to TAT, bleeding risk was non-significantly lower for OAC+clopidogrel (HR 0.78, 
95% CI: 0.55 to 1.12) and significantly lower for OAC+aspirin and aspirin+clopidogrel. There 
was no increased risk of recurrent coronary events with either OAC+clopidogrel (HR 0.69, 
95%CI 0.48-1.00), OAC+aspirin (HR 0.96, 95%CI 0.77-1.10) or aspirin+clopidogrel (HR 
1.17, 95%CI 0.96-1.42), but aspirin+clopidogrel was associated with increased risk of stroke 
(HR1.50, 95%CI 1.03-2.20) vs TAT. The low rate of PCI (<50%) amongst the population, lack 
of prospective randomisation, and potential for cofounding limits the generalisability of these 
data to contemporary PCI population. 
Recent RCT have investigated DOAC vs VKA based TAT and OAC+AP strategies in 
patients with AF undergoing PCI or with recent ACS.40, 42-44 These studies have demonstrated 
lower bleeding events with DOAC based strategies and lower bleeding events with OAC+AP 
compared to TAT with the exception of the edoxaban based trial which was non inferior to 
VKA. 
These trials demonstrated lowering bleeding events amongst patients receiving DOAC 
(bleeding event rate ranged from 10.5% to 17% depending on trial) compared to 14.7% to 
26.7% amongst patients receiving VKA. These trials were underpowered to examine ischaemic 
outcomes and therefore the optimal antithrombotic strategy that minimises bleeding events 
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while also preventing stroke and recurrent coronary ischaemic events is still unknown. 
Furthermore, these trials included patients that were primarily undergoing elective PCI for 
stable angina or medically managed ACS patients. Therefore, these results may not be 
applicable to the contemporary PCI population which predominantly undergo PCI for an ACS. 
Despite the limitations in the data, these prospective trials provide the best evidence to 
guide practice in managing this clinical situation. Current European and North American 
guidelines recommend a tailored approach to prescribing antithrombotic therapy in this 
population based on thrombotic and bleeding risk, and thus limiting overall exposure to TAT 
(figure 1.8).125, 126 
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Figure 1.8 Management algorithm for AF patients presenting with elective PCI or ACS 
undergoing PCI. 
From Lip et al. Eur Heart J. 2018; 39: 2847-2850.125 
 
  
Chapter one  33 
USING REAL-WORLD DATA TO IDENTIFY AND DESCRIBE GAPS IN THE DELIVERY 
OF THE EVIDENCED BASED MEDICINE 
Despite an extensive evidence base into the management of IHD and AF, the delivery of 
evidence-based medicine is frequently suboptimal. Identifying and characterising gaps in the 
management of patients has the potential to improve clinical outcomes and reduce the burden 
of disease at both an individual and population level. The following provides a brief outline of 
the objectives of each of the results chapters presented in this thesis: 
 
OBJECTIVES OF CHAPTER 2 
Real-world data on antiplatelet use post-PCI suggests that delay in access or premature 
discontinuation of P2Y12 antagonist treatment is associated with an increase in adverse 
outcomes.127, 128 However, these studies have not taken account of the intended duration of 
therapy or bleeding events that may occur, resulting in cessation of antiplatelet treatment.  
 Our objectives were (i) to analyse the early discontinuation rate of P2Y12 antagonists 
post PCI, (ii) explore factors associated with early discontinuation and (iii) analyse the risk of 
major adverse cardiovascular events (MACE: death, acute coronary syndrome, 
revascularisation or stroke) associated with discontinuation from a pre-specified prescribing 
instruction of one year.129 
 
OBJECTIVES OF CHAPTER 3 
In September 2019 the European Society of Cardiology & European Atherosclerosis Society 
updated their guidelines for the management of dyslipidaemia, recommending more intensive 
lowering of lipids in patients with known or at high risk (or above) of CVD. It is unknown 
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what proportions of patients at very high CVD risk achieve, or do not achieve, recommended 
levels of LDL-C (non-HDL-C) and/or TGs; and how these respective patient groups are treated. 
The objectives of this study were to document (i) lipid lowering treatment (LLT) and (ii) 
achievement of prior and current ESC/EAS lipid targets in a contemporary national cohort of 
patients post-percutaneous coronary intervention (PCI), who would be considered to be at very 
high CVD risk according to the ESC/EAS classification.130 
 
OBJECTIVES OF CHAPTER 4  
In patients with non-valvular atrial fibrillation (NVAF) prescribed warfarin, the UK National 
Institute for Health and Care Excellence (NICE) defines poor INR control as a TTR of <65%, 
any 2 INRs within a 6-month period of ≤1.5 (“low”), 2 INRs ≥5 within 6months, or any INR 
≥ 8 (“high”).  
Variability in INR control described by frequency of very low or very high INRs (as 
defined by NICE), as distinct from TTR, has not been previously described. The objectives of 
this study were (i) to quantify the number of patients with NVAF prescribed warfarin who 
exhibit NICE-defined poor INR control and (ii) describe the demographic and clinical 
characteristics of these patients, as well as the relationship between these characteristics and 
poor INR control.131 
 
OBJECTIVES OF CHAPTER 5 
In patients with NVAF prescribed warfarin, the association between guideline defined ‘poor’ 
INR control and bleeding outcomes has not been fully characterised. The objectives of this 
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study were to (i) quantify bleeding rates, and (ii) evaluate associations between bleeding, 
comorbidities, and poor INR control. 
 
OBJECTIVES OF CHAPTER 6 
Real world data examining outcomes in patients with AF who have undergone PCI are limited 
and the association between bleeding and ischaemic outcomes has not been fully evaluated. 
Our objectives were to analyse the rate of hospitalisation for major cardiovascular events, 
haemorrhage and mortality in patients with AF in the first year after successful PCI, accounting 
for risk factors and antithrombotic regimen.   
 
OBJECTIVES OF CHAPTER 7 
In this conclusion chapter we bring together the key themes from this thesis; summarise the 
gaps identified in the provision of evidenced based medicine, discuss the strengths, and 
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METHODS 
This section provides detail on how I collected, processed, and analysed the data used in this 
Ph.D. Acquiring and processing the cardiac intervention and discharge prescribing datasets, as 
well as the identification of the extensive list of codes used for the classification of 
cardiovascular disease, haemorrhagic events, comorbidities, risk factors, and medicines 
represented a substantial proportion of the time taken to complete this Ph.D. Therefore, I have 
given additional emphasis on those processes here. In addition, the methodology specific to 
each of the studies is contained within the respective outcome chapters. 
 
SECURE ANONYMISED INFORMATION LINKAGE DATABANK 
The data used in this Ph.D. was predominantly accessed and processed using the Secure 
Anonymised Information Linkage (SAIL) Databank.132-134 SAIL is part of the national 
electronic-health records research infrastructure for Wales and contains anonymised data that 
is routinely collected from health and social care systems. The following core datasets held 
within SAIL were used for this PhD: the Patient Episode Database for Wales (PEDW),135 
which records hospital admission and discharge dates, diagnoses and operational procedures, 
demographic data, and date of death where applicable, for patients attending hospital in Wales; 
the Welsh Longitudinal General Practice (WLGP) dataset136 containing demographic, clinical 
and prescribing data for approximately 80% of primary care practices across Wales; the Welsh 
Demographic (WDS) dataset,137 which contains basic demographic information and history of 
individuals’ residence in Wales and registration with GP practices; and the Welsh Index of 
Multiple Deprivation (WIMD) 2011,138 an area-based deprivation measure. Further detail on 
some of these core datasets is provided later in this chapter. 
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GOVERNANCE, ETHICS AND APPROVALS  
SAIL provides a secure environment for the processing of person-based data and does not 
receive or handle identifiable data. The anonymised data is only made available for research 
projects that offer a potential for benefit and those that have been approved by an information 
governance review panel (IGRP). The IGRP contains independent members from the National 
Research Ethics Committee (NREC) and British Medical Association (BMA), as well as lay 
members of the public.  
Each of the studies presented within this Ph.D. used anonymised patient data that is 
routinely collected for clinical and administrative purposes; therefore, a separate ethics 
approval was not required, however, each study was approved by the SAIL IGRP.  
In line with standard operating procedures for both SAIL and Swansea Bay University 
Health Board (SBUHB), permission was granted from the data holder of the Cardiac 
intervention dataset, Dr Geraint Jenkins for the use of that data within this Ph.D. The SBUHB 
Caldicott guardian approved accessing and transfer of both the cardiac intervention and 
discharge medication dataset to SAIL. 
 
PROCESSING OF DATA WITHIN THIS THESIS 
In this chapter, I have detailed sections of pertinent methodology that I believe will help explain 
and justify each of the steps taken from identifying and accessing data to analysing and 
presenting. I have provided examples of the structured query language (SQL) I used for data 
linkage and data processing with examples of the outputs from my SQL queries; these 
examples are provided to highlight relevant steps, and I have endeavoured to provide these in 
a chronological order.  
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I have concentrated on detailing the methodology from chapter two; this was the first 
study that I undertook within this thesis, it is where I developed much of the methodology and 
created lists of diagnostic, comorbidity, risk factor and prescribing codes that were utilised in 
subsequent chapters. It also describes the additional process of managing a dataset external to 
the SAIL databank and transporting that data into SAIL.  
  
CORONARY INTERVENTION DATASET 
In addition to the core datasets held within SAIL, for chapter two it was necessary to identify 
patients undergoing percutaneous coronary intervention (PCI) from the Regional Cardiac 
Centre at Morriston Hospital and record their discharge prescribing data relevant to the 
admission. These patients were identified from the coronary intervention dataset held at the 
centre. This dataset contains demographic, procedural (form of PCI undertaken; stent type, 
number and position, and antithrombotic strategy) and clinical data (presenting 
electrocardiogram (ECG), indication for PCI, comorbidities, and risk factors). Data held within 
this dataset is entered at the time of the procedure by the medical team performing the 
intervention.  
 
DISCHARGE PRESCRIBING DATA 
For patients discharged home following PCI from the regional centre, their discharge 
medication list was identified from the SBUHB electronic transfer of care (ETOC) or discharge 
system. The ETOC system provides a summary of information for the patients GP regarding 
their admission to hospital. The medication section of the ETOC details changes to the patient’s 
medicines including those that were stopped, dose changes and new medicines that were started 
and intended durations. 
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Initially the individual patient discharge medication regimen was identified by 
manually searching the ETOC system for records correlating to the admission period for the 
PCI. However, this process was laborious and extremely time consuming. With thanks to Mr 
John Fitzgerald from the SBUHB information technology department we were able to link the 
demographic data and date of intervention from the cardiac intervention dataset to the ETOC 
system to automate the download of prescription data for the corresponding hospital admission. 
Where there was either no medication entered on the ETOC or no ETOC for the hospital 
admission the patient’s medical notes were screened for a paper record of the discharge 
prescription, these data was then entered into a spreadsheet and checked by a second person 
for transcription errors.  
 
ANONYMISATION OF PERSON DATA 
Datasets transferred to SAIL such as the coronary intervention dataset and prescribing dataset 
require an anonymisation process to protect personal identifiable data (figure 1.9). Firstly, 
demographic data is split from any clinical or event component. Both of these files have a 
unique identifier applied. The demographic data is transferred to the NHS Wales Informatics 
Service (NWIS) and the clinical information with unique identifier is transferred to SAIL.  
NWIS anonymises and encrypts the demographic data. Each individual record is 
assigned an Anonymous Linking Field (ALF). This anonymised demographic data is then sent 
to SAIL to be recombined with the clinical data. As a final safeguard SAIL further encrypts 
the ALF to a project encrypted ALF (ALF_PE) before the data is made available. The ALF_PE 
is a unique identifier, assigned to each individual. Within each project, the same individual can 
be identified from each of the core datasets using the ALF_PE. 
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Figure 1.9 Example of anonymisation of datasets for transfer and use within SAIL. 
 
PROCESSING DISCHARGE PRESCRIBING DATASET WITHIN SAIL 
The discharge prescribing dataset contained the following columns: ALF_PE; date of 
intervention; drug name, strength, direction, and duration. Data within the drug name and 
strength columns contained a mixture of structured and unstructured data, while all the data 
within the direction and duration columns were unstructured due to it being manually entered 
into the ETOC system. The drug name column contained both capitalised and lowercase forms 
for the same drug and the misspelled names (figure 1.10); strength may be presented as 
‘milligrams’, ‘MG’ or ‘mg’ or ‘75mg’ and ‘75 mg’, and there were numerous ways of 
expressing the same duration (figure 1.11). Searching or selecting data in this unstructured 
format would be liable to error and inefficient so it was necessary to format or ‘clean’ the data 
into a structure that could easily be processed (figure 1.12).  
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Figure 1.10 SQL query displaying the frequency of drug names and highlighting the spelling 
& misspelling of clopidogrel. 
 
Figure 1.11 SQL showing different durations for clopidogrel 
select count (drug), drug from sail0441v.saildrug 
group by drug 
 4530 ASPIRIN 
 3424 CLOPIDOGREL 
 2167 ATORVASTATIN 
 1879 SIMVASTATIN 
 1485 LANSOPRAZOLE 
 1099 RAMIPRIL 
  946 GLYCERYL TRINITRATE 
  922 CLODPIDOGREL 
  // 
  19 clopidogrel 
 
select count (duration),duration from sail0441v.saildrug d 
where  d.drug like '%CLO%' 
group by duration 
841 1 YEAR 
746 1YEAR 
518 12 Months 
419 12 MONTHS 
331 1 Year(s) 
302 12 Month(s) 
225 1 MONTH 
110 Ongoing 
92 1 Month(s) 






30 1 month 
28 1 Months 
28 6 Months 
26 3 Months 
24 3 Month(s) 
20 30 Day(s) 
17 ONGOING 




13 28 Day(s) 
12 6 MONTHS 
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Figure 1.12 SQL used to ‘clean’ and structure the prescribing data 
 
create  table sailw441v.saildrug_ammend as( 
select d.*, 
d.duration as duration_orig,  case when duration in ('12MONTHS','12 months','1 YEAR-
','1YEAR','1year','12 Month(s)','1 MONTH FOLLOWED BY 75MG OD FOR ONE YEAR','1 YEAR','12 
MONTHS','12 months','12 MONTHS FOR GP TO REVIEW','1 Year(s)','12 MonthS','12 MONTHD','1 
year','1YEAR','12 Months') then '1 year'           -- 1 year 
 when duration in ('30 days','12 months','ONE MONTH','1 Month','1 Months','30 
Day(s)','28 Day(s)','30 Days','4 Week(s)','31 Days','28days', 
     '4 Weeks','28 Days','1 MO0NTH','1 MO0NTH','28 DAYS','1 month','4 WEEKS','28 
Day(s)','1 Month','1 Month(s)','1MONTH','1month','4 Weeks','28 DAYS','30 Days','31 
Days','1 Months','1 MONTH') then '1 month'           -- 1 month 
     when duration in ('1 Week(s)','14 Day(s)','4 Day(s)','5 Day(s)','15 Day(s)','2 
weeks','12 Days','7 Day(s)','3 Days','1 week','1 WEEK', 
     '2 Week(s)','20 Day(s)','7 Days','22 Day(s)','3 Day(s)','3 Days','13 Day(s)','18 
Day(s)','18 Days','2 WEEKS DUE TO RAPID ENDOTHELIASATION OF GENOUS STENT', 
     '24 Day(s)','5 Days','4 Days','21 DAYS','22 DAYS','25  DAYS','26 DAYS','stop on 
discharge','18 days','3 Days','less than 1 month','14 DAYS','25 days') 
      then 'less than 1 month'     
     when duration in 
('ONGOING','INDEFINITELY','INDEFINTELY','life','l','lifelong','lIFELONG','liFELONG','LON
G TERM','Ongoing','INDEFINITELY','INDEFINTELY','ongoing','Life 
Long','LIFELONG','lifeLONG','ONGOING','L','life','LONGTERM','LiFELONG') then 'life' 
     when duration in('6 Months','6 MONTHS','6MONTH','6 months','6 
Month(s)','6months','6 MONTHS THEN REPLACED WITH WARFARIN') then '6 months' 
     when duration in('3 Months','3 Month(s)','3MONTH','3months','3 
months','3MONTHS','90 Day(s)','3 MONTHs') then '3 months' 
     when duration in('U','u','UNSPECIFED','unspecified','uNSPECIFIED','UNSPECIFIED') 
then 'unspecified' 
else duration end as duration_ammended, 
 d.drug as drug_orig, case  when drug in 
('CLOPIDOGREL','CLODPIDOGREL','clopidogrel') then 'clopidogrel' 
 when drug in('aspirin','ASPIRIN','ASPIRIN E/C','ASPIRIN EC','ASPIRIN M/R') then 
'aspirin' 
 when drug in ('warfarin','WARFARIN','WARFARIN SODIUM') then 'warfarin' 
 when drug in ( 'ATORVASTATIN','ATORVASTAIN','ATORVASASTATIN','ATORVSTATIN') then 
'atorvastatin' 
 when drug in 
('simvastain','simvastatin','SIMVASTATIN','simvastatn','SIMWASTATIN') then 'simvastatin' 
 when drug in ('prasugrel','PRASUGREL','PRASUGREL 10MG TABLETS','PRASUGREL 5MG 
FILM COATED TABLETS') then 'prasugrel' 
 else drug end as drug_ammended,  
 d.strength as strength_orig,  case when strength in ('80mg','80MG','80 
mg','80','80 MG') then '80' 
 when strength in ('40mg od','40mg','40MG','40 mg','40 MG') then '40' 
 when strength in ('20mg','20MG','20 mg','20 MG') then '20' 
 when strength in ('10MG','10mg','10 mg','10 MG') then '10' 
 when strength in ('60 MG','60MG','60mg') then '60' 
 when strength in ('30MG') then '30' 
 when strength in ('25mg') then '25' 
 when strength in ('50MG') then '50' 
  
 else strength end as strength_ammended 
 
from sail0441v.saildrug d)with no data; 
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At this point we had obtained a list of patients (anonymised to an ALF_PE) who had undergone 
a PCI at Morriston hospital, the date of PCI and a list of medications prescribed at discharge. 
The next step was to create datasets of hospital admissions, discharges and diagnoses to 
identify admission dates and discharge dates relevant to the PCI and use this dataset to describe 
comorbidities and patient outcomes of interest.  
 
PATIENT EPISODE DATABASE FOR WALES AND HOSPITAL CODING STANDARDS 
Before describing the process in creating hospital datasets, I will take the opportunity to explain 
how data from a patient hospital admission is collected and processed. 
For each patient hospitalised in Wales, the Patient Episode Database for Wales (PEDW) 
records the admission and discharge dates, diagnoses and operational procedures and 
demographic data.135 Date of death is also recorded when the patient dies within hospital. These 
records are completed at ‘finished consultant episode’ (FCE). Within each FCE, one primary 
and one or more secondary diagnosis using the International Classification of Disease, 10th 
Revision (ICD-10) is recorded.  
The International Statistical Classification of Diseases and Related Health Problems, 
Tenth Revision 4th Edition (ICD-10), is a standardised coding system for both mortality (cause 
of death) and morbidity (diagnoses). The classification of mortality and morbidity using the 
ICD-10 system is a mandatory national requirement for NHS. This includes both day cases, 
scheduled and unscheduled hospital care. The ICD-10 system translates diagnoses and cause 
of death to alpha-numeric codes. The use of these codes allows for the easy storage and retrieval 
of information. These data are collected and stored in datasets such as the Hospital Episodes 
Statistics (HES) in England, Patient Episode Data for Wales (PEDW), Scottish Morbidity 
Chapter one  44 
Records (SMR), Cancer Registries, National Service Frameworks, Care Pathways, 
Performance Indicators, Commissioning Data Sets and other Central Returns. 
Clinical coders apply the ICD-10 codes according to an established criterion, providing 
consistent information for statistical purposes. Clinical coders use the medical record to assign 
the ICD-10 codes. The medical record may contain handwritten or computerised record, 
correspondence, discharge letters, clinical work sheets, care pathways and diagnostic test 
reports.   
For example, Patient X is admitted to Princess of Wales Hospital in Bridgend for an 
Acute Myocardial Infarction (AMI) on the 1st of February 2016. Patient X remains solely under 
the care of Consultant A for the next seven days and is then discharged home. Within the 
medical notes it is written that Patient X had a MI. In this case there is one FCE and the ICD-
10 code I21.9 (Unspecified MI) is applied by the clinical coder. In this same example, if ST-
Elevation Myocardial Infarction or STEMI had been written in the notes then I21.3 (Acute 
transmural myocardial infarction of unspecified site) would be applied. Similarly, if Non-ST 
Elevation Myocardial Infarction or NSTEMI had been written then I21.4 (Acute 
subendocardial myocardial infarction) would be applied.   
If this episode had occurred before the 1st April 2015 then I21.9 would have been 
applied for either MI, STEMI or NSTEMI before this date. If the patient had a documented 
‘STEMI of the inferior wall’ then the code I21.1 (Acute transmural myocardial infarction of 
inferior wall) would be applied regardless if this episode was before or after the 1st April 2015. 
Hence the code applied is dependent on the detail of the diagnoses written in the medical record 
and whether it occurred before or after a change in the criteria for coding was applied on the 
1st April 2015. 
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ICD-10 codes are applied per FCE. For patients transferred between hospitals ≥ 1 FCE 
will be recorded and if a patient is transferred between consultants within a single hospital, 
then an FCE will apply to each consultant episode. 
 Clinical coding for patients who present with acute coronary syndromes (ACS) is 
particularly challenging as the care may be transferred between multiple consultants at different 
hospitals and between separate organisations or health boards. Within SAIL, consecutive FCE 
within a single hospital admission are grouped as patient ‘spells’ and where patients are 
transferred between hospitals during a single period of care spells are grouped into 
‘superspells’ (figure 1.13).  
Figure 1.13 Schematic of classifications of spells and superspells during a single period of care 
at multiple hospitals 
 
Clinical coders apply ICD-10 codes to co-morbidities that a patient may present with but only 
if it is documented in a patient’s notes. For example, in a patient presenting with an MI who 
also has hypertension written in the notes then ICD-10 codes I21.9 (unspecified MI) and I10.x 
(Essential (primary) Hypertension) would be recorded in a secondary position. If the patient 
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was known to be hypertensive either from blood pressure recording documented on the 
observation chart or previously diagnosed prior to the admission but not recorded in the 
medical notes the diagnosis of hypertension cannot be inferred by the coder and therefore 
cannot have the relevant ICD-10 code applied. Likewise, atrial fibrillation observed on an 
electrocardiograph (ECG) but not written in the medical notes will not be documented by a 
clinical coder. 
 
CLASSIFICATION OF INTERVENTIONS AND PROCEDURES 
Operational and procedural codes are also applied for each FCE following the Office of 
Population Censuses and Surveys Classification of Interventions and Procedures version 4 
(OPCS-4). Clinical coders apply OPCS-4 codes to the procedures recorded in the medical 
record for each consultant episode within the hospital provider spell.  
Following expert advice from Miss Tracy Francis, Lead Clinical Coding Auditor for 
SBUHB and then scrutiny and agreement between Prof. Halcox, Dr Dave Smith and myself 
we collated a list of OPCS-4 codes to identify patients who have undergone PCI (and also 
revascularisation by CABG) (see chapter two supplementary table 3). 
 
CREATING HOSPITAL DATASETS 
Within SAIL hospital datasets were created by linking together the individual tables containing 
details of spells (including start and end date, route of admission, individual hospital code), 
superspells, diagnostic and/or operational codes for the relevant patients (ALF_PE) (figure 
1.14). Following this it was necessary to group and chronologically order the spells within each 
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superspell and identify the date of the first spell (true admission date) and the date of the last 
spell (true discharge date) (figure 1.15).  
 
 
Figure 1.14 SQL for creating hospital tables 
  
create table sailw441v.aspice_hosp_OPCS_data as( 
--insert into sailw441v.aspice_hosp_OPCS_data 
select distinct ops.*,aspice.system_ID_PE 
from sail0441v.apice_alf aspice 
inner join 
 
(SELECT DISTINCT spell.ALF_PE,AGE_EPI_STR_YR, SPELL.admis_dt AS SPELL_START,  
admis_mthd_cd, SPELL.DISCH_DT, SPELL.DISCH_DESTINATION_CD, SPELL.SPELL_DUR, 
EPI.spell_num_pe, SPELL.REF_ORG_CD, EPI.EPI_STR_DT, 
EPI.epi_end_dt, EPI.epi_dur,EPI.epi_num, x.oper_cd_123, X.OPER_DESC_123, 
z.oper_cd,z.oper_desc_4, OPER.OPER_num,SPELL.DUR_ELECT_WAIT, 
EPI.CON_SPEC_CD_OF_TREAT, 
EPI.prov_unit_cd,EPI.CURR_PROV_UNIT_CD, super.person_spell_num_PE, dense_rank() 
over (partition by spell.alf_pe, super.person_spell_num_pe order by 
spell.admis_dt)  
as spell_seq FROM SAIL0441V.PEDW_SPELL_20160420 SPELL 
 
INNER JOIN SAIL0441v.PEDW_EPISODE_20160420 EPI 
ON SPELL.PROV_UNIT_CD = EPI.PROV_UNIT_CD  
AND SPELL.SPELL_NUM_PE = EPI.SPELL_NUM_PE  
left JOIN SAIL0441v.PEDW_DIAG_20160420 DIAG 
ON SPELL.PROV_UNIT_CD = DIAG.PROV_UNIT_CD 
AND SPELL.SPELL_NUM_PE = DIAG.SPELL_NUM_PE 
and EPI.epi_num = DIAG.epi_num 
left JOIN SAIL0441V.PEDW_OPER_20160420 OPER 
ON SPELL.PROV_UNIT_CD = OPER.PROV_UNIT_CD 
AND SPELL.SPELL_NUM_PE = OPER.SPELL_NUM_PE 
and EPI.epi_num = OPER.epi_num 
left JOIN SAILREFRV.ICD10_DIAG_CD y 
ON y.DIAG_CD = DIAG.DIAG_CD 
left JOIN SAILREFRV.OPCS4_OPER_CD_123 x 
on X.OPER_CD_123 = OPER.OPER_CD_123 
left JOIN SAILREFRV.OPCS4_OPER_CD z 
on z.OPER_CD = OPER.OPER_CD 
left join sail0441v.PEDW_SUPERSPELL_20160920 super 
on super.spell_num_PE = SPELL.spell_NUM_PE) ops 
 
on aspice.alf_pe = ops.alf_pe; 
)with no data ; 
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Figure 1.15 SQL code to identify start date and end date of each hospital admission  
 
Once each superspell had an identified start and end date it was necessary to identify the first 
hospital admission during the study period that corresponded with the index PCI. Hospital 
admissions occurring prior to the first admission during the study period for a PCI would then 
help inform previous diagnoses, comorbidities and prior revascularisation events. Hospital 
admissions post discharge for the index PCI would then inform the outcome events. 
 
WELSH LONGITUDINAL GENERAL PRACTICE DATASET 
The Welsh Longitudinal General Practice (WLGP) dataset136 contains demographic, clinical 
and prescribing data for approximately 80% of primary care practices across Wales. This 
dataset was joined to the patients of interest (ALF_PE), with the date of admission and 
discharge for the primary PCI. Events recorded in the WLGP were denoted as occurring before 
create table sailw441v.OPCSmaster as ( 
--insert into sailw441v.OPCSmaster 
select distinct a.*, b.min_spell_start,b.max_disch_dt from 




(select * from sailw441v.aspice_hosp_OPCS_data) h 
inner join 
(select distinct system_id_pe, person_spell_num_pe, min(spell_start) as 
min_spell_start, max(disch_dt) as max_disch_dt from 
sailw441v.aspice_hosp_OPCS_data 
group by system_id_pe, person_spell_num_pe) i 
on h.system_id_pe = i.system_id_pe 
and h.person_spell_num_pe = i.person_spell_num_pe 
and (h.disch_dt = i.max_disch_dt or h.spell_start = i.min_spell_start) 
) b 
on a.system_id_pe = b.system_id_pe 
and a.person_spell_num_pe = b.person_spell_num_pe 
order by a.system_id_pe, a.person_spell_num_pe,a.spell_seq 
) 
with no data; 
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or after the index admission. Events entered in the WLGP are recorded using Read codes which 
is a thesaurus of clinical terms and provide the standard vocabulary by which clinicians can 
record patient findings, procedures and prescription.  
PATIENT OUTCOMES, CO-MORBIDITIES AND PRESCRIPTIONS  
In order to create a list or ‘dictionary’ of relevant comorbidities, adverse events and prescribed 
drugs a number of methods were undertaken for identifying the Read, ICD-10 and OPCS-4 
codes of interest.  
Firstly, the NHS Read code browser was searched to identify the relevant codes 
documented in primary care. The Read code system is structured into sections containing 
history/symptoms; diagnostic procedures; laboratory procedures; infectious diseases; diseases 
by organ system, and drugs by organ system. Similarly, ICD-10 and OPCS-4 codes can be 
searched from the relevant online browsers.  
Using the hospital datasets, it was possible to rank the frequency of ICD-10 codes 
applied to patients identified as undergoing PCI (figure 1.16). I also searched for relevant key 
words such as ‘failure’ (figure 1.17) to identify patients with heart failure or ‘diabet’ for 
diabetes, within the hospital and GP datasets. 
NHS commissioning groups publish online list of Read codes for common conditions 
for the purpose of supporting the Quality Operating Framework (QoF). These were used to 
cross check the lists of Read codes we had identified using the above methods. 
Using these range of methods, it was eventually possible to triangulate the codes and 
agree a final list between Prof Halcox and myself. 
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Once lists of the relative diagnoses, risk factors and prescriptions had been created and 
joined to the respective hospital and GP datasets It was then possible to assign these as 
happening before (or during the index admissions) and classify as comorbidities/pre-existing 
treatment or after the admission and therefore could be used to identify outcomes of interest or 
prescriptions issued post index event. 
 The list of diagnostic codes assembled for this thesis is extensive (~100 pages). To 
avoid unnecessary documentation and printing within this written thesis I have provided these 
online:  
https://github.com/DHARRISSWAN/diagnostic_codes/blob/master/Suppl_table1_05022019.docx 
The SQL used to assemble the final chapter of this thesis (and representative of all the chapters) 




To ensure the veracity of the data a number of checks were made. During each stage of data 
processing, simple counts of patients and lines of data were made to ensure there was no 
unintended loss or gain of data. All coding was checked by a data analyst with experience of 
cardiac datasets, Dr Arron Lacey. All outputs and statistical analyses were reviewed by Prof 
Gravenor and Prof Halcox prior to submission to journals and this thesis. 
  




Figure 1.16 SQL code and results of searching hospital datasets for the word ‘failure’ 
select count (distinct alf_pe),pref_term_30, event_cd from 
sailw441v.GP_before_first 
where pref_term_30 like '%failure%' 
group by pref_term_30,event_cd 
126;Left ventricular failure;G581. 
73;Heart failure;G58.. 
49;Congestive heart failure;G580. 
29;Chronic renal failure;K05.. 
21;Seen in heart failure clinic;9N0k. 
18;Acute renal failure;K04.. 
9;Referral heart failure clinic;8HTL. 
8;Heart failure annual review;662W. 
8;Heart failure confirmed;1O1.. 
6;Compensation for renal failure;7L1A. 
6;Renal failure unspecified;K06.. 
5;Congestive heart failure monit;662T. 
<5;Heart failure norm eject frac;G583. 
<5;[D]Respiratory failure;R2y1. 
<5;End stage renal failure;K050. 
<5;Respiratory failure;H59.. 
<5;Secondary ovarian failure;C1631 
<5;[D]Respiratory failure NOS;R2y1z 
<5;Admit heart failure emergency;8H2S. 
<5;DNA heart failure clinic;9N4w. 
<5;Heart failure follow-up;8HBE. 
<5;Heart failure monit 2nd letter;9Or4. 
<5;Heart failure monitoring admin;9Or.. 
<5;[X] Hepatic failure;J625. 
<5;Acute hepatic failure;J6000 
<5;Acute left ventricular failure;G5810 
<5;Alcoholic hepatic failure;J6130 
<5;Chroncongestive heart failure;G5801 
<5;Chronic type 2 respir failure;H593. 
<5;Decompensated cardiac failure;G5802 
<5;Heart failure 6 month review;662p. 
<5;Heart failure info given to pt;67D4. 
<5;Heart failure NOS;G58z. 
<5;Heart failure resolved;21264 
<5;Other acute renal failure;K04y. 
<5;Other ovarian failure;C163. 
<5;Renal failure after care;SP154 
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Figure 1.17 SQL code and results showing the frequency of ICD-10 codes during a hospital 
admission for a PCI 
  
SELECT DIAG_CD_1234,  count (DISTINCT alf_pe ), diag_desc_4 FROM  
sailw441v.aw_Hosp_master  WHERE bafta = 'during'AND diag_num  = '1' GROUP BY 
DIAG_CD_1234,diag_desc_4  ORDER BY DIAG_CD_1234  
 
I251 13697 Atherosclerotic heart disease 
I219 4114 Acute myocardial infarction, unspecified 
I211 3871 Acute transmural myocardial infarction of inferior wall 
I210 2851 Acute transmural myocardial infarction of anterior wall 
I214 2607 Acute subendocardial myocardial infarction 
I200 1750 Unstable angina 
I249 1004 Acute ischaemic heart disease, unspecified 
R074 701 Chest pain, unspecified 
I248 532 Other forms of acute ischaemic heart disease 
I209 480 Angina pectoris, unspecified 
I212 409 Acute transmural myocardial infarction of other sites 
I213 349 Acute transmural myocardial infarction of unspecified site 
R072 297 Precordial pain 
I229 216 Subsequent myocardial infarction of unspecified site 
K831 180 Obstruction of bile duct 
C250 164 Malignant neoplasm of head of pancreas 
C155 118 Malignant neoplasm of lower third of oesophagus 
R073 117 Other chest pain 
T828 107 Oth comps of cardic & vasc prosthet devs implants & grafts 
C221 99 Malignant neoplasm, intrahep bile duct carcinoma 
I501 89 Left ventricular failure 
I258 82 Other forms of chronic ischaemic heart disease 
I48X 77 Atrial fibrillation and flutter 
I259 75 Chronic ischaemic heart disease, unspecified 
I472 70 Ventricular tachycardia 
C259 69 Malignant neoplasm of pancreas, unspecified 
T855 65 Mech comp gastrointestinal prosth devs implants & grafts 
I500 60 Congestive heart failure 
C159 59 Malignant neoplasm of oesophagus unspecified 
I460 58 Cardiac arrest with successful resuscitation 
J181 56 Lobar pneumonia, unspecified 
R17X 55 Unspecified jaundice 
K830 51 Cholangitis 
I350 49 Aortic (valve) stenosis 
R55X 49 Syncope and collapse 
K805 43 Calculus of bile duct without cholangitis or cholecystitis 
I490 41 Ventricular fibrillation and flutter 
I221 38 Subsequent myocardial infarction of inferior wall 
R060 38 Dyspnoea 
I208 36 Other forms of angina pectoris 
I442 35 Atrioventricular block, complete 
C160 34 Malignant neoplasm of cardia of stomach 
C240 34 Malignant neoplasm of extrahepatic bile duct 
I220 33 Subsequent myocardial infarction of anterior wall 
T825 32 Mech compl of other cardiac & vascular devices and implants 
C154 31 Malignant neoplasm of middle third of oesophagus 
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CONTRIBUTIONS 
The results chapters within this thesis are presented as submitted to the journals. Each of these 
chapters were drafted by myself and reviewed and amended following comments from the co-
authors. The datasets in chapters 2, 3 and 5 were created by myself with input and validation 
from Dr Arron Lacey, Ashley Akbari and Fatemeh Torabi. The SAIL team assembled the 
datasets for chapters 4 and 5 using SQL code that I provided for the TTR calculation and using 
the list of clinical codes that I developed earlier in this thesis. All statistical analyses were 
conducted by myself with the exception of the following: (i) in chapter 4, I specified all tests 
to be conducted, however, the R code for the lasso test was written by the SAIL team and the 
output was reviewed by myself, (ii) in chapter 5, I specified all analyses to be carried out, 
however, Fatemeh Torabi wrote and implemented the code for the regression analyses. I 
provided the list of and justification for the covariates to be included in the analyses as well as 
review of data and interpretation for all outputs. 
 
The results chapters within this thesis have been in the active voice with the pronoun 'we' 
throughout for consistency with published manuscripts. 
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CHAPTER 2.  
EARLY DISCONTINUATION OF P2Y12 ANTAGONISTS AND ADVERSE CLINICAL 
EVENTS POST PERCUTANEOUS CORONARY INTERVENTION – A HOSPITAL & 
PRIMARY CARE LINKED COHORT 
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ABSTRACT 
BACKGROUND 
Early discontinuation of P2Y12 antagonists post percutaneous coronary intervention (PCI) may 
increase risk of stent thrombosis or non-stent recurrent myocardial infarction.  
Our aims were (i) to analyse the early discontinuation rate of P2Y12 antagonists post 
PCI, (ii) explore factors associated with early discontinuation and (iii) analyse the risk of major 
adverse cardiovascular events (MACE: death, acute coronary syndrome, revascularisation or 
stroke) associated with discontinuation from a pre-specified prescribing instruction of one year. 
METHOD AND RESULTS 
We studied 2,090 patients (2011-15) who were recommended for clopidogrel for 12m 
(+aspirin) post-PCI within a retrospective observational population cohort. Relationships 
between clopidogrel discontinuation and MACE were evaluated over 18m follow up. 
Discontinuation of clopidogrel in the first four quarters was low at 1.1%, 2.6%, 3.7% 
and 6.1% respectively. Prior revascularisation, prior ischaemic stroke and age >80years (y) 
were independent predictors of early discontinuation. In a time-dependent multiple regression 
model, clopidogrel discontinuation and bleeding (HR=1.82[1.01-3.30] and HR=5.32[3.14-
8.94] respectively) were independent predictors of MACE as were age <49y and ≥60y (vs those 
aged 50-59y), hypertension, CKD stage 4+, prior revascularisation, ischaemic stroke and 
thromboembolism. Furthermore, in those with both bleeding and clopidogrel discontinuation 
HR for MACE was 9.34[3.39-25.70]. 
CONCLUSIONS 
Discontinuation of clopidogrel is low in the first year post-PCI, where a clear discharge 
instruction to treat for 1 year is provided. While this is reassuring from the population level, at 
an individual level discontinuation earlier than the intended duration is associated with an 
increased rate of adverse events, most notably in those with both bleeding and discontinuation.  
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BACKGROUND 
Poor medication adherence is often associated with adverse patient events across multiple 
disease outcomes. This is of particular concern in the setting of modern cardiac intervention 
with stent implantation for acute coronary syndromes (ACS) where discontinuation of 
antiplatelet therapy risks both stent stenosis and non-stent related myocardial infarction. As 
such the use of dual antiplatelet therapy (DAPT), aspirin plus a P2Y12 inhibitor, in patients 
undergoing coronary revascularization is an established treatment strategy in the prevention of 
short- and long-term thrombotic complications.1-3 
Current guidelines recommend a minimum of 12 months DAPT for patients presenting 
with ACS undergoing coronary PCI with stent implantation, reduced to at least 6 months in the 
presence of risk factors for bleeding.4, 5 In patients with stable coronary artery disease, a 
minimum of 6 months is recommended following drug eluting stents (DES) implantation and 
at least one month following a bare metal stent (BMS) or in those with a high risk of bleeding. 
The presence of comorbidities such as atrial fibrillation (AF) may necessitate the need for 
concomitant anticoagulation and therefore shorter durations of DAPT may be warranted. 
Likewise, the need to undergo surgery in the future may also mandate shorter durations of 
DAPT. 
A number of observational studies have shown that an increase in major adverse cardiac 
events (MACE) is associated with a delay in access to prescriptions for P2Y12 inhibitors 
following coronary PCI,6, 7 or premature discontinuation following a myocardial infarction 
(MI) or stent implantation.8-13 Rates of discontinuation vary between studies with some 
reporting 13% discontinuation within 30 days,10 and others up to 40 to 50% within one year. 8, 
9 However, these studies have not identified the intended duration of therapy post discharge or 
taken account of comorbidities that may warrant shorter durations of DAPT. Furthermore, the 
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study populations were predominantly medically treated ACS,8, 14 or in case of the PARIS 
registry, predominantly stable angina patients undergoing PCI.15  
Our objectives were to (i) analyse the rate of early discontinuation of clopidogrel 
following discharge from hospital in a post PCI population where the duration of DAPT was 
specified for one year (ii) explore potential factors associated with discontinuation in 




We undertook a retrospective observational cohort study using linked anonymised healthcare 
data from the Secure Anonymised Information Linkage (SAIL) Databank,16, 17 for patients 
undergoing PCI at a tertiary cardiac centre in Wales. The study population was identified from 
the cardiac intervention database and included patients who were discharged from hospital 
(between January 2011 and November 2015) following PCI for either stable or acute coronary 
artery disease. Follow up was for eighteen months. Patients who underwent coronary artery 
bypass grafting (CABG) during the index admission or had a prior or contemporary diagnosis 
of AF were excluded from the study. 
This study makes use of anonymised patient data, therefore informed consent was not 
required. Approval for the study was granted by the SAIL Information Governance Review 
Panel (IGRP). All data can be made available to researchers via standard SAIL IGRP protocols.  
DATASETS AND LINKAGE  
The cardiac intervention dataset contains procedural, clinical and demographic data on patients 
undergoing PCI. Information on the prescribing of antithrombotic therapy was obtained from 
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the hospital discharge summaries. These datasets were linked to the Welsh Longitudinal 
General Practice (WLGP) dataset to record the continuity of antithrombotic therapy and 
presence of co-morbidities, risk factors and demographics18. Date of death, where relevant, was 
identified form the Annual District Death Extract (ADDE)19 containing mortality records from 
the Office of National Statistics (ONS) and deprivation quintile was assigned using the Welsh 
Index of Multiple Deprivation (WIMD), an area-based deprivation measure.20 
For each patient hospitalised in Wales, the Patient Episode Database for Wales (PEDW) 
records the admission and discharge dates, diagnoses and operational procedures and 
demographic data. Date of death is also recorded when the patient dies within hospital. These 
records are completed at ‘finished consultant episode’ (FCE). Within each FCE, one primary 
and one or more secondary diagnosis using the International Classification of Disease, 10th 
Revision (ICD-10) is recorded. Operational and procedural codes are also applied for each FCE 
following the Office of Population Censuses and Surveys Classification of Interventions and 
Procedures version 4 (OPCS-4). PEDW was used to describe cardiac revascularization (either 
PCI or CABG) and major bleeding events prior to the index admission (see supplementary 
table 2.1 for ICD-10 Codes used to identify bleeding events). Major bleeding events included 
gastrointestinal bleeds, intracranial bleeds, urinary tract bleeds and airway bleeds. 
Both PEDW and WLGP datasets were searched for prior history or contemporary 
diagnosis of vascular disease (peripheral artery disease or aortic plaque), AF/flutter, MI, 
ischemic stroke, thromboembolism and heart failure. 
INDEX EVENT DATA 
For each patient, the first entry in the cardiac intervention database occurring during 
the study period was identified as the index intervention. The date of admission and discharge 
were identified either side of the index intervention using the PEDW dataset. Prescribing data 
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corresponding to the index intervention was extracted from the electronic discharge summaries. 
Where an electronic discharge summary was not available, paper copies of the discharge 
summary, where available were searched and the prescribing data was recorded. 
 
P2Y12 ANTAGONIST PRESCRIBING AND DISCONTINUATION 
Prescribing of P2Y12 antagonists post discharge was recorded within consecutive three-month 
periods following the date of discharge from hospital. Discontinuation was deemed to have 
occurred when there was a three-month period without a P2Y12 antagonist prescription prior to 
the intended date of treatment cessation. The precise time to discontinuation is unknown but 
was approximated as the centre point within the first three-month period where no P2Y12 
antagonist had been prescribed i.e. 46 days for the first three-month period, 137 days for the 
second three-month period; 228 days, 319 days, 411 and 501 days for the third to sixth-three-
month period respectively.  
 
STATISTICAL ANALYSES 
Baseline variables and patient characteristics including demographics, lifestyle behaviours and 
medical history were presented as percentages and means with standard deviations. Differences 
between those prescribed P2Y12 therapy for one year and all other regimes were compared 
using the c2 test for categorical variables and the two-sample t-test for continuous variables. A 
Cox proportional-hazards model was used to determine the baseline characteristics associated 
with ‘time to discontinuation’ from the prescribing instruction at the point of discharge from 
hospital. Bleeding subsequent to PCI, occurring during the period of intended prescription 
duration was included as a time dependent covariate. Hazard ratios (HRs) and 95% Confidence 
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Intervals (CI) were calculated for the respective clinical variables. In analysing time to 
discontinuation, death during the follow up was treated as a censoring event and hence we  
assumed that the time to death (or other loss to follow-up) was not related to the time-to-
attrition distribution. 
 
The primary clinical end point was a combination of death of any cause, subsequent 
readmission to hospital for an MI, unstable angina (UA), acute ischemic heart disease, ischemic 
stroke or transient ischemic attack (TIA) or readmission after 30 days from the index discharge 
date for either CABG, or recurrent coronary PCI (See supplementary tables 2.2 and 2.3 for 
ICD-10 and OPCS codes used to establish these endpoints). A Cox proportional hazards model 
was used to determine characteristics of the cohort associated with this adverse composite 
outcome, specifically the effect of discontinuation was modelled as a time-dependent covariate. 
In estimating the effect of discontinuation, we attempted to control for expected risk factors by 
including the key baseline characteristics in the Cox model. In addition, we had to control for 
effects of bleeding, again as a time-dependent covariate. We created a covariate with 4 levels 
representing the overall time dependent classification: no discontinuation and no bleed, 
discontinuation occurred but no bleed, bleed occurred but no discontinuation and finally, both 
events have occurred. For those patients with an adverse outcome only discontinuation and/or 
bleeding events occurring prior to the endpoint were included in the analysis. All models were 
run in SPSS software (version 22.0; SPSS, Inc., Chicago, IL). Variables were initially 
considered separately in univariable analyses; the final multivariable cox model was selected 
by minimising the Akaike information criterion (AIC) (with a comparison to model selection 
using Bayesian information criteria (BIC)). 
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RESULTS 
STUDY POPULATION  
Of the 5,532 patients undergoing PCI during the study period, 3,066 (55.4%) were discharged 
and had a complete linked healthcare dataset available (figure 2.1).  A further 397 (7.2%) were 
excluded who had AF or underwent a CABG procedure during the index admission. Of the 
final 2,770 patients meeting the inclusion criteria 2,090 (75.5%) were prescribed clopidogrel 
for one year (plus aspirin 75mg once daily for life). Of this cohort the mean age was 63.2 years, 
73.5% were male and 86.5% underwent PCI for an ACS (table 2.1).  
 
 
Figure 2.1 Study population cohort selection 
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Table 2.1 Demographics and medical history of patients by discharge prescribing intention of P2Y12 Inhibitors. 
 Clopidogrel for 1 year Other regimens P value 
 
Percentage of total group 





Mean age, (SD) 63.2 (11.8) 66.6 (12.3) <0.001 
Characteristic, n(%)    
     Male 1537 (73.5) 450 (66.2) 0.001 
    Obese 511 (24.4) 181 (26.6) 0.097 
    Smoker 784 (37.5) 237 (34.9) 0.579 
Deprivation index   0.08 
    1 (most deprived) 337 (16.1) 129 (18.9)  
    2 411 (19.7) 129 (18.9)  
    3 489 (23.4) 166 (24.4)  
    4 415 (19.9) 106 (15.9)  
    5 (least deprived) 






Prior medical history, n(%)    
    Hypertension 851 (40.7) 303 (44.6) 0.074 
    Ischemic heart disease 612 (29.3) 242 (35.6) 0.002 
    Myocardial infarction 351 (16.8) 144 (21.2) 0.01 
    Coronary revascularization              203 (9.7) 98 (14.4) 0.001 
    Ischemic stroke 115 (5.5) 46 (6.8) 0.22 
    Heart failure 259 (12.4) 67 (9.9) <0.001 
    Peripheral vascular disease 81 (3.9) 46 (6.8) 0.002 
    Thromboembolism 14(0.7) 9 (1.3) 0.10 
    Diabetes 382 (18.3) 156 (23.0) 0.007 
    Chronic kidney disease stage 4+ 16 (0.8) 10 (1.5) 0.097 
    Chronic liver disease 24 (1.1) 7 (1.0) 0.80 
    Dyslipidemia 380 (18.2) 149 (21.9) 0.031 
Continued on next page. 
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Table 2.1 continued. 
 Clopidogrel for 1 year Other regimens P value 
Prior medical history, n(%)    
    Dementia 9 (0.4) 4 (0.6) 0.60 
    Prior bleeding events  205 (9.8) 89 (13.1) 0.16 
Medication prescribed within 1 year prior to admission, n(%) 
    Aspirin 711 (34.0) 282 (41.5) <0.001 
    P2Y12 antagonist 230 (11.0) 107 (15.8) 0.001 
    Statins 924 (44.2) 347 (51.0) 0.002 
Clinical syndrome, n(%)   0.045 
    Acute coronary syndrome 1,808 (86.5) 563 (82.8)  
    Stable coronary disease 282 (13.5) 117 (17.2)  
 
In comparison with those prescribed any other regimen on discharges, these patients 
had a lower mean age, lower rate of previous diagnoses for ischemic heart disease; MI, prior 
coronary revascularization, heart failure or dyslipidaemia, and were less likely to have been 
prescribed in the year prior to the index event either aspirin, P2Y12 inhibitors or statins (further 
comparisons between those included and those excluded [with or without discharge prescribing 
data available] is contained in supplementary table 2.4). 
CLOPIDOGREL DISCONTINUATION 
The rate of discontinuation during the periods 0 to 3 months, 3 to 6 months, 6 to 9 months and 
9 to 12 months post discharge was approximately 1.1%, 2.6%, 3.7% and 6.1% respectively 
(figure 2.2). Between 12 to 15 months 47% had discontinued clopidogrel, and 76.2%. by 15 to 
18 months. 
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Figure 2.2 Discontinuation of clopidogrel post PCI in those recommended to continue for one 
year 
 
Factors associated with clopidogrel discontinuation during the first 12 months included: 
increasing age, hypertension, ischemic heart disease (IHD), prior MI, prior coronary 
revascularization, ischemic stroke, heart failure, vascular disease, prior bleeding events and 
bleeding during the follow up period (figure 2.3). After adjusting for all baseline 
characteristics, previous revascularization, previous ischemic stroke and age groups 80 or older 
were independently associated with discontinuation (table 2.2). 
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Figure 2.3. Characteristics associated with clopidogrel discontinuation within one year of 
discharge during follow up using univariable cox proportional hazards model 
DEATH AND MAJOR CARDIOVASCULAR EVENTS 
The incidence of death or major cardiovascular events in those who had no discontinuation or 
bleeding events post discharge was 9.5 per 100 person year (95% CI, 8.39-10.74); in patients 
who had discontinued clopidogrel but had no bleeding events the incidence was 15.2 (95% CI, 
6.72-24.24); in patients who had a bleeding event but no discontinuation it was 41.9 (95% CI, 
21.38-60.10); and in patients who had both bleeding and discontinuation it was 64.6 per 100 
person years (95% CI, 1.29-127.96). 
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Table 2.2 Multivariable Cox proportional hazard model of characteristics associated with clopidogrel 
discontinuation  
Covariate* Hazard ratio  Lower CI Upper CI P value 
Age     
     ≤ 49 1.61 0.84 3.08  
    50-59 Reference   0.005 
    60-69 1.47 0.86 2.53  
    70-79 1.51 0.84 2.69  
    ≥ 80 3.25 1.79 5.88  
Previous revascularization 2.09 1.32 3.33 0.002 
Previous ischemic stroke 1.95 1.12 3.39 0.018 
*The following variables were included in the mutually adjusted model: age; gender; presenting clinical 
syndrome; hypertension; prior coronary revascularization; prior bleeding events; ischemic stroke; heart failure; 
vascular disease; thromboembolism; diabetes; chronic kidney disease stage 4+; chronic liver disease, 
dyslipidemia; and dementia. Lower CI and upper CI indicates the lower and upper 95% confidence intervals. 
 
Patient characteristics associated with death or major cardiovascular events included: 
age 49 or less or 60 and above compared to those aged 50 to 59, hypertension, prior MI, prior 
coronary revascularization, ischemic stroke, heart failure, vascular disease, thromboembolism, 
diabetes, CKD, chronic liver disease, clopidogrel discontinuation and bleeding during follow 
up (figure 2.4).  
Characteristics independently associated with death or major cardiovascular events in 
a multivariable Cox proportional hazards model included age less than 49 and 70 and above 
compared to those aged 50-59; previous coronary revascularization; a history of 
thromboembolism, CKD stage 4 or 5 and ischemic stroke (table 2.3). After adjustment for these 
factors, the time dependent effects of discontinuation and bleeding were significantly 
associated with death or major cardiovascular events. For discontinuation alone, there was an 
estimated hazard ratio of 1.82 [95%CI (1.01-3.30)] compared to patients with no 
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discontinuation and no bleeding events. Similarly, the occurrence of bleeding alone in those 
without discontinuation was associated with an increased risk of death or major cardiovascular 
events [HR= 5.30, 95%CI (3.14-8.94)]. Notably, the combined effect of having both 
discontinuation and bleeding was associated the greatest likelihood of adverse events [HR = 
9.34, 95%CI (3.39-25.70)].  
 
Figure 2.4. Characteristics associated with death or major cardiovascular adverse events 
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Table 2.3 Multivariable Cox proportional hazard model of characteristics associated with adverse clinical 
outcomes 
Covariate* HR Lower CI Upper CI P value 
Age decile    0.019 
     ≤49 1.94 1.27 2.96  
    50- 59 Reference    
    60-69 1.36 0.95 1.94  
    70-79 1.57 1.09 2.29  
    ≥80 1.72 1.10 2.68  
Hypertension 1.30 1.02 1.66 0.03 
Chronic kidney disease stage 4+ 2.30 1.01 5.22 0.048 
Previous revascularization 1.47 1.06 2.03 0.021 
Previous ischemic stroke 1.96 1.34 2.86 <0.001 
Previous thromboembolism 3.18 1.48 6.83 0.003 
Time dependent variable of clopidogrel discontinuation and/or bleed                                               <0.001 
     (1) Discontinuation only 1.82 1.01 3.30  
     (2) Bleed only 5.30 3.14 8.94  
     (3) Discontinuation and bleed 9.34 3.39 25.70  
*The following variables were used in the model selection procedure: age; gender; presenting clinical 
syndrome; hypertension; prior coronary revascularization; prior bleeding events; ischemic stroke; heart 
failure; vascular disease; thromboembolism; diabetes; chronic kidney disease stage 4+; chronic liver disease, 
dyslipidemia; dementia and time dependent variables or clopidogrel discontinuation, bleeding and both 
discontinuation and bleeding. Lower CI and upper CI indicates the lower and upper 95% confidence 
intervals. 
 
As a comparison, model selection was also explored using BIC. This resulted in 
selection of fewer patient characteristics, however the effects of bleeding and clopidogrel 
discontinuation were retained in the final model as statistically significant.  
For completeness, the characteristics associated with the individual outcomes of MI, 
stroke, revascularization, and death are presented in supplementary tables 2.5 and 2.6. 
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Assessment of risk factors associated with bleeding was not a primary objective of this study, 
but none the less an important consideration. In a multivariable analysis prior bleeding events 
[HR=2.82, 95% CI (1.67-4.76)], chronic kidney disease [HR=6.15, 95% CI (2.22-17.08)] and 
chronic liver disease [HR=3.62 (1.14-11.51)] were independently associated with bleeding 
events during follow up (supplementary table 2.7). These variables were not independently 
associated with risk of clopidogrel discontinuation.  
 
DISCUSSION 
This is the first real-world outcome study examining the rate of clopidogrel discontinuation 
following PCI where the intended prescribing duration of DAPT is known. Notably, 
discontinuation of P2Y12 inhibitor therapy is low in this population, where a specified 
prescribing instruction to continue for 12 months is provided, in contrast to other studies where 
the prescribing duration was not known. Furthermore, despite the low discontinuation rate, 
discontinuation was still identified as an important predictor of adverse outcomes in this 
population, especially in those with concomitant bleeding. 
The observed rate of discontinuation is in marked contrast with findings from previous 
studies where it had been suggested that up to a half of patients post MI discontinue therapy 
within 12months.8 We note this was observed in an historical ACS patient group who were 
predominantly treated medically as opposed to receiving contemporary PCI therapy. 
Nevertheless, our observed rate of discontinuation was still lower than expected. There are a 
number of possible explanations for this difference, including greater contemporary 
recognition of the importance of continued use of P2Y12 inhibitors post PCI, improved 
communication of the prescribing intention from secondary to primary care and possibly the 
Chapter two 84 
availability of free prescriptions to all patients in Wales. However, addressing these questions 
was outside the scope of this study. 
Amongst those patients who discontinued clopidogrel earlier than the initial intended 
period, the hazard of death or major cardiovascular events was greater compared to those who 
continued therapy, as expected and in keeping with previous studies.8, 21 Other independent 
predictors of adverse outcomes included ischemic stroke and previous revascularization; both 
likely markers of diffuse or severe cardiovascular disease. However, both ischemic stroke and 
previous revascularization were also predictors of discontinuation. Whether these contrasting 
findings are a consequence of shared risk factors such as aging, comorbidities or the index PCI 
being a consequence of poor adherence to medication is unknown. 
Other independent predictors of discontinuation included advanced age, which has 
previously been shown to be a predictor of early discontinuation of clopidogrel post MI. 
Bleeding events measured as a time dependent variable were not an independent predictor of 
discontinuation, contrasting with observations from a previous study. 8 It is possible that those 
patients with prior bleeding events or at higher risk of bleeding may have been instructed for a 
shorter course of DAPT at discharge and were therefore not included in this analysis. The 
exclusion of patients undergoing CABG and those with AF, both groups of which are at higher 
risk of bleeding and subsequent discontinuation of P2Y12 treatment, may explain this 
observation. We found no association between deprivation quintiles and clopidogrel 
discontinuation, nor deprivation quintiles and major adverse outcomes in univariable analyses. 
Therefore, deprivation index was not included in the final multivariable analyses. 
In this study, we documented gastrointestinal bleeds; intracranial bleeds, urinary tract 
bleeds and airway bleeds in order to be consistent with previous studies, 22 but bleeding events 
occurring in other organ systems may have had major clinical outcomes and resulted in 
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cessation of therapy. However, the lack of an accepted standard for defining relevant bleeding 
events and defining their severity in real-world datasets is a recognised limitation for studies 
such as these. 
 Bleeding events were also highly predictive of adverse outcomes, as expected. 
Bleeding is a recognised adverse consequence of antiplatelet therapy and is associated with a 
greater incidence of death and ischemic events.1, 3, 23, 24 We found that the greatest risk of death 
or major cardiovascular events occurred in those with both discontinuation and bleeding events 
in our cohort. Whilst it is not possible to identify the specific cause of adverse outcomes in this 
group, it is recognised that contributing factors to worse outcomes includes the triggering of 
pro-thrombotic and pro-inflammatory responses following a bleed, combined with 
discontinuation of antiplatelet therapy leading to a rebound increased risk of ischemic events. 
While discontinuation was reassuringly low in the first 12 months, it is notable that 
continuation of prescribing beyond 12 months was high with almost a quarter (24% [n=427] 
of 1,779 patients with follow up data up to 18months post discharge) of patients still receiving 
a prescription for clopidogrel between 15 to 18 months after discharge from the index event. 
Possible reasons for continuation of clopidogrel include recurrent ischemic events, however, 
we noted that only 22.5% (n=96) within this group had a documented readmission for recurrent 
major cardiovascular event during follow up. It is possible that further clinical events occurred 
that led to a decision to continue or change therapy, although it is unlikely that this was the 
case for the majority of patients. As prescriptions are provided free in Wales, there is no 
financial disincentive to stop treatment, which may explain the relatively high numbers of 
patients continuing treatment beyond the recommended period. 
As the dataset only examined outcomes up to 18 months, there was insufficient power 
to explore the relationship between extended prescriptions beyond 12 months and the effect on 
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either cardiovascular events or bleeding due to relatively low numbers and short exposure 
times. 
 
STRENGTHS AND LIMITATIONS OF THIS STUDY 
We believe that this study further refines our understanding of the impact of P2Y12 
discontinuation on clinical outcomes. By identifying the discharge prescribing intention, we 
have avoided overestimation by excluding those with shorter durations of DAPT. Thus, 
although our analysis only evaluates 40% of the entire PCI population, we believe that these 
patients are representative of the majority of the post PCI population who are recommended to 
receive one year of DAPT, as our analysis has excluded patients requiring anticoagulation, 
those undergoing surgery and those without a complete linked dataset. There were also many 
clinical and demographic differences between those directed to one year of clopidogrel and the 
remaining group who had greater prevalence of risk factors for both cardiovascular and 
bleeding events. By keeping those higher risk patients in the analyses, overrepresentation of 
these important risk factors would likely have led to further overestimation of the actual 
relationship between discontinuation and adverse cardiovascular events. Furthermore, the 
exclusion of those with AF and/or undergoing CABG, who are at higher risk of bleeding and 
subsequent discontinuation of P2Y12 inhibitors, has likely further reduced the rate of 
discontinuation and the effect of bleeding events leading to discontinuation. 
There are several limitations to this study. While we have identified the prescribing 
intention from hospital, we were not able to identify the quantity of medication issued from 
either hospital or primary care, therefore we were unable to calculate precisely when an 
individual’s prescription would have finished if taken according to instruction. In the WLGP 
dataset we noted that prescriptions were usually issued every month, but occasionally repeated 
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every two months. Within a three-month period if no prescription had been issued it was 
possible to assume that either a one-month or two-month supply made in the previous quarter 
had been exhausted. Discontinuation was deemed to have occurred when there was a three-
month period without a P2Y12 antagonist prescribed. Using this method, we were able to detect 
periods where we had greater certainty that an individual’s prescription was likely to have 
finished but we lacked the precision for identification of shorter periods of discontinuation. 
As with any observational studies, we cannot determine whether the association 
between clopidogrel discontinuation and adverse outcomes was causal or may have been 
confounded by the influence of unrecorded co-morbidities including unrecorded bleeding 
events, the under-utilisation of other prognostically relevant medicines or new undocumented 
behaviours. The prescribing and potential discontinuation from aspirin was not accounted for 
in this study. In the UK aspirin is widely available without a prescription and is inexpensive 
therefore the assessment of aspirin discontinuation from the WLGP dataset may have led to 
classifications of periods of discontinuation when a patient may have self-medicated. 
It was not possible to identify the cause of discontinuation in this study. While the 
recording of prescriptions issued from the WLGP dataset is robust, currently it is not possible 
to identify the dispensing of those prescriptions. Access to prescription dispensing records in 
addition to the prescribing records from the WLGP dataset would have improved the sensitivity 
of capturing periods ‘off treatment’ and the association between non-adherence as well as 
discontinuation and adverse outcomes. Furthermore, it is not possible to identify if patients 
took the medication as intended, as is the case in most clinical studies. Therefore, this study 
does not confirm whether compliance with medication and periods of discontinuation could be 
attributed to either intentional or unintentional patient non-compliance or intentional prescriber 
discontinuation. It is possible that patients recorded as having discontinued clopidogrel 
received prescriptions either privately or from out-patient hospital appointments, although rare 
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in Wales, neither of which would have been captured in this study. However, this would likely 
further increase the true difference in the effect of discontinuation on adverse outcomes. 
During the study period international guidelines changed to preferentially 
recommended the use of the more potent P2Y12 antagonists such as ticagrelor or prasugrel. 
However, due largely to financial restrictions within the Welsh health service clopidogrel 
remained the mainstay of treatment for ACS during this time. Although this paper addresses 
the use of clopidogrel post PCI, we believe this paper remains of critical value as it illustrates 
the importance of knowing the schedule duration of any therapy before drawing conclusions 
on the impact of early discontinuation. Although not addressed in this study one may expect 
the adverse impact of poor concordance with newer more effective therapies to be even greater. 
Lastly, this observational study was conducted within a health service that is both 
accessible and free at the point of care, including the free provision of medication. This should 
be born in mind when comparing the results of this study to those systems where access to 
health care and affordability may influence therapy and outcomes at a population level. 
CONCLUSION 
In conclusion, this study has demonstrated that identifying the intended duration of P2Y12 
antagonist therapy on discharge following a PCI is essential for determination of the correct 
rate of premature discontinuation in real world outcome studies. The rate of discontinuation 
was reassuringly low in this patient group and much lower than anticipated in previous studies. 
While this is reassuring from the population level, at an individual level, discontinuation of 
P2Y12 antagonist therapy earlier than the intended duration is associated with an increased rate 
of adverse events. Our data emphasise the importance of improving processes to ensure optimal 
concordance with evidence based preventative therapy post PCI. 
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SUPPLEMENTARY MATERIAL 
MAJOR BLEEDING EVENTS 
Major bleeding events were classified as gastrointestinal bleeds, intracranial bleeds, urinary 
tract bleeds and airway bleeds resulting in admission to hospital. 
Supplementary table 2.1 ICD-10 Codes for major bleeding events 
Bleeding event Code Description 
Intracranial hemorrhage I608 Other subarachnoid hemorrhage 
Intracranial hemorrhage I602 Subarachnoid hemorrhage from anterior communicating artery 
Intracranial hemorrhage I604 Subarachnoid hemorrhage from basilar artery 
Intracranial hemorrhage I600 Subarachnoid hemorrhage from carotid siphon and bifurcation 
Intracranial hemorrhage I607 Subarachnoid hemorrhage from intracranial artery unspecified 
Intracranial hemorrhage I601 Subarachnoid hemorrhage from middle cerebral artery 
Intracranial hemorrhage I606 Subarachnoid hemorrhage from other intracranial arteries 
Intracranial hemorrhage I603 Subarachnoid hemorrhage from posterior communicating artery 
Intracranial hemorrhage I605 Subarachnoid hemorrhage from vertebral artery 
Intracranial hemorrhage I609 Subarachnoid hemorrhage unspecified 
Intracranial hemorrhage I629 Intracranial hemorrhage (non-traumatic) unspecified 
Intracranial hemorrhage I613 Intracerebral hemorrhage in brain stem 
Intracranial hemorrhage I614 Intracerebral hemorrhage in cerebellum 
Intracranial hemorrhage I611 Intracerebral hemorrhage in hemisphere cortical 
Intracranial hemorrhage I610 Intracerebral hemorrhage in hemisphere subcortical 
Intracranial hemorrhage I612 Intracerebral hemorrhage in hemisphere unspecified 
Intracranial hemorrhage I615 Intracerebral hemorrhage intraventricular 
Intracranial hemorrhage I616 Intracerebral hemorrhage multiple localized 
Intracranial hemorrhage I619 Intracerebral hemorrhage unspecified 
Intracranial hemorrhage I618 Other intracerebral hemorrhage 
Intracranial hemorrhage I691 Sequelae of intracerebral hemorrhage 
Intracranial hemorrhage I692 Sequelae of other non-traumatic intracranial hemorrhage 
Intracranial hemorrhage S064 Epidural hemorrhage 
Intracranial hemorrhage S065 Traumatic subdural hemorrhage 
Intracranial hemorrhage S066 Traumatic subarachnoid hemorrhage 
Gastrointestinal hemorrhage K250 Gastric ulcer acute with hemorrhage 
Gastrointestinal hemorrhage K254 Gastric ulcer chronic or unspecified with hemorrhage 
Gastrointestinal hemorrhage K260 Duodenal ulcer acute with hemorrhage 
Gastrointestinal hemorrhage K264 Duodenal ulcer chronic or unspecified with hemorrhage 
Gastrointestinal hemorrhage K270 Peptic ulcer acute with hemorrhage 
Gastrointestinal hemorrhage K280 Gastrojejunal ulcer acute with hemorrhage 
Gastrointestinal hemorrhage K920 Hematemesis 
Gastrointestinal hemorrhage K921 Melaena 
Gastrointestinal hemorrhage K922 Gastrointestinal hemorrhage unspecified 
Airway hemorrhage J942 Hemothorax 
Airway hemorrhage R042 Hemoptysis 
Airway hemorrhage R048 Hemorrhage from other sites in respiratory passages 
Urinary tract hemorrhage R31X Unspecified hematuria 
Urinary tract hemorrhage N028 Recurrent and persistent hematuria  
Urinary tract hemorrhage N029 Recurrent and persistent hematuria unspecified 
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PRIMARY END POINT CODES 
The primary end point was death due to any cause, subsequent readmission to hospital for an 
MI, unstable angina, acute ischemic heart disease, ischemic stroke or transient ischemic attack 
(TIA) or readmission after 30 days from the index discharge date for either CABG, or recurrent 
coronary PCI.  
Supplementary table 2.2 ICD10 codes for major adverse outcomes 
Diagnosis Code Description of code 
MI I219 Acute myocardial infarction unspecified 
MI I214 Acute subendocardial myocardial infarction 
MI I210 Acute transmural myocardial infarction of anterior wall 
MI I211 Acute transmural myocardial infarction of inferior wall 
MI I212 Acute transmural myocardial infarction of other sites 
MI I213 Acute transmural myocardial infarction of unspecified site 
MI I220 Subsequent myocardial infarction of anterior wall 
MI I221 Subsequent myocardial infarction of inferior wall 
MI I228 Subsequent myocardial infarction of other sites 
Acute ischemic heart 
disease 
I249 Acute ischemic heart disease  
Unstable angina I200 Unstable angina 
Ischemic Stroke / TIA I661 Occlusion and stenosis of anterior cerebral artery 
Ischemic Stroke / TIA I663 Occlusion and stenosis of cerebellar arteries 
Ischemic Stroke / TIA I660 Occlusion and stenosis of middle cerebral artery 
Ischemic Stroke / TIA I664 Occlusion and stenosis of multiple and bilateral cerebral arteries 
Ischemic Stroke / TIA I668 Occlusion and stenosis of other cerebral artery 
Ischemic Stroke / TIA I662 Occlusion and stenosis of posterior cerebral artery 
Ischemic Stroke / TIA I669 Occlusion and stenosis of unspecified cerebral artery 
Ischemic Stroke / TIA I64X Stroke not specified as hemorrhage or infarction 
Ischemic Stroke / TIA I651 Occlusion and stenosis of basilar artery 
Ischemic Stroke / TIA I652 Occlusion and stenosis of carotid artery 
Ischemic Stroke / TIA I653 Occlusion and stenosis of multiple and bilateral pre cerebral arts 
Ischemic Stroke / TIA I658 Occlusion and stenosis of other precerebral artery 
Ischemic Stroke / TIA I659 Occlusion and stenosis of unspecified precerebral artery 
Ischemic Stroke / TIA I650 Occlusion and stenosis of vertebral artery 
Ischemic Stroke / TIA G458 Other transient cerebral ischemic attacks and related syndrome 
Ischemic Stroke / TIA G459 Transient cerebral ischemic attack unspecified 
Ischemic Stroke / TIA I636 Cerebral infarct due cerebral venous thrombosis nonpyogenic 
Ischemic Stroke / TIA I632 Cerebral infarct due unspecifed occlusion or stenos precerebral arteries 
Ischemic Stroke / TIA I630 Cerebral infarct due to thrombosis of precerebral arteries 
Ischemic Stroke / TIA I634 Cerebral infarction due to embolism of cerebral arteries 
Ischemic Stroke / TIA I631 Cerebral infarction due to embolism of precerebral arteries 
Ischemic Stroke / TIA I633 Cerebral infarction due to thrombosis of cerebral arteries 
Ischemic Stroke / TIA I639 Cerebral infarction unspecified 
Ischemic Stroke / TIA I635 Cerebral infarct due unspecified occlusion or stenos cerebral arts 
Ischemic Stroke / TIA I638 Other cerebral infarction 
Ischemic Stroke / TIA I693 Sequelae of cerebral infarction 
Ischemic Stroke / TIA I694 Sequelae of stroke not specified as hemorrhage or infarction 
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Supplementary table 2.3 OPCS codes (versions 4.5 to 4.8) for major adverse outcomes 
Procedure Code Description 
CABG K401 Saphenous vein graft replacement of one coronary artery 
CABG K402 Saphenous vein graft replacement of two coronary arteries 
CABG K403 Saphenous vein graft replacement of three coronary arteries 
CABG K404 Saphenous vein graft replacement of four or more coronary arteries 
CABG K408 Other specified saphenous vein graft replacement of coronary artery 
CABG K409 Unspecified saphenous vein graft replacement of coronary artery 
CABG K411 Autograft replacement of one coronary artery 
CABG K412 Autograft replacement of two coronary arteries 
CABG K413 Autograft replacement of three coronary arteries 
CABG K414 Autograft replacement of four or more coronary arteries 
CABG K418 Other specified other autograft replacement of coronary artery 
CABG K419 Unspecified other autograft replacement of coronary artery 
CABG K421 Allograft replacement of one coronary artery 
CABG K422 Allograft replacement of two coronary arteries 
CABG K423 Allograft replacement of three coronary arteries 
CABG K424 Allograft replacement of four coronary arteries 
CABG K428 Other specified allograft replacement of coronary artery 
CABG K431 Prosthetic replacement of one coronary artery 
CABG K442 Revision of replacement of coronary artery 
CABG K451 Double anastomosis of mammary arteries to coronary arteries 
CABG K453 Anastomosis of mammary artery to left anterior descending coronary artery 
CABG K454 Anastomosis of mammary artery to coronary artery NEC 
CABG K471 Endarterectomy of coronary artery 
Coronary PCI K49 Transluminal balloon angioplasty of coronary artery 
Coronary PCI K491 Percutaneous transluminal balloon angioplasty of one coronary artery 
Coronary PCI K492 Percutaneous transluminal balloon angioplasty of multiple coronary arteries 
Coronary PCI K493 Percutaneous transluminal balloon angioplasty of bypass graft of coronary artery 
Coronary PCI K494 Percutaneous transluminal cutting balloon angioplasty of coronary artery 
Coronary PCI K498 Other specified transluminal balloon angioplasty of coronary artery 
Coronary PCI K499 Unspecified transluminal balloon angioplasty of coronary artery 
Coronary PCI K503 Percutaneous transluminal injection of therapeutic substance into coronary artery 
Coronary PCI K504 Percutaneous transluminal atherectomy of coronary artery 
Coronary PCI K75 Percutaneous transluminal balloon angioplasty and insertion of stent into coronary artery 
Coronary PCI K751 Percutaneous transluminal balloon angioplasty and insertion of 1-2 drug-eluting stents into coronary artery 
Coronary PCI K752 Percutaneous transluminal balloon angioplasty and insertion of 3 or more drug-eluting stents into coronary artery 
Coronary PCI K753 Percutaneous transluminal balloon angioplasty and insertion of 1-2 stents into coronary artery 
Coronary PCI K754 Percutaneous transluminal balloon angioplasty and insertion of 3 or more stents into coronary artery NEC 
Coronary PCI K758 Other specified percutaneous transluminal balloon angioplasty and insertion of stent into coronary artery 
Coronary PCI K759 Unspecified percutaneous transluminal balloon angioplasty and insertion of stent into coronary artery 
Coronary PCI Y141 Insertion of expanding covered metal stent into organ NOC 
Coronary PCI Y142 Insertion of expanding metal stent into organ NOC 
Coronary PCI Y143 Insertion of metal stent into organ NOC 
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Supplementary table 2.4. Demographics and medical history of patients included and excluded in the analysis    
* N=3,459 
 Included Excluded P 
 
Percentage of overall  
n=2,090 
60.4 
n = 1,369 
39.6 
 
Mean age, (SD) 63.2 (11.8) 65.9 (12.2) <0.001 
Characteristic, n(%)    
     Male 1537 (73.5) 942 (68.8) 0.003 
    Obese 511 (24.4) 345 (25.2) 0.62 
    Smoker 784 (37.5) 496 (36.2) 0.45 
Deprivation index   0.12 
    1 337 (16.4) 250 (18.2)  
    2 411 (20.0) 260 (18.9)  
    3 489 (23.9) 337 (24.6)  
    4 415 (20.2) 229 (16.7)  
    5 398 (19.4) 264 (19.3)  
     Unknown 40 (1.9) 29 (2.1)  
Prior medical history, n(%)    
    Hypertension 851 (40.7) 608 (44.4) 0.03 
    Ischemic Heart Disease 612 (29.3) 525 (38.3) <0.001 
    Myocardial Infarction 351 (16.8) 280 (20.5) 0.006 
    Coronary revascularization 203 (9.7) 209 (15.3) <0.001 
    Ischemic Stroke 115 (5.5) 97 (7.1) 0.06 
    Heart Failure 259 (12.4) 237 (17.3) <0.001 
    Vascular Disease 81 (3.9) 81 (5.9) <0.001 
    Thromboembolism 14(0.7) 17 (0.7) 0.36 
    Diabetes 382 (18.3) 297 (21.7) 0.01 
    CKD Stage 4+ 16 (0.8) 16 (1.2) 0.22 
    Chronic liver Disease 24 (1.1) 13 (0.9) 0.58 
    Dyslipidemia 380 (18.2) 288 (21.0) 0.04 
    Dementia 9 (0.4) 9 (0.7) 0.36 
    Prior bleeding events  205 (9.8) 164 (12.0) 0.04 
    
    Aspirin 711 (34.0) 610 (44.6) <0.001 
    P2Y12 antagonist 230 (11.0) 265 (19.6) <0.001 
    Statins 924 (44.2) 733 (53.5) <0.001 
Clinical syndrome, n(%)   <0.001 
    ACS 1,808 (86.5) 1,030 (75.2)  
    Stable 282 (13.5) 339 (24.8)  
*Comparisons made here are between those meeting the inclusion criteria and prescribed clopidogrel for one 
year (n=2090) and those not meeting the inclusion criteria but had linked data available before the index 
admission, survived at least one day after discharge but did not have AF or received CABG during the index 
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INDIVIDUAL OUTCOMES OF MI, ISCHEMIC STROKE, CORONARY REVASCULARIZATION AND 
DEATH 
 
The primary outcome measure (the composite of MI, ischemic stroke, coronary 
revascularization 30 days’ post discharge and death) occurred in 286 (13.7%) of the cohort. 
The number of patients having an MI during follow up was 167 (8.0%), ischemic stroke 31 
(1.5%), coronary revascularization 100 (4.8%) and death 46 (2.2%). For completeness we 
modelled baseline characteristics and the time dependent effects of discontinuation and /or 
bleeding against these individual outcome measures in a multivariable Cox-proportional 
hazard model (supplementary table 2.5). In these models we found no significant association 
between discontinuation and/or bleeding on coronary revascularization. We also calculated the 
event rate per 100 patient years (supplementary table 2.6). In the case of MI, revascularization, 
and stroke there were no patients who had both clopidogrel discontinuation and bleeding events 
prior to the adverse outcome. 
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Supplementary table 2.5. Multivariable Cox proportional hazard model of characteristics associated with the 
independent adverse outcomes of MI, ischemic stroke, coronary revascularization or death 
 MI Ischemic Stroke Revascularization Death 
 HR (95% CI), p 
value 
HR (95% CI), p 
value 
HR (95% CI), p 
value 
HR (95% CI), p 
value 
Covariate  - - - 
Age decile  - - - 
     ≤49 2.44 (1.42-4.2), - - - 
    50- 59 Reference, p=0.21 - - - 
    60-69 1.71 (1.05-2.78) - - - 
    70-79 1.96 (1.19-3.22) - - - 
    ≥80 1.99 (1.08-3.67) - - - 
Hypertension - 2.29 (1.06-4.97), 
p=0.035 
- - 
Liver disease 2.74 (1.21-6.22), 
p=0.016 
- - - 



















- - 3.33 (1.03-10.73), 
p=0.04 
- 




    Stable CAD 










- - - 
Time dependent variable of discontinuation and/or bleed                         





Reference, p<0.001 - Reference, 
p<0.001 
     (1) 
Discontinuation only 
1.76 (0.76-4.05) - - 6.00 (2.44-14.76) 
     (2) Bleed only 5,78 (2.88-11.60) 9.78 (3.30-28.95) - 5.94 (1.79-19.72) 
(3) Discontinuation 
and         bleed 
- - - 61.47 (21.18-
178.39) 
*The following variables were included in the model: age; gender; presenting clinical syndrome; hypertension; 
prior coronary revascularization; prior bleeding events; ischemic stroke; heart failure; vascular disease; 
thromboembolism; diabetes; CKD stage 4+; chronic liver disease, dyslipidemia; dementia and time dependent 
variables or clopidogrel discontinuation, bleeding and both discontinuation and bleeding. Only variables 
associated with one or more outcomes are presented.  The final variables were selected in a multivariable co 
model by minimizing the Akaike information criterion. 
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Supplementary table 2.6. Individual event rate* for Stroke, MI, coronary revascularization and death 
according to presence of clopidogrel discontinuation and/or bleed 
 MI Ischemic stroke Coronary 
revascularization 
Death 
No discontinuation and no 
bleed 
5.34 0.08 3.02 1.22 
Discontinuation only 17.43 0.07 12.43 6.06 
Bleed only 18.75 10.5 8.38 6.06 
Discontinuation and bleed - - - 64.6 
*Event rate calculated in events per 100 patient years. 
 
Supplementary table 2.7. Multivariable Cox proportional hazard model of characteristics associated with 
bleeding events during follow up 
Covariate HR CI lower CI upper p 
Prior bleeding 2.82 1.67 4.76 <0.001 
CKD stage 4+ 6.15 2.22 17.08 <0.001 
Chronic liver disease 3.62 1.14 11.51 <0.001 
*The following variables were included in the model: age; gender; presenting clinical syndrome; 
hypertension; prior coronary revascularization; prior bleeding events; ischemic stroke; heart failure; vascular 
disease; thromboembolism; diabetes; CKD stage 4+; chronic liver disease and dyslipidemia.  
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CHAPTER 3 
ACHIEVEMENT OF EUROPEAN GUIDELINE-RECOMMENDED LIPID LEVELS 
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ABSTRACT 
AIMS 
2019 ESC/EAS guidelines recommend more aggressive lipid targets in high and very high-risk 
patients and addition of adjuvant treatments to statins in uncontrolled patients. We aimed to 
assess (i) achievement of prior and new ESC/EAS lipid targets and (ii) lipid lowering therapy 
(LLT) prescribing in a nationwide cohort of very high-risk patients. 
METHODS  
We conducted a retrospective observational population study using linked health-data in 
patients undergoing percutaneous coronary intervention (PCI) (2011-17). Follow-up was one-
year post discharge. 
RESULTS 
10,071 patients had a documented LDL-C level, of whom 48% had an LDL-C <1.8mmol/L 
(2016 target) and (23%) <1.4mmol/L (2019 target). 5,340 had non-HDL-C documented with 
57% <2.6mmol/L (2016) and 37% <2.2mmol/L (2019). In patients with recurrent vascular 
events, fewer than 6% of the patients achieved the 2019 LDL-C target of <1.0mmol/L. 10,592 
had triglyceride (TG) levels documented, of whom 14% were ≥2.3mmol/L and 41% 
≥1.5mmol/L (2019).  
 High intensity (HI-statins) were prescribed in 56.4% of the cohort, only 3% were 
prescribed ezetimibe, fibrates or prescription-grade N-3 fatty acids. Prescribing of these agents 
was lower amongst patients above target LDL-C, non-HDL-C and TG. Females were more 
likely to have LDL-C, non-HDL-C and TG levels above target.  
CONCLUSION 
There was a low rate of achievement of new ESC/EAS lipid targets in this large post-PCI 
population and relatively low rates of intensive LLT prescribing in those with uncontrolled 
lipids. There is considerable potential to optimise LLT further through statin intensification 
and appropriate use of novel LLT, especially in women.   
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BACKGROUND 
Cardiovascular disease (CVD) carries a high burden of morbidity and mortality.1 Patients with 
established CVD are at higher risk of recurrent events, however, the progressive 
implementation of evidence-based therapies has improved survival and reduced recurrence of 
major adverse cardiovascular events (MACE).2 Randomised controlled trials (RCTs) have 
consistently shown that the use of statins improves clinical outcomes in patients with, and at 
increased risk of, CVD. Furthermore, use of higher intensity statins leads to better outcomes 
than less intensive statin therapy.3 The impact of statin therapy on clinical outcomes is directly 
related to the achieved reduction of Low-density lipoprotein cholesterol (LDL-C) levels. 
However, patients with increasing LDL-C still have progressively worse outcomes, despite 
statin therapy.3 
The addition of ezetimibe to statin therapy confers a modest improvement in patient 
outcomes in keeping with its modest reduction in LDL-C.4 Recent RCTs have demonstrated 
that more intensive lipid lowering therapy with the addition of Proprotein convertase 
subtiliskin/kexin type 9 (PCSK9) inhibitors to statins, leads to further improvement in clinical 
outcomes.5, 6 The REDUCE-IT study has also shown that the addition of high-dose omega-3 
fatty acid treatment (icosapent-ethyl 2g twice/day) improves outcomes in high risk patients 
with moderate hypertriglyceridemia (1.7-5.6mmol/L, [150-499mg/dL]) on statin therapy.7 
The European Society of Cardiology and European Atherosclerosis Society (ESC/EAS) 
have recently updated their guidelines for management of dyslipidaemia in which they 
recognise the implications of these new clinical trial data.8 It is now recommended that LDL-
C reduction of ≥50% from baseline and a LDL-C goal of <1.4mmol/L [<55mg/dL] in very high 
CVD risk patients, (reduced from <1.8mmol/L [70g/dL], in the 2016 guidelines) and 
<1.0mmol/L [<40mg/dL] in patients with recurrent atherosclerotic cardiovascular events 
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within the previous 2 years.8, 9 These guidelines recommend the addition of ezetimibe to statin 
therapy and PCSK9 inhibitors in patients who are not at goal despite taking maximally tolerated 
statin dose +/- ezetimibe. There is also an emphasis on the importance of considering non-
HDL-C levels as secondary treatment targets, especially in those individuals with elevated 
triglycerides (TG). Furthermore, in patients at high risk (or above) with triglyceride levels 
between 1.5 and 5.6mmol/L despite statin therapy, N-3 fatty acids (N-3) should be considered. 
It is unknown what proportions of patients at very high CVD risk achieve, or do not 
achieve, these recommended levels of LDL-C, non-HDL-C and/or TGs; and how these 
respective patient groups are treated. A better understanding of these relationships will identify 
not only the therapeutic gap, but also the potential opportunity to optimise CVD risk 
management at an individual and population level. The objectives of this study were to 
document (i) lipid lowering treatment (LLT) and (ii) achievement of prior and current 
ESC/EAS lipid targets in a contemporary national cohort of patients post-percutaneous 
coronary intervention (PCI), who would be considered to be at very high CVD risk according 
to the ESC/EAS classification. 
METHODS 
We undertook a retrospective observational cohort study using linked anonymised electronic 
health record (EHR) data for patients undergoing PCI in Wales, UK between January 2012 and 
December 2017. Access to data and linkage was performed using the Secure Anonymised 
Information Linkage (SAIL) Databank.10, 11 SAIL is part of the national e-health records 
research infrastructure for Wales; the following linked data sources are held within SAIL: 
secondary care hospital admission data within the Patient Episode Database for Wales 
(PEDW),12 primary care General Practitioner (GP) data within the Welsh Longitudinal General 
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Practice (WLGP)13, demographic data and GP registration history within the Welsh 
Demographic Service Dataset(WDSD) (see supplement for further details).14  
Study subjects included those ≥18 years of age at the time of first PCI, who were 
discharged and had at least 90 days of follow-up data available in the WLGP data. An index 
date was assigned to the date of the first PCI during the study period for each patient. Follow-
up was for one-year from the discharge date of the index hospital admission. The WLGP data 
was used to describe the presence of hypertension, ischemic heart disease, chronic kidney 
disease (CKD) stage 4+, chronic liver disease (including cirrhosis, fibrosis, chronic hepatitis 
and chronic active hepatitis, fatty liver, sclerosis of the liver, unspecified alcoholic liver 
damage, hepatic failure), dementia, prescriptions for lipid lowering therapy and recorded lipid 
levels. Both PEDW and WLGP data were used to describe a prior history of myocardial 
infarction and a prior or contemporary (at time of index admission) diagnosis of peripheral 
vascular disease (PVD), heart failure, atrial fibrillation (AF), diabetes mellitus and ischaemic 
stroke. PEDW was also used to identify if the index admission was for an acute coronary 
syndrome (ACS) and identify patients with hospital admission for a non-embolic 
stroke/transient ischaemic attack (TIA) or ACS within two years prior to the index hospital 
admission. 
 
LIPID LEVELS AND PRESCRIPTIONS FOR LIPID MODIFYING THERAPY 
The time to the first lipid profile and the lowest LDL-C, non-HDL-C and TG between 28 days 
and one-year post discharge was documented for each patient. Prescriptions for lipid lowering 
therapy (LLT) including statins, ezetimibe, fibrates and prescription-grade N-3 were identified 
during the follow up period. 
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LLT prescribed in the 90 days immediately post discharge and within 90 days prior to 
the lowest LDL-C and non-HDL-C were classified as high intensity statin (HI-statin; 
atorvastatin ≥40mg/d and rosuvastatin ≥20mg/d), non-high intensity (NI-statin; any other statin 
prescription), combination of ezetimibe and/or fibrate with either HI- or NI-statin (combination 
statin) and other treatments including ezetimibe and/or fibrate (other treatment) without a co-
prescription of statin or no treatment. 
LLT prescribed within the 90 days prior to the lowest TG level were classified as statin 
(either HI- or NI-statin); combination fibrate and/or N-3 with statin (combination statin), 
fibrate and/or N-3 (other) or no treatment. 
We identified the number (and proportion) of patients achieving (i) LDL-C < or ≥: 1.4 
and 1.8mmol/L; (ii) non-HDL-C < or ≥: 2.2 and 2.6mmol/L [< or ≥:65 and 100mg/dL]; (iii) 
TG < or ≥ 1.5 and 2.3mmol/L [135 and 200mg/dL] and their respective LLT regimen. 
We also evaluated the number (and proportion) of patients with recurrent events within 
2 years achieving LDL-C <or ≥ 1.0mmol/L and non-HDL-C < or ≥ 1.8mmol/L and their 
respective LLT regimens. 
 
STATISTICAL ANALYSIS 
Baseline variables including patient characteristics, medical history and LLT are presented as 
mean and standard deviation for continuous variables, and as frequency and percentage for 
categorical variables. Comparisons between groups with and without lipid profiles documented 
during follow up were performed using 2-sample t- test for normally distributed continuous 
variables and χ2 for categorical variables, as appropriate. A multivariable binary logistic 
regression analysis was then conducted to identify independent variables associated with the 
Chapter three 105 
absence of a lipid profile. Variables included in this analysis included age, sex, hypertension, 
diabetes mellitus, CKD stage 4+, chronic liver disease, dementia, heart failure, ischaemic 
stroke, PVD, AF, ACS during the index admission and LLT prescribed in the first 90 days 
post-discharge. 
Next, we investigated the association between achieved lipid levels (LDL-C> 
>1.4mmol/L, non-HDL-C>2.2mmol/L and TG>1.5mmol/L) as the dependent variable in a 
binary logistic regression model. Variables in this model included age, sex, hypertension, 
diabetes mellitus, CKD stage 4+, chronic liver disease, dementia, heart failure, ischaemic 
stroke, PVD, AF, ACS during the index admission and LLT prescribed in the first 90 days 
post-discharge. Model selection for all multivariable analyses was conducted using forward 
stepwise approach in SPSS version 22.0.  
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RESULTS 
We identified 22,164 patients who had undergone a PCI during the study period, of whom 
15,203 met the study inclusion criteria with a total of 14,577 years of follow up data 
(supplementary figure 3.1). The mean follow-up was 349 days (SD= 46.7days), mean age was 
64.9years (SD= 11.9) and 10,933 (71.9%) were male (table 3.1). Of these, 11,048 (72.7%) had 
a lipid profile documented in their record during the year post discharge, of whom 1,154 
(10.4%) had their first lipid profile within 28 days of discharge (figure 3.1). Overall, 8,573 
(56.4%) of patients were prescribed high intensity statins and the prescribing rate was 
considerably higher amongst those who presented with an ACS during the index admission 
[7,269 (68.5%) v 1,304 (28.4%), p<0.001]. 
Patients who were female, had a history of CKD stage 4+, dementia, ischaemic stroke, 
AF and PVD were independently less likely to have a documented lipid in the year post 
discharge (supplementary table 3.1). Patients with diabetes mellitus, prescribed LLT and had 
an ACS during the index admission were independently more likely to have a lipid profile. 
 
Figure 3.1 Time to first post-discharge lipid profile  
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Table 3.1. Cohort characteristic and comparison between those with and without a documented lipid profile in 
the first-year post-discharge -post-PCI 
 Total cohort  
N = 15,203 
With lipid profile 
N = 11,048  
Without lipid profile 
N= 4,155 
 P Value* 
Percent of total cohort 100% 72.7% 27.3%  
Mean Age (SD) 64.9 (11.9) 64.6 (11.4) 66.6 (13.0)  <0.001 
Male N (%) 10,933 (71.9) 8,077 (73.1) 2,856 (68.7)  <0.001 
Past medical history, N(%) 
   Hypertension 6,331 (41.6) 4,581 (41.5) 1,750 (42.1)  0.46 
   Ischemic heart disease 4,029 (26.5) 2,934 (26.6) 1,095(26.4)  0.80 
   Previous MI 2,489 (16.4) 1,809 (16.4) 680 (16.4) 0.99 
   Previous 
revascularisation 
1,414 (9.3) 1,013 (9.2) 401 (9.7)  0.36 
   Diabetes 3,516 (23.1) 2,769 (25.1) 747 (18.0)  <0.001 
   CKD stage 4+ 182 (1.2) 96 (0.9) 86 (2.1)  <0.001 
   Liver disease 182 (1.2) 131 (1.2) 51 (1.2)  0.83 
   Dementia 91 (0.6) 47 (0.4) 44 (1.1)  <0.001 
   Heart failure  2,203 (14.5) 1,583 (14.3) 620 (14.9)  0.35 
   Ischemic stroke 1,011 (6.7) 690 (6.2) 321 (7.7)  0.001 
   Peripheral vascular 
disease 
939 (6.2) 626 (5.7) 313 (7.5)  0.001 
   Atrial Fibrillation 1,634 (10.7) 1,105 (10.0) 529 (12.7)  <0.001 
ACS during index 
admission 
10,617 (69.8) 7,978 (72.2) 2,639 (63.5)  <0.001 
Recurrent cardiac 
atherosclerotic event or 
non-embolic ischaemic 
stroke within two years  
1,020 (6.7) 715 (8.0) 305 (8.6)  0.26 
   Stroke with two years  347 (2.3) 235 (2.6) 112 (3.2) 0.10 
   MI within two years 682 (4.5) 480 (5.4) 202 (5.7) 0.46 
   Cardiac revascularisation                    
within two years  
73 (0.5) 54 (0.6) 19 (0.6) 0.63 
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Table 3.1 continued. 
 Total cohort 
N = 15,203 
With lipid profile 
N = 11,048 
Without lipid profile 
N= 4,155 
P Value* 
LLT prescribed within 90 
days post discharge 
   <0.001 
    No lipid lowering 
therapy 
993 (6.5) 379 (3.4) 614 (14.8)  
    High Statin 8,573 (56.4) 6,399 (57.9) 2,174 (52.3)  
    Non-high intensity statin 5,179 (34.1) 3,914 (35.4) 1,265 (30.4)  
    Statin & otherϮ 311 (2.0) 242 (2.2) 69 (1.7)  
   Other LLT 147 (1.0) 114 (1.0) 33 (0.8)  
*P value for comparison between those with and without a lipid profile; CKD indicates Chronic Kidney 
Disease; ACS indicates Acute Coronary Syndrome; LLT indicates lipid lowering therapy, Other LLT 
indicates ezetimibe and/or fibrate. 
Ϯ Other LLT includes prescriptions for ezetimibe and/or fibrate. 
 
LDL- C LEVELS 
Of the 11,048 with any lipid profile, 10,071 patients had an LDL-C documented between 28 
days and one year (mean lowest LDL-C= 1.90mmol/L, SD=0.79) (figure 3.2a). Of these, 4,812 
(47.8%) had an LDL-C below the 2016 EAS/ESC target of 1.8mmol/L, but only 2,353 (23.4%) 
were below the 2019 target of 1.4mmol/L. 
A total of 1,020 (6.7%) of patients had experienced an atherosclerotic event within two 
years prior to the index PCI (including 347 (2.4%) with a stroke, 682 (4.5%) with a MI and 73 
(0.5%) who had undergone a coronary revascularisation) of whom 627 had documented LDL-
C. Of these 627, Only 33 (5.3%) had LDL-C levels below the new 2019 ESC/EAS target of 
1.0mmol/L (Figure 3.2c). 
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Figure 3.2 Post discharge lipid results 
(a) Lowest LDL-C recorded between 28 and 365 days in 10,071 patients, (b) lowest non-HDL-C recorded between 
28 and 365days in 5,340 patients, (c) lowest LDL-C recorded between 28 and 365 days in 627 patients with 
recurrent events and (d) lowest non-HDL-C recorded in 314 patients with recurrent events. 
 
Considering patients with documented LDL-C levels greater than 1.8 and 1.4mmol/L, 2,437 
(46%) and 4,082 (53%) respectively were prescribed high intensity statins; 117 (2.2%) and 146 
(1.9%) were prescribed a combination of ezetimibe and/or fibrate plus a statin, and 103 (2.0%) 
and 109 (1.4%) prescribed ezetimibe and/or fibrate without a statin (figure 3.3). 
Of the 594 of patients with recurrent events within 2 years and LDL-C ≥1.0mmol, 312 
(52.5%) were prescribed high intensity statins; 214 (36.0%) were prescribed standard intensity 
statins, 19 (3.1%) were prescribed ezetimibe and/or a fibrate in addition to a statin, 12 (2.0%) 
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were prescribed either ezetimibe and/or fibrate without a statin and 37 (6.2%) patients were 
not prescribed any LLT. 
 
Figure 3.3 Prescribed lipid lowering therapy in patients at or above (a) 2019 & (b) 2016 
ESC/EAS guideline LDL-C targets. 
Other treatment indicates prescription for ezetimibe or fibrates; statin and other indicates prescription for either 
high intensity or standard intensity statin plus either ezetimibe or fibrate. Ϯ Governance restrictions within SAIL 
prohibit the reporting of numbers <5. Due to the low number of patients prescribed ‘other’ lipid lowering treatment 
with a LDL-C <1.4 we have grouped these patients with no treatment. 
 
 
Characteristics independently associated with LDL-C ≥1.4mmol/L in a binary logistic 
regression analyses include female sex and PVD. Diabetes mellitus, increasing age and the 
presence of an ACS during the index admission were independently associated with achieving 
the 2019 target LDL-C <1.4mmol/L (supplementary table 3.2). 
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NON-HDL-C LEVELS 
Non-HDL-C levels were documented 5,340 patients (mean lowest non-HDL-C =2.6mmol/L, 
SD= 0.97) of which 2,286 (42.8%) had a non-HDL-C ≥2.6mmol/L and 3,366 (63.0%) ≥ 
2.2mmol/L (figure 3.2b). Amongst those with recurrent atherosclerotic events, 314 patient had 
non-HDL-C results documented of which only 40 (12.7%) were below the threshold of 
1.8mmol/L (figure 3.2d). 
The distribution of LLT regimens was similar in patients below or above target non-
HDL-C to those observed in those at and not at LDL-C targets (supplementary figure 3.2). 
Characteristics independently associated with non-HDL-C >2.2mmol/L included 
female sex, hypertension and PVD (supplementary table 3.3). ACS during the index admission, 
increasing age and LLT but not diabetes were predictive of a non-HDL-C < 2.2mmol/L 
TG Levels 
A total of 10,592 patients had TG levels recorded between 28 days and one year (mean 
lowest TG= 1.54mmol/L, SD=1.01), of whom 1,524 (14.4%) had TG≥2.3mmol/L and 4,314 
(40.7%) had TG≥1.5mmol/L (figure 3.4). 
Of those patients with TG ≥2.3mmol/L and ≥1.5, 1,313 (86.2%) and 3,847 (89.2%) 
were prescribed statins respectively, 62 (4.1%) and 122 (2.0%) prescribed fibrates and/or N-3 
and 133 (8.7%) and 312 (7.2%) were not prescribed any LLT (figure 3.5). 
In a multivariable analysis, variables independently associated with TG>1.5mmol/L 
included female sex, hypertension, CKD stage 4+, ischaemic stroke, PVD, and diabetes 
mellitus (supplementary table 3.4). 
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Figure 3.4 Lowest Triglyceride recorded between 28 and 365 days in 10,592 patients 
 
 
Figure 3.5 Number of patients and lipid lowering therapy according to Triglyceride levels. 
*Other treatment indicates either fibrate or N-3 fatty acid.  
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DISCUSSION 
This is the first real world study examining the prescribing of lipid lowering therapy and 
achieved lipid levels against the recently published ESC/EAS guideline targets in a national 
cohort of patients’ post-PCI. This analysis was conducted in order to examine the potential 
implications for changes in management strategy at a system level in this important patient 
population. Notably, just under half (47.8%) of very high-risk patients had LDL-C below the 
2016 ESC/EAS target of 1.8mmol/L in the year post-PCI, but fewer than a quarter (23.4%) 
were below the 2019 target of 1.4mmol/L. Furthermore, fewer than 6% of patients with 
recurrent atherosclerotic events achieved the new target of 1.0mmol/L where the index PCI 
was within 2 years of a prior admission for an ACS or non-embolic ischaemic stroke.  
We also found that over 40% of patients had TG levels at or above 1.5mmol/L, the 
threshold for the new recommendation for consideration of high-dose N-3 prescription. In 
keeping with our findings, a recent Canadian real-world study has shown that approximately 
25% of patients with atherosclerotic cardiovascular disease had moderately elevated TG with 
controlled LDL-C, with an increased event rate seen in these patients compared to those with 
TG of 1.0mmol/L.15 
We found the prescribing of HI-statins to be considerably lower amongst patients with 
LDL-C levels not at target. Whilst it is possible that a proportion of these patients were 
intolerant of HI-statins, it is likely that a high proportion of patients prescribed NI-statins with 
LDL-C above the 1.4 and 1.8mmol/L respective targets, would be tolerant of HI-statins, given 
prior reported levels of statin intolerance in 10-20% of statin treated patients.16-18 Furthermore, 
the (co-)prescribing of other LLTs, such as ezetimibe or fibrate, was also low. 
Similarly, amongst those patients with recorded TG levels ≥2.3mmol/L and 
≥1.5mmol/L, the prescribing of fibrate or N-3s were also low with < 3% of patients prescribed 
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these treatments alone or with statin therapy. However, these therapies are not endorsed by the 
UK National Institute for Health and Care Excellence (NICE).19 
Although HI-statin prescription is recommended by NICE, only 56.4% of the patients 
in this study were receiving this treatment. However, our observed HI-statin prescribing rate 
was considerably higher than documented in previous observational studies of patients with 
MI, which have reported high intensity statin use in between only 4 and 31% of MI patients.16, 
20, 21 Although, those studies were in different health care systems to the UK, 16, 21 and in 
historical MI populations,16 rather than a recent post PCI population, ACS was the indication 
for PCI in the majority of patients in our cohort (69.8%). 
To allow assessment of response to treatment and consideration that LDL-C levels tend 
to fall transiently after an ACS, ESC guidelines recommend that lipid levels should be 
consequently (re-)evaluated 4-6 weeks after an ACS. Therefore, in this study we only analysed 
lipid profiles recorded beyond 28 days post-PCI. For patients with ≥1 result we identified the 
lowest lipid levels recorded between 28 days and one-year and documented the LLT 
prescription in the period preceding the lowest relevant result. Thus, the results of this study 
do not represent long term lipid prescribing or lipid control beyond 1-year. However, LLT 
prescribing, treatment concordance and lipid control has previously been shown to decrease 
significantly over time.22, 23 
Just under three quarters (73.1%) of our cohort had a lipid profile recorded during the 
first-year post discharge. Females and those with a history of CKD stage 4+, ischaemic stroke, 
AF and/or PVD were less likely to have lipid levels and have lipid levels not at target. 
Importantly, these are clinical characteristics associated with worse outcomes and provide 
further evidence of gender disparity in the management of CVD risk.24 
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Notably patients with an ACS during the index admission were almost 2.5 times more 
likely to be prescribed HI-Statin than those undergoing PCI for stable disease and more likely 
to have lipids checked in the year post discharge. These observations are possibly due to the 
differences in clinical pathways between ACS and elective patients undergoing PCI for stable 
coronary artery disease who are less likely to have changes made to longer term CVD 
prevention regimens at that point in time.  
The 2016 non-HDL-C and LDL-C targets were achieved in 57% and 48% of patients, 
whereas the 2019 respective targets were achieved in 37% and 23% of patients. Importantly, 
whilst diabetic patients were more likely to achieve LDL-C targets this was not the case for 
non-HDL-C, emphasising the importance of considering this measure in this very high-risk 
population. 
Two recent registry studies looked at the effectiveness of LDL-C control in populations 
with coronary artery disease (CAD).25, 26 In both these registries approximately 42% of ACS 
patients had LDL-C levels below the 2016 ESC/EAS target of < 1.8mmol/L, but only 28% of 
stable CAD achieved this. 
Both of these studies emphasise the difficulty faced in achieving adequate LDL-C 
control across high-risk populations, even considering the less stringent 2016 targets. These 
registry findings are consistent with ours which also reflects the challenges in achieving the 
even more stringent 2019 targets. It is likely that increased use of novel therapies will be 
required, where appropriate in order to close this therapeutic gap. 
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STRENGTHS AND LIMITATIONS 
We believe that by identifying important gaps in the achievement of ESC/EAS guideline target 
lipid levels, this study has demonstrated the potential opportunity for improved secondary 
prevention of CVD through optimisation of evidence-based lipid lowering therapy. Although 
the data in this study represent practice prior to the publication of the 2019 guidelines, this is a 
recent, representative cohort of very high-risk patients who would now qualify for more 
aggressive LDL-C, non-HDL-C and TG targets according to the new guidelines. 
There are a number of potential limitations to this study. While we identified the 
prescribing of LLT from primary care GP data, we were not able to identify the quantity of 
medication prescribed, whether it was dispensed, or if the patient complied with therapy. This 
study makes no assumptions on medication compliance which is often low in chronic 
conditions, particularly with statins.27, 28 Therefore, the prescribing of LLT reported in this 
study likely describes a best-case management scenario. 
We did not identify any patients post PCI who were prescribed PCSK9 inhibitors in our 
dataset. These agents were only approved for use within the UK National Health Service (NHS) 
in June 2016.29, 30 Although the prescribing of these treatments is mainly provided though 
specialist hospital outpatient clinics, whose data was not available for this study, the uptake of 
PCSK 9 inhibitors within Wales has been very low. Therefore, it is unlikely that the absence 
of the prescribing data for these treatments would have significantly changed these results. 
It was not possible to characterise the reasons why over a quarter of our patients did not 
have a lipid profile documented in their primary care EHR data during the year post discharge. 
It is unlikely that this was due to ‘loss to follow-up’ as we only included patients with ≥90days 
follow-up (mean follow-up =349 days), which should have allowed sufficient time post-PCI to 
record lipid profiles. Patients without lipid levels typically had higher risk characteristics. It is 
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unknown whether this difference observed in lipid monitoring is explained by confounding 
factors or a risk-treatment paradox. It is possible that some patients had lipid profiles 
documented post-discharge within secondary care pathology datasets that were not available 
for this study, however longer-term risk factor management is undertaken in primary care for 
the vast majority of patients in Wales in both the primary and secondary prevention settings. 
Lipid profiles recorded during the index admission were also not available for this 
study. While we categorised patients at or above target levels, we were not able to calculate 
the percentage LDL-C reduction from baseline. It is therefore likely that an even greater 
number of patients would not have achieved both a ≥50% reduction in LDL-C and a target 
level. 
In this study, 6.7% of patients were classified as having recurrent atherosclerotic events, 
including a previous hospital admission for an ACS, coronary revascularisation, non-embolic 
stroke or TIA within 2 years before the index PCI. Due to ambiguity of clinical coding of 
peripheral vascular disease within the secondary care hospital admissions PEDW data, we were 
unable to accurately detect acute peripheral vascular events and therefore these were not 
included. We noted that a far greater number of our patient cohort had experienced clinical 
atherosclerotic events over 2years before the index PCI (table 3.1). 
It was beyond the scope of this study to evaluate the relationships between early post-
PCI lipid levels, LLT strategy and clinical outcomes in the first year post-PCI. The purpose of 
this short report was to characterise the nature of LLT and achievement of lipid targets 
according to contemporary ESC/EAS9 guidance at the time of PCI and to document the 
potential for further optimisation of lipid management in this very high-risk cohort with 
reference to the new guideline targets and recommended treatments. Therefore, future 
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prospective evaluation will be required to evaluate the nature of any changes in lipid 
management and impact on lipid levels and clinical outcomes at a population level. 
A last, but important consideration is that the data for this study were obtained from 
patients treated in the Welsh NHS, where the cost of health care, including prescription drugs, 
is entirely free at the point of delivery. This mitigates against potential barriers of affordability 
of follow-up consultation, lipid monitoring and medication purchasing. These would be 
important considerations when comparing the findings of our study to other healthcare systems, 
where greater discrepancies in quality of care might be expected in more economically 
disadvantaged individuals and populations.31 
 
CONCLUSION 
We have identified a relatively low rate of prescribing of high intensity statins with or without 
additional evidence-based LLT agents in a large post-PCI patient population, as well as a 
relatively low proportion of these patients achieving the new EAS/ESC lipid targets. Our data 
suggest that there is considerable potential to optimise LLT through statin intensification and 
appropriate use of novel LLT. This would be expected to increase the proportion of very high-
risk patients achieving target lipid levels and improve clinical outcomes at an individual and 
population level. However, the budgetary impact of novel management strategies and thus 
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SUPPLEMENTARY MATERIAL  
Supplementary table 3.1 Multivariable binary regression analysis of variables associated with the absence of 
a documented lipid profile during follow up. 
Covariate OR Lower CI Upper CI P 
Female 1.18 1.09 1.28 <0.001 
CKD stage 4+ 2.26 1.65 3.09 <0.001 
Dementia  2.35 1.52 3.63 <0.001 
Ischaemic stroke 1.19 1.03 1.38 .018 
AF 1.20 1.07 1.35 0.002 
PVD 1.41 1.22 1.64 <0.001 
ACS during index admission 0.77 0.71 0.84 <0.001 
Diabetes mellitus 0.56 0.50 0.62 <0.001 
LLT     
   No LLT Reference   <0.001 
   HI statin 0.25 0.22 0.29 <0.001 
   NI stain 0.22 0.18 0.25 <0.001 
   Other LLT* 0.21 0.14 0.31 <0.001 
   Statin & other LLT* 0.63 0.46 0.85 <0.001 
*Other LLT indicates the prescribing of ezetimibe and/or fibrate. 
The following variables were included in the model: age, sex, hypertension, diabetes mellitus, CKD stage 4+, chronic liver disease, 
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Supplementary table 3.2. Multivariable binary regression analysis of variables associated with LDL-C 
≥1.4mmol/L 
Covariate OR Lower CI Upper CI P 
Age 0.98 0.98 0.99 <0.001 
Female 1.83 1.63 2.06 <0.001 
PVD 1.43 1.13 1.80 <0.001 
ACS during index admission 0.62 0.55 0.71 <0.001 
Diabetes mellitus 0.59 0.53 0.66 <0.001 
LLT     
   No LLT Reference   <0.001 
   HI Statin 0.13 0.08 0.19  
   NI statin  0.32 0.21 0.49  
   Other LLT 1.74 0.59 5.11  
   Statin other LLT 0.31 0.17 0.55  
*Other LLT indicates the prescribing of ezetimibe and/or fibrate. 
The following variables were included in the model: age, sex, hypertension, diabetes mellitus, CKD stage 4+, chronic liver disease, 
dementia, heart failure, ischaemic stroke, PVD, AF, ACS during the index admission and LLT 
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Supplementary table 3.3 Multivariable binary regression analysis of variables associated with non-HDL-C 
≥2.2mmol/L 
Covariate OR Lower CI Upper CI P 
Age 0.97 0.96 0.97 <0.001 
Female 1.82 1.58 2.09 <0.001 
PVD 1.65 1.22 2.22 0.001 
ACS during index admission 0.57 0.49 0.67 <0.001 
Hypertension 1.14 1.01 1.29 0.038 
LLT     
   No LLT Reference   <0.001 
   HI Statin 0.09 0.06 0.15  
   NI statin  0.24 0.15 0.39  
   Other LLT 2.47 0.56 10.94  
   Statin other LLT 0.42 0.20 0.89  
*Other LLT indicates the prescribing of ezetimibe and/or fibrate. 
The following variables were included in the model: age, sex, hypertension, diabetes mellitus, CKD stage 4+, chronic liver disease, 
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Supplementary table 3.4 Multivariable binary regression analysis of variables associated with triglycerides 
≥1.5mmol/L 
Covariate OR Lower CI Upper CI P 
Age 0.98 0.97 0.98 <0.001 
Female 1.26 1.14 1.38 <0.001 
Hypertension 1.21 1.11 1.32 <0.001 
CKD stage 4+ 1.83 1.16 2.88 0.009 
Ischaemic stroke 1.33 1.12 1.59 0.001 
Atrial fibrillation  0.85 0.73 0.98 0.025 
PVD 1.48 1.24 1.77 <0.001 
ACS during index admission 0.77 0.71 0.85 <0.001 
Diabetes mellitus 1.91 1.74 2.11 <0.001 
LLT     
   No LLT Reference   <0.001 
   Other LLT* 0.91 0.49 1.68  
   Statin  0.55 0.45 0.66  
   Statin other LLT 0.68 0.49 0.94  
*Other LLT indicates the prescribing of a fibrate and/or N-3. 
The following variables were included in the model: age, sex, hypertension, diabetes mellitus, CKD stage 4+, chronic liver disease, 






















22,164 Patients undergone 
PCI between January 2012 
and December 2017  
Minimum of 90 days WLGP 
data prior to index PCI  
16,254 
Incomplete data linkage 
prior to index PCI                       
5910 
Survived index admission with 
linked data post discharge 
15,775 
Died during the index admission    476 
No linked data post discharge     3 
Total                               479 





Died within 90 days                          436             
< 90 days linked data                       136 
 Total                                                   572            
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Supplementary Figure 3.2 Number of patients and lipid lowering therapy according to non-
HDL-C level. 
*Governance restrictions within SAIL prohibit the reporting of numbers <5. Due to the low number of patients prescribed ‘other’ lipid 
lowering treatment with a non-HDL-C < 2.2, we have grouped these patients with no treatment. 
< 2.2 mmol/L ≥2.2mmol/L < 2.6 mmol/L ≥2.6 mmol/L
Other 66 5 63
No treatment or other* 21
No treatment 242 38 223
Statin & other 14 88 34 68
Non high intensity statins 293 981 554 720
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ABSTRACT 
AIMS 
In patients with non-valvular atrial fibrillation (NVAF) prescribed warfarin, the UK National 
Institute of Health and Care Excellence (NICE) defines poor anticoagulation as a TTR of 
<65%, any 2 INRs within a 6-month period of ≤1.5 (“low”), 2 INRs ≥5 within 6-months, or 
any INR ≥ 8 (“high”). 
Our objectives were to (i) quantify the number of patients with poor INR control and 
(ii) describe the demographic and clinical characteristics associated with poor INR control. 
 
METHOD AND RESULTS 
Linked anonymised health record data for Wales (2006-2017) was used to evaluate patients 
prescribed warfarin who had at least 6 months of INR data.  
32,380 patients were included. In total, 13,913 (43.0%) patients had at least one of the 
NICE markers of poor INR control. Importantly, in the 24,123 (74.6%) of the cohort with an 
acceptable TTR (≥65%), 5,676 (23.5%) had either low or high INR readings at some point in 
their history. In a multivariable regression female gender, age (≥75), excess alcohol, diabetes 
heart failure, ischaemic heart disease and respiratory disease were independently associated 
with all markers of poor INR control. 
 
CONCLUSION 
Acceptable INR control according to NICE standards is poor. Of those with an acceptable TTR 
(>65%) one quarter still had unacceptably low or high INR levels according to NICE criteria. 
Thus, only using TTR to assess effectiveness with warfarin has the potential to miss a large 
number of patients with non-therapeutic INRs who are likely to be at risk of stroke, systemic 
embolism and bleeding.  
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BACKGROUND  
Warfarin is the most common oral anticoagulant prescribed to reduce the risk of stroke in 
patients with atrial fibrillation (AF). Warfarin, like other Vitamin K antagonists (VKAs), has 
several limitations, including many drug-drug and drug-food interactions.1 Furthermore, 
patient characteristics and comorbidities can lead to high intra-and inter-patient variability in 
response.2, 3 In patients with non-valvular AF (NVAF) without any other indication for 
anticoagulation, current guidelines recommend an International Normalised Ratio (INR) range 
of 2.0 – 3.0.4-6 The net clinical benefit of warfarin is associated with the proportion of time that 
INR values are maintained within the therapeutic range, referred to as the time in therapeutic 
range (TTR).7, 8 Subtherapeutic INR results are associated with an increase in 
thromboembolism9, while supertherapeutic INR results are associated with increased risk of 
bleeding including haemorrhagic stroke.10-12 
In the UK, the National Institute for Health and Care Excellence (NICE) recommends 
that, in patients prescribed warfarin for AF to, “Reassess anticoagulation for a person with poor 
anticoagulation control shown by any of the following: two INR values higher than 5 or one 
INR value higher than 8 within the past 6 months; two INR values less than 1.5 within the past 
6 months; [and/or] TTR less than 65%.”13 NICE advises that “If anticoagulation control cannot 
be improved, then the risks and benefits of alternative stroke prevention strategies should be 
discussed with the patient.” For patients with non-valvular atrial fibrillation (NVAF) 
alternative anticoagulation with direct oral anticoagulants (DOACs) can now be provided. 14, 
15 
A number of observational studies and clinical trials have reported the TTR of patients 
prescribed VKAs for AF,3, 10, 16-21 with the average TTR in these studies ranging from 53.7-
68.4%, highlighting the increased risk of stroke and systemic embolism with subtherapeutic 
INRs, as well as the excess bleeding risk with supertherapeutic INRs. However, the wider 
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variability in INR control described by frequency of very low or very high INRs (as defined 
by NICE), as distinct from TTR, has not been previously described. This is of particular 
importance as it would characterise important therapeutic gaps at both an individual and 
population level, which are not captured by TTR alone.  
The objectives of this study were (i) to quantify the number of patients with NVAF 
prescribed warfarin who exhibit NICE-defined poor INR control and (ii) describe the 
demographic and clinical characteristics of these patients, as well as the relationship between 
these characteristics and poor INR control. 
  
Chapter four 133 
METHOD 
STUDY DESIGN AND DATA SOURCES  
A retrospective observational cohort study was conducted using linked anonymised healthcare 
data for patients prescribed warfarin for NVAF between January 2006 and April 2017 in Wales, 
United Kingdom, using the Secure Anonymised Information Linkage (SAIL) Databank.22-24 
SAIL is part of the national e-health records research infrastructure. The following datasets 
held within SAIL were linked: the Patient Episode Database for Wales (PEDW),25 which 
records hospital admission and discharge dates, diagnoses and operational procedures, 
demographic data, and date of death where applicable for the population of Wales; the Welsh 
Longitudinal General Practice (WLGP) dataset26 containing demographic, clinical and 
prescribing data for approximately 76% of primary care practices across Wales; the Welsh 
Demographic (WDS) dataset,27 which contains basic demographic information and history of 
individuals’ residence in Wales and registration with GP practices; and the Welsh Index of 
Multiple Deprivation (WIMD) 2011,28 an area-based deprivation measure.   
Study subjects included those who had a diagnosis of AF/atrial flutter recorded in the 
WLGP dataset at any point prior to or during the study period and who were at least 18 years 
old at time of diagnosis. Patients were excluded if they had valvular AF (defined as AF in the 
presence of mitral stenosis, rheumatic mitral valve disease, prior mitral valve surgery and any 
metallic prosthetic heart valve), were pregnant during the study period, or had a history of Deep 
Vein Thrombosis (DVT) or Pulmonary Embolism (PE). This AF cohort was then restricted to 
patients who were prescribed warfarin during the study period and had at least 6 months of 
recurrent INR tests recorded in the WLGP dataset during the study period (excluding the first 
6 weeks after start of treatment; a period when the warfarin dose is typically still being tailored 
to the patient’s needs).  
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MEDICAL HISTORY, DEMOGRAPHIC INFORMATION AND PRESCRIPTIONS 
A census date was assigned to each patient from when they met all of the inclusion criteria. 
Demographic data, prior diagnoses, and comorbidities (chosen to reflect standard stroke and 
bleeding risk classification, and comorbidities of major organ systems) prior to the census date 
for each patient were identified. Individual age was calculated at the census date. The presence 
of heart failure, hypertension, vascular disease (defined as prior myocardial infarction (MI) or 
peripheral vascular disease (PVD) including peripheral artery disease and aortic plaque), prior 
stroke (including TIA), gender and age were used to calculate the individual CHA2DS2-VASc 
score. In addition, the presence of the following were also identified prior to the census date 
for each patient (see supplementary table 1 for list codes): chronic kidney disease (CKD) stage 
4+, chronic liver disease (including cirrhosis, fibrosis, chronic hepatitis and chronic active 
hepatitis, fatty liver, sclerosis of the liver, unspecified alcoholic liver damage, hepatic failure), 
dementia, thyroid disease (both hyper and hypothyroidism), epilepsy and respiratory disease, 
ischaemic heart disease (including stable, unstable and MI), haemorrhagic stroke, major 
bleeding events (including respiratory bleeds, urinary tract bleeds, intracranial bleeds and 
gastrointestinal bleeds) and excess alcohol consumption  
 
CALCULATION OF INDIVIDUAL TIME IN THERAPEUTIC RANGE (TTR) AND IDENTIFICATION OF 
LOW AND HIGH INRS 
NICE recommends using the Rosendaal method for calculating TTR; this method assumes a 
linear change in INR between consecutive tests (for example, if two consecutive INR tests are 
2.5 and 3.5 with 30 days between tests, the method estimates that 15 days were in range, and 
15 days were out of range.29 Thus, the estimated TTR is 50% during that 30 days period). 
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In this study, a modified Rosendaal method was used to calculate individual TTR. 
Following the census date for each patient, the first 6 weeks of INR results were excluded, to 
account for any initiation period. Individual INR results were identified, as well as the time 
span between them; when the interval between INR results was greater than 84 days, the INR 
test results were excluded from the overall calculation of individual TTR. The calculation 
began again when there were two INR results within 84 days carried out because long gaps 
between INR tests most likely represented periods where treatment was discontinued. An INR 
value of less than 2.0 was considered subtherapeutic and an INR value greater than 3.0 was 
considered supertherapeutic.  
Patients were categorised as having: (i) “unacceptable” or “acceptable” individual TTR 
control (< 65% or ³ 65% respectively); (ii) “low” INRs (two INR results <1.5 in any 6-month 
period), or (iii) “high” INRs defined by two INR results greater than 5 in any 6 month period 
or one result greater than 8. In addition, these three markers were combined into an overall 
“poor” INR control category, which included all patients with at least one of these NICE-
defined indicators of poor control. Patients without any NICE criteria of poor INR control were 
categorised as “adequate” INR control. 
 
STATISTICAL METHODS 
Baseline variables and characteristics of patients included in the analysis were presented as 
percentages or means with standard deviations. Characteristics of patients with each of the 
three markers of poor control, as well as the overall poor control category, were compared to 
those with “acceptable” INR control (defined as the absence of any marker of poor control). 
Differences in these characteristics between groups were summarised using chi-squared tests 
for categorical variables and independent t-tests for continuous variables. Next, we investigated 
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two sets of multivariable models for the adverse outcomes. First, a binary logistic regression 
model was constructed with CHA2DS2-VASc score and deprivation index (using WIMD 
quintiles) as the predictors, and “poor” control vs “adequate” as the primary (binary) dependent 
outcome. This model was repeated with “unacceptable” TTR, “low” INR, and “high” INR as 
the dependent outcome (in each case in a binary comparison with “adequate” INR control).  
The second set of models attempted to identify all independent risk factors, by testing 
all available predictors from the baseline co-morbidities and risk factors (including those 
components within the CHA2DS2-VASc score), age, gender and WIMD quintile. Binary 
dependent variables were the same as above (each of the three individual markers of poor 
control, as well as the overall poor control category, in comparison with a baseline good 
control). For this exploratory analysis, a large number of independent variables were 
considered, and the final set of predictors was chosen based on a search of all models (without 
interactions) and minimising the Bayesian Information Criterion (BIC).30 Model selection was 
also carried out using the lasso regularisation method,31 to check for consistency in the 
variables found in the final models. Analysis was carried out using SPSS version 22.0 and the 
package glmnet in R.32  
 
MISSING DATA 
Comparisons were made between those included in the final cohort for analysis and (i) those 
with NVAF prescribed warfarin but with less than 6 months of INR test results for analysis, 
and (ii) those where there was no INR recorded in the WLGP dataset (see supplementary table 
4.2). Finally, within the final cohort for analysis, comparisons were made between those with 
and without deprivation index data available (see supplementary table 4.3). 
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RESULTS 
Over 4 million patient records were identified in the SAIL Databank during the study period; 
110,592 had a diagnosis of AF and were aged over 18 at the time of diagnosis, of whom a total 
of 32,380 met the final inclusion criteria for this study (figure 4.1). During a mean follow-up 
time of 4.3 years per patient, the mean TTR was 72.6%; 42.5% of the cohort was female; the 
mean age was 73.5 years (standard deviation = 9.7 years); and the median CHA2DS2-VASc 
score was 3 (table 4.1).  
 
Figure 4.1 Inclusion criteria for study cohort  
 
 Eligible population in SAIL 
N=4,066,696 




• DVT or PE (N=7,341) 
• Valvular AF (N=12,607) 







Not followed up 
N=17,986 
• <6months. Follow up (N=2,349) 
• No INR test results (N=5,403) 
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Table 4.1 Cohort demographics and medical history.  
            N = 32,380 
 N (%) 
Age <65 5,412 (16.7) 
    65-74 10,875 (33.6) 
    >=75 16,093 (49.7) 
Female 13,751 (42.5) 
Deprivation index (quintile)  
   1 (most deprived) 5,309 (17.5) 
   2 5,875 (19.3) 
   3 6,728 (22.1) 
   4 5,862 (19.3) 
   5  6,645 (21.8) 
CHA2DS2-Vasc score  
   0 and 1 4,356 (13.5) 
   2 5,949 (18.4) 
   3 7,242 (22.4) 
   4 6,814 (21.0) 
   5 4,281 (13.2) 
   6 2,495 (7.7) 
   >=7 1,243 (3.8) 
Excessive alcohol intake 850 (2.6) 
Cancer 6,134 (18.9) 
CKD stage 4+ 375 (1.2) 
Dementia 364 (1.1) 
Diabetes 6,876 (21.2) 
Epilepsy 206 (0.6) 
Haemorrhagic stroke 204 (0.6) 
Heart failure 7,264 (22.4) 
Hypertension 21,234 (65.6) 
Ischaemic heart disease 9,641 (29.8) 
Ischaemic stroke 6,661 (20.6) 
Liver disease 611 (1.9) 
Major bleeding event 4,536 (14.0) 
Peripheral vascular disease 1,883 (5.8) 
Respiratory disease 6,305 (19.5) 
Thromboembolism 426 (1.3) 
Thyroid disease 4079 (12.6) 
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In total, 13,913 (43.0%) patients had at least one of the NICE markers of poor INR control 
(figure 4.2). Of this group, 8,237 (25.4%) had an unacceptable TTR (<65%) and 9,781 (30.2%) 
had two low INR readings within a six-month period. Overall, 3,148 (9.7%) had high INRs 
during the study period, including 2,649 (8.2%) that had two or more INR results greater than 
5 in a 6-month period, and 961 (3.0%) had an INR of greater than 8.  
In the 24,143 (74.6%) cohort with an acceptable TTR (≥65%), many had other signs of 
poor INR control: 5,090 (21.1%) had low INRs and 1,217 (5.0%) had high INRs. Overall, of 
those with acceptable TTR, 5,676 (23.5%) had either low or high INR readings at some point 
in their history. 
 
When considering European Society of Cardiology guidelines, which recommend a 
TTR ≥70%; 11, 876 (36.7%) of patients’ TTR fell below this threshold.6 Furthermore, of the 
20,504 patients with recommended TTR ≥70%, 3,990 (19.5%) patients met the NICE criteria 
for low or high INRs (supplementary figure 4.2). 
 
Patient characteristics associated with one or more signs of poor INR control include 
female sex, increasing social deprivation, increasing CHA2DS2-VASc score, heart failure, prior 
bleeding events, cancer, ischaemic heart disease, PVD, ischaemic stroke, thromboembolism, 
thyroid disease, respiratory disease, diabetes, epilepsy, dementia, excessive alcohol intake, 
liver disease, and CKD stage 4+(figure 4.3). Increasing CHA2DS2-VASc score from 2 was 
associated with an increasing likelihood of each marker of poor INR control, including the 
overall combined marker of poor INR control (figure 4.4). 
 
Chapter four 140 
 
Figure 4.2 Number of patients with poor INR control according to NICE criteria.  
 
MULTIVARIABLE MODELLING 
In the first set of models, a CHA2DS2-VASc score of 3 or more was significantly associated 
with all markers of poor INR control (table 4.2). A similar relationship was observed between 
higher levels of deprivation and the risk of poor INR control.  
In the second set of models, exploring all possible independent variables, after BIC 
model selection, age, female gender, excess alcohol consumption, heart failure, ischaemic heart 
disease, respiratory disease and diabetes were independently associated with all measures of 
poor INR control (table 4.3). Peripheral vascular disease was associated with ‘poor control’, 
‘high INRs’ and ‘TTR < 65%’ while prior major bleeding and dementia were associated with 
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‘poor control’ and ‘TTR < 65%’. Ischaemic stroke was only associated with ‘high INRs’ and 
deprivation index was only associated with ‘TTR < 65%’. Highest adjusted odds ratios, across 
all markers or poor control, were detected for excess alcohol consumption, which is also 
predictive of bleeding. 
 
Figure 4.3 Characteristics associated with poor INR control. 
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Figure 4.4 INR control verses thromboembolic risk 
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Table 4.2 Multivariable logistic regression model of INR control verses deprivation index and CHA2DS2-
VASc score 
Predictor Poor Control Low INRs High INRs TTR <65% 
Deprivation index* (quintiles). Adjusted odds ratio (95% CI) 
  5 (Least 
deprived) 
Reference, 












overall p value 
<0.001 
  4 1.02 (0.95-1.10) 
 
0.99 (0.92-1.08) 1.05 (0.93-1.20) 1.07 (0.98-1.17) 
  3 1.12 (1.05-1.21) 
 
1.11 (1.02-1.19) 1.18 (1.05-1.33) 1.21 (1.12-1.32) 
  2 1.17 (1.09-1.26) 
 
1.12 (1.03-1.21) 1.31 (1.16-1.48) 1.32 (1.22-1.44) 





1.18 (1.09-1.28) 1.36 (1.20-1.54) 1.41 (1.30-1.54) 
CHA2DS2-VASc Score. Adjusted odds ratio (95% CI) 
0 or 1 
Reference, 
overall p value <0.001 
 
Reference, 








overall p value 
<0.001 
 
2 0.94 (0.86-1.02) 
 
0.90 (0.82-0.98) 1.02 (0.87-1.19) 0.91 (0.82-1.01) 
3 1.13 (1.05-1.23) 
 
1.11 (1.01-1.21) 1.39 (1.19-1.61) 1.14 (1.04-1.26) 
4 1.27 (1.17-1.37) 
 
1.20 (1.10-1.32) 1.72 (1.49-2.01) 1.36 (1.23-1.50) 
5 1.53 (1.39-1.67) 
 
1.39 (1.26-1.53) 2.21 (1.85-2.65) 1.76 (1.58-1.95) 
6 1.62 (1.46-1.79) 
 
1.46 (1.30-1.63) 2.22 (1.90-2.59) 1.99 (1.77-2.25) 
≥7 1.82 (1.60-2.07) 
 
1.69 (1.46-1.96) 2.57 (2.07-3.20) 2.37 (2.04-2.75) 
*Deprivation index used is the WIMD quintile.28 
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Table 4.3 Multivariable regression models of patient characteristics verses INR control. 
 Poor Control 
Adjusted odds 
ratio, (95% CI), p 
Low INRs 
Adjusted odds ratio, 
(95% CI), p 
High INRs 
Adjusted odds 
ratio, (95% CI), p 
TTR <65% 
Adjusted odds 
ratio, (95% CI), p 
Age ≤64 Reference, <0.001 Reference, <0.001 Reference, <0.001 Reference, <0.001 
   65-74 0.84 (0.78-0.90) 0.82 (0.76-0.88) 0.88 (0.78-1.01) 0.76 (0.70-0.84) 
   ≥75 1.07 (1.00-1.15) 0.99 (0.92-1.06) 1.19 (1.06-1.35) 1.19 (1.09-1.28) 




















  1.23 (1.14-1.32), 
<0.001 
Cancer     
CKD stage 4+     
Dementia 1.51 (1.22-1.89), 
0.001 
  1.83 (1.44-2.33), 
<0.001 










    























  1.24 (1.13-1.36), 
0.001 
 
Liver disease     
PVD 1.25 (1.13-1.38), 
<0.001 




     











    
     
Deprivation indexa  
(quintiles) 
 
    
  5 (Least deprived)    Reference, <0.001 
  4    1.03 (0.95-1.13) 
  3    1.15 (1.06-1.26)  
  2    1.23 (1.13-1.35) 
  1 (most deprived)    1.28 (1.17-1.40) 
 All patient characteristics shown in table 4.1 were modelled, only characteristics that were significant in any 
of models are shown in the table.  
a Deprivation index used is the WIMD quintile.28 
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We found very good match between the variables selected by the BIC and Lasso model 
selection procedures (classifying by inclusion/exclusion the match was 78.9% for ‘poor 
control’, 89.4% for ‘Low’, 89.4% for ‘High’, 89.4% for ‘TTR < 65%’; see supplementary table 
4.4). All predictors highlighted above were consistently selected by both procedures. BIC 
selection tended to be more conservative, with slightly fewer variables selected in the final 
models. 
DISCUSSION 
This is the first population study examining the effectiveness of warfarin therapy according to 
the NICE clinical guideline criteria for INR indicators of poor anticoagulation control, across 
a population with NVAF. In this study, only 57.0% of patients had adequate INR control 
according to NICE criteria. Increasing stroke risk, as assessed by the CHA2DS2-VASc score, 
was associated with a greater risk of poor INR control, as were many individual clinical 
characteristics that are also associated with increased risk of stroke or bleeding. Unlike 
previous studies, not only was TTR evaluated but also the NICE criteria for unacceptably low 
and high INR levels. Importantly, we found that almost a quarter of those patients with 
acceptable TTR (>65%) demonstrated evidence of unacceptably low or high INR levels 
according to NICE criteria during the study period. These findings suggest that the risk of 
stroke, systemic embolism and/or bleeding, at both an individual patient and a population level, 
may be under-appreciated if TTR is followed as the sole measure of effectiveness of 
anticoagulation. Whilst it is important to recognize that the specific relationships between 
NICE low and high criteria and risks of major bleeding and stroke have not been definitively 
characterized, these are pragmatic values identifying very low and high INR readings in 
chronically treated patients, defined by an expert consensus panel that should mandate clinical 
attention in UK practice.  
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This study evaluated the impact of multiple clinical and demographic factors in one of 
the largest real-world studies of INR control in patients with NVAF. Increasing CHA2DS2-
VASc score (above 3), and hence increasing stroke risk, was strongly associated with poor INR 
control. As these patients are at the greatest thromboembolic risk and therefore likely to derive 
the greatest absolute benefits from effective anticoagulation, our data emphasise the particular 
importance of close monitoring and appropriate treatment selection in these vulnerable 
individuals. Individual risk factors for stroke including diabetes, heart failure, PVD, ischaemic 
heart disease and female gender were independently associated with markers of poor INR 
control. Prior major bleeding events and excess alcohol consumption, both risk factors for 
bleeding, were also associated with poor INR control. This is likely to reflect that patients with 
increasing comorbidity have an increasing number of potential influences on warfarin 
bioavailability and coagulation factor synthesis. 
Previous studies have demonstrated that increasing CHA2DS2-VASc score, as well as 
comorbidities including heart failure, diabetes, CKD, chronic obstructive pulmonary disease, 
female sex, and lower income, are associated with lower TTR. 2, 3, 21. The models presented in 
our study confirm this finding, and also show that both CHA2DS2-VASc score and multiple 
individual comorbidities are associated with low and high INRs. It is not known whether it is 
the direct physiological effect of these comorbidities, or medications prescribed for them, that 
are responsible for poor INR control; however, the observed association between increasing 
stroke risk and risk factors for bleeding associated with poor INR control warrants increased 
vigilance in those patients with increasing risk of stroke or bleeding. 
The mean TTR of our cohort was higher than recorded in many previous studies, and 
the number of patients achieving adequate TTR had improved each year during the study 
(supplementary figure 4.1). Previous studies have suggested that INR management within 
anticoagulation clinics is associated with better TTR control.3, 33 This study does not make 
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comparisons between individual anticoagulation services or models of service delivery. There 
are several ways of delivering anticoagulation services in Wales, with many anticoagulation 
services being provided within primary care GP services. This may have contributed to the 
high TTR observed in this study, because it is also possible that patients who are difficult to 
control are managed within specialist anticoagulation services within secondary care, and their 
data were not included in this study. Furthermore, those with troublesome INR control may 
have been switched to direct oral anticoagulants (DOACs), a newer class of medications that 
were introduced in the latter period of this study. 
The observation that the number of patients with adequate TTR increased across the 
study period, yet the number with low or high INRs remained relatively constant, is of interest 
but unexplained. It may be possible to improve TTR across the population through improved 
monitoring, interventions or patient selection, but less easy to prevent low or high INRs in 
response to acute events or changes to medication, especially in patients with multiple 
comorbidities that impact on INR variability.34-36 
We excluded AF patients with “valvular AF” (mitral stenosis, rheumatic mitral valve 
disease, prior mitral valve surgery or any metallic prosthetic heart valve), those with a history 
of DVT or PE and those pregnant during the study period. These patients may have had 
“individualised” INR targets, which would not necessarily have been identifiable in the SAIL 
databank and may potentially have biased the study towards a greater number of patients with 
‘poor INR control’ when applying specific NICE and/or ESC criteria for AF. Thus, we decided 
to take a conservative approach by excluding them from the analyses. Furthermore, our clinical 
experience suggests that these more complex patients are more often managed via specialist 
secondary care haematology led anticoagulation services and their INR results would not have 
been available for analysis in this study. 
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STRENGTHS AND LIMITATIONS OF THIS STUDY 
This is the first study that has investigated not just TTR, but also low and high INR events, as 
markers of poor therapeutic control with warfarin therapy, allowing us to highlight that there 
is a substantial cohort of patients likely to be at risk of poor outcomes who may be missed if 
TTR is the sole focus.  
The use of a large, data-rich, linked population data source is a particular strength of 
this study. The linked primary and secondary care data held by SAIL enable the investigation 
of a very large cohort of individuals longitudinally over a period of years and across multiple 
data sources, giving a much more complete picture of patient treatment, health, and 
characteristics than previous studies. 
In calculating the TTR, NICE guidance recommends excluding the first six weeks of 
INR results and calculating the TTR over a maintenance period of six months. This 
recommendation was incorporated into the methodology of this study. During the study period 
it is possible that there were temporary discontinuations of warfarin therapy due to acute 
illness, in response to elevated INR results or admissions to hospital. In order to address this, 
periods where there was a gap of greater than 84 days between INR readings were excluded, 
but this is an imperfect measure, and it is not possible to definitively identify gaps in treatment.  
Although it may be argued that periods of temporary discontinuation should be 
excluded from assessing INR control according to NICE criteria, unless patients receive 
alternative treatment to reduce the risk of stroke, they are exposed to an increased risk of 
thromboembolic events. The destabilisation of INR control during acute illnesses and the 
prolonged subtherapeutic or supertherapeutic coagulation during gaps in anticoagulation is a 
recognised limitation in the use of warfarin. 
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In total there were 17,986 patients identified with NVAF and prescribed warfarin that 
were excluded from the study, of which 5,403 did not have any INR readings available, and a 
further 10,234 that had insufficient INR readings (less than 6 months) to analyse. It is not 
known why 5,403 patients did not have INR readings recorded but it is possible that these 
patients were managed via coagulation clinics outside of the primary care setting and their 
results are not incorporated into the WLGP dataset. It is not known what effect the 
incorporation of their results into this study would have made; however, these patients had a 
significantly higher rate of nearly all comorbidities and higher prevalence of excess alcohol 
consumption that were associated with greater likelihood of poor INR control in the models 
presented in this study.   
In the final cohort 1,961 (6.1%) had a missing deprivation index and were therefore 
excluded from the multivariable analyses. This group had slightly lower prevalence of 
comorbidities (other than excess alcohol consumption), suggesting an overall lower risk group 
than those included in the multivariable analyses. Regardless, all major comorbidities were 
well represented in the multivariable models and the inclusion of this group would not be 
expected to have a significant impact on the observed associations. 
Some patients may have had different, individualized INR targets, which would not be 
evaluable in this study. By identifying and excluding patients with valvular AF and those with 
other indications for anticoagulation, both groups with potentially higher INR targets, we have 
limited overestimates of poor INR control. The linkage of hospital and GP datasets has further 
improved the identification and exclusion of patients. However, it remains possible that 
undocumented valvular disease, multiple DVTs or PEs, or individually adjusted INR targets, 
may have resulted in the inclusion of patients with a targeted INR range outside of 2 to 3, who 
would then potentially be misclassified as having poor INR control. 
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Due to the nature of the study, it was not possible to detect whether excess alcohol 
consumption has an interacting effect on warfarin, directly affected the INR, or was a marker 
of poor compliance. 
CONCLUSION 
In this study, forty three percent of Welsh patients had at least one marker of poor INR control. 
Of those with an acceptable TTR (>65%) one quarter still had unacceptably low or high INR 
levels according to NICE criteria. Paradoxically, patients at the highest risk of stroke and with 
risk factors for bleeding were most likely to have poor INR control and may benefit from closer 
attention to therapeutic effectiveness and alternative anticoagulation strategies where 
appropriate. If TTR is used as the sole measure of warfarin’s therapeutic effectiveness, the risk 
of stroke, systemic embolism and bleeding may well be under-estimated. Further work is 
required to define the specific level of risk associated with NICE and other guidelines’ criteria 
for poor INR control and seek to identify novel measures of INR control for optimal risk 
stratification. 
While the results of this study suggest there is considerable opportunity to improve both 
embolic and bleeding risk, the relationship between poor INR control and these clinical 
outcomes remains to be determined. Nevertheless, in accordance with NICE guidelines, almost 
a half of NVAF patients prescribed warfarin for thromboembolic risk reduction warrant review 
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SUPPLEMENTARY MATERIAL  
 
Supplementary Figure 4.1 Change in INR control across the study period 
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Supplementary Figure 4.2 Number of patients with TTR<70% or have low or high INRs 
using the NICE low and high criteria. 
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Supplementary table 4.1 Diagnostic codes 
The list of diagnostic codes is extensive and therefore has been provided online: 
https://github.com/DHARRISSWAN/diagnostic_codes/blob/master/Suppl_table1_05022019.docx 
Supplementary table 4.2 Cohort characteristics and comparisons to patients with INR readings that were not 
available and those with insufficient INR readings for inclusion  
 Cohort analysed INR not available Insufficient INR readingsa 
 N=32380 N=5403 N=10234 
 Mean (SD) Mean (SD), Pb Mean (SD), Pc 
Age 70.40 (10.61) 70.14 (11.75), 0.098 71.13 (11.89), <0.001 
CHA2DS2Vasc score 3.38 (1.70) 3.70 (1.93), <0.001 3.58 (1.87), <0.001 
 N (%) N (%), Pb N (%), Pc 
Female 13751 (42.5) 2179 (40.3), 0.003 4302 (42.0), 0.448 
Deprivation index (quintile)    
      1 (most deprived) 5309 (17.5) 927 (17.9), <0.001 1769 (18.5), 0.118 
      2 5875 (19.3) 926 (17.9) 1848 (19.3) 
      3 6728 (22.1) 1056 (20.4) 2142 (22.4) 
      4 5862 (19.3) 819 (15.9) 1778 (18.6) 
      5 (least deprived) 6645 (21.8) 1437 (27.8) 2040 (21.3) 
Excess alcohol intake 850 (2.6) 194 (3.6), <0.001 346 (3.4), <0.001 
Cancer 6134 (18.9) 1677 (31.0), <0.001 2312 (22.6), <0.001 
CKD stage 4+ 375 (1.2) 195 (3.6), <0.001 263 (2.6), <0.001 
Dementia 364 (1.1) 346 (6.4), <0.001 309 (3.0), <0.001 
Diabetes 6876 (21.2) 1417 (26.2), <0.001 2476 (24.2), <0.001 
Epilepsy 206 (0.6) 53 (1.0), 0.006 88 (0.9), 0.021 
Haemorrhagic stroke 204 (0.6) 137 (2.5), <0.001 72 (0.7), 0.461 
Heart failure 7264 (22.4) 1991 (36.8), <0.001 2921 (28.5), <0.001 
Hypertension 21234 (65.6) 3351 (62.0), <0.001 6471 (63.2), <0.001 
Ischaemic heart disease 9641 (29.8) 1892 (35.0), <0.001 3383 (33.1), <0.001 
Ischaemic stroke 6661 (20.6) 1298 (24.0), <0.001 2223 (21.7), 0.013 
Liver disease 611 (1.9) 263 (4.9), <0.001 299 (2.9), <0.001 
Major bleeding event 4536 (14.0) 1533 (28.4), <0.001 1864 (18.2), <0.001 
Peripheral vascular disease 1883 (5.8) 481 (8.9), <0.001 778 (7.6), <0.001 
Respiratory disease 6305 (19.5) 1238 (22.9), <0.001 2308 (22.6), <0.001 
Thromboembolism 426 (1.3) 109 (2.0), <0.001 180 (1.8), 0.001 
Thyroid disease 4079 (12.6) 723 (13.4), 0.114 1344 (13.1), 0.162 
a This group contains patients with a diagnosis of NVAF, prescribed warfarin but with less than 6months of 
INR available for analysis. b P value for comparison between INR not available group and the cohort group 
analysed. c P value for comparison between INR insufficient group. 
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Supplementary table 4.3 Comparisons between those with deprivation index data present and missing from the 
final cohort  
N=32,380 
  Deprivation index present Deprivation index missing 
  N=30419 N=1961 
 Mean (SD) Mean (SD), Pa 
Age 70.48 (10.53) 69.05 (11.74), <0.001 
CHA2DS2Vasc score 3.39 (1.69) 3.24 (1.76), <0.001 
 N (%) N (%), Pa 
Female 12987 (42.7) 764 (39.0), 0.001 
Excess alcohol intake 784 (2.6) 66 (3.4), 0.041 
Cancer 5788 (19.0) 346 (17.6), 0.137 
CKD stage 4+ 351 (1.2) 24 (1.2), 0.864 
Dementia 335 ( 1.1) 29 (1.5), 0.154 
Diabetes 6471 (21.3) 405 (20.7), 0.534 
Epilepsy 190 ( 0.6) 16 (0.8), 0.376 
Haemorrhagic stroke 194 ( 0.6) 10 (0.5), 0.585 
Heart failure 6818 (22.4) 446 (22.7), 0.755 
Hypertension 20029 (65.8) 1205 (61.4), <0.001 
Ischaemic heart disease 9086 (29.9) 555 (28.3), 0.148 
Ischaemic stroke 6236 (20.5) 425 (21.7), 0.224 
Liver disease 577 ( 1.9) 34 (1.7), 0.668 
Major bleeding event 4343 (14.3) 193 (9.8), <0.001 
Peripheral vascular disease 1789 ( 5.9) 94 (4.8), 0.052 
Respiratory disease 5938 (19.5) 367 (18.7), 0.399 
Thromboembolism 404 ( 1.3) 22 (1.1), 0.5 
Thyroid disease 3840 (12.6) 239 (12.2), 0.597 
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Supplementary table 4.4 Multivariable regression models of patient characteristics verses INR control using 
BIC and Lasso models. 
 Poor Control Low INRs High INRs TTR <65% 
 BIC Lasso BIC Lasso BIC Lasso BIC Lasso 
Age  Ö Ö Ö  Ö  Ö Ö 
Female Ö Ö Ö Ö Ö Ö Ö Ö 
Excess alcohol Ö Ö Ö Ö Ö Ö Ö Ö 
Major bleeding 
events 
Ö Ö Ö Ö   Ö Ö 
Cancer         
CKD stage 4+  Ö      Ö 
Dementia Ö Ö     Ö Ö 
Diabetes Ö Ö Ö Ö Ö  Ö Ö 
Epilepsy         
Heart Failure Ö Ö Ö Ö Ö Ö Ö Ö 
Hypertension         
Ischaemic heart 
disease 
Ö Ö Ö Ö Ö Ö Ö Ö 
Ischaemic Stroke  Ö   Ö    
Liver disease        Ö 
PVD Ö Ö  Ö Ö Ö Ö Ö 
Respiratory disease Ö Ö Ö Ö Ö Ö Ö Ö 
Thromboembolism         
Thyroid disease  Ö       
Deprivation indexb  
(quintiles) 
 
 Ö     Ö Ö 
Match between BIC 
and Lasso model 
selectionc  
78.9% 89.5% 89.5% 89.5% 
a All patient characteristics shown in table 1 were modelled, only characteristics that were significant in any 
of models are shown in the table.  
b Deprivation index used is the WIMD quintile.28 
c  The match between BIC and Lasso model selection was calculated by the sum of variables that were 
selected by both models and not selected by both variables divided by the total number of variable in the 
models. 
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CHAPTER 5 
 
BLEEDING EVENTS ASSOCIATED WITH POOR INR CONTROL IN A NATIONAL 
COHORT PRESCRIBED WARFARIN FOR NON-VALVULAR ATRIAL 
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ABSTRACT 
AIMS 
In patients with non-valvular atrial fibrillation (NVAF) prescribed warfarin, the association 
between ‘poor’ International Normalized Ratio (INR) control and bleeding outcomes has not 
been fully characterised. This study set out to (i) quantify bleeding rates, and (ii) evaluate 
associations between bleeding, comorbidities, and poor INR control (ESC and NICE criteria). 
METHODS AND RESULTS 
Linked, anonymised, population-scale, patient-level data for Wales from the SAIL Databank 
(2006-17) were used to evaluate individual patients’ INR control. 35,035 patients were 
included, mean follow-up 4.3y, mean TTR 71.9%, mean CHA2DS2-VASc score 3.5 (SD=1.7). 
The percentage of time spent in poor INR control using the ESC criteria [TTR<70%] was 
40.9% and NICE criteria [TTR<65% or 2 INRs <1.5 within 6 months or 2 INRS >5 within 6-
months, or any INR>8] was 34.0%.  
Across the study period, 5,766 bleeds occurred in 5,039 patients (during periods of INR 
calculation). The event rates during periods of adequate and poor INR control were 3.3 and 4.8 
per 100 patient years respectively (similar between NICE and ESC criteria). Using a time-
varying Cox model, poor INR control according to ESC (HR=1.42 [1.34-1.50], <0.001) and 
NICE (HR=1.38 [1.31-1.46], <0.001) criteria were independently associated with bleeding risk 
as were increasing age, prior bleeding events, and chronic kidney disease. 
CONCLUSION 
Periods of guideline-defined poor INR control are associated with significantly higher bleeding 
event rates, independently of common comorbidities that are recognised as risk factors for 
stroke and bleeding.  
Chapter five 162 
INTRODUCTION  
Successful therapeutic use of warfarin has several important practical limitations, including 
high intra and inter-patient variability requiring regular monitoring of the International 
Normalised Ratio (INR).1, 2 In patients with non-valvular atrial fibrillation (NVAF), and 
without any other indication for anticoagulation, the target INR is in the range 2-3.3-7 The net 
clinical benefit is associated with the proportion of time that INRs are maintained in this range 
(time in therapeutic range [TTR]).8 9 Subtherapeutic INRs are associated with an increased risk 
of stroke and thromboembolism, while supratherapeutic INRs are associated with an increased 
risk of bleeding.8, 10, 11 
Guidelines stress the importance of assessing INR control, achieving adequate TTR, 
and reassessing ongoing anticoagulation with warfarin if high TTR cannot be achieved. 
European Society of Cardiology (ESC) 4 and Unites States (US) 5 guidelines recommend a 
TTR of ≥ 70%, while the United Kingdom National Institute of Health and Care Excellence 
(NICE) defines ‘poor’ anticoagulation as any of the following: (i) TTR of <65%; (ii)2 INR 
values less than 1.5 within the past 6 months (‘low’) or 2 INR values higher than 5 within the 
past 6 months (‘high’) or 1 INR value higher than 8.6 
We have previously demonstrated that a large proportion of patients exhibited 
suboptimal INR control according to the NICE guideline criteria in a large population based 
study 12. However, the likelihood of bleeding associated with suboptimal control, according to 
guideline criteria has not been fully addressed in a large-scale, real-world population. 
The objectives of this study were to (i) quantify bleeding events in patients prescribed 
warfarin for non-valvular atrial fibrillation (NVAF), and (ii) evaluate the association between 
bleeding events, patient clinical/demographic characteristics, and poor INR control (defined 
using NICE and European/American guideline criteria). 
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METHODS 
A retrospective, observational, cohort study was conducted using linked, anonymised, 
population-scale, electronic health record (EHR) data for 35,035 patients prescribed warfarin 
for NVAF between January 2006 and December 2017 in Wales, United Kingdom, using the 
Secure Anonymised Information Linkage (SAIL) Databank.13-15 SAIL is part of the national e-
health records research infrastructure for Wales (holding > 4million linked patient records 
across primary and secondary care along with other administrative and specialist data). The 
following data sources held within SAIL were linked at individual patient level: the Patient 
Episode Database for Wales (PEDW),16 which records hospital admission and discharge dates, 
diagnoses and operational procedures, demographic data, and date of death (where applicable) 
for the population of Wales; the Welsh Longitudinal General Practice (WLGP) dataset17 
containing demographic, clinical, and prescribing data for approximately 80% of primary care 
practices across Wales; the Welsh Demographic Dataset (WDSD)18, which contains basic 
demographic information and history of individuals’ residence in Wales, their registration 
history with General Practices (GP); and Lower layer Super Output Area (LSOA) 2001 which 




Patients eligible for the study comprised of those who had a diagnosis of AF/atrial flutter 
recorded in the WLGP data,12 at any point prior to or during the study period (2006-17) and 
who were at least 18-years old at time of diagnosis. Patients were excluded if they had valvular 
AF (defined as AF in the presence of mitral stenosis, rheumatic mitral valve disease, prior 
mitral valve surgery and any metallic prosthetic heart valve) or had a history of Deep Vein 
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Thrombosis (DVT) or Pulmonary Embolism (PE) prior to, or within 6-months, of being eligible 
to enter the study. Those who had a diagnosis of DVT, PE, or valvular AF appearing more than 
6-months after baseline were censored at the point of new diagnosis but not excluded from the 
study. In addition, any patient who was pregnant during the study was excluded. 
 
TEMPORAL CALCULATION OF INR CONTROL  
In addition to the exclusion criteria, the cohort was then restricted to patients who had at least 
6-months of recurrent INR tests recorded in the WLGP (excluding the first 6-weeks after start 
of treatment, a period when the warfarin dose is typically still being tailored to the patient’s 
needs), a minimum of 4 INRs in a rolling 6-month period (suppl. material ‘temporal INR 
control, figure 5.1 & 5.2a-5.2d) with no gap greater than 84 days between any two consecutive 
INR results and a gap of between 90 to 183 days between the first and last reading within a 6-
month period. In addition, there needed to be a warfarin prescription in any 84-day window. 
Individual TTR was calculated at each INR results using the modified Rosendaal method.20 
Based on these criteria, an algorithm was developed to allow the temporal calculation 
of INR control, and assign patients to ‘adequate’ or ‘poor’ INR control cohorts at each INR 
reading. Three criteria of poor INR control were assessed: (1) NICE poor INR control, 
categorised as having one (or more) of the following (i) TTR <65%, (ii) “low” INRs (two INR 
results <1.5 in any 6-month period) (iii) “high” INRs, defined as two INR results greater than 
5 in any 6-month period or one result greater than 8; (2) ESC/US criteria of poor INR control, 
defined as periods of TTR <70%; and (3) a modified ESC/US criteria for poor INR control, 
defined as TTR < 70% or any “low” or “high” INRs as per NICE criteria. Periods outside of 
‘poor’ criteria were classed as ‘adequate’ INR control. 
Patients could move between adequate or poor control, leave for any period during 
which there were insufficient or no INR results or no warfarin prescription available, and re-
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enter when there was another 6-month window with sufficient INR results and warfarin 
prescriptions to evaluate. 
An index date was assigned to each patient from when they met all of the inclusion 
criteria. The number of days a patient was in good and/or poor control was calculated to the 
end of 2017. Patients were censored at death, when a bleeding event occurred (including bleeds 
occurring during a period when INR control was not calculated), or when lost to follow-up 
(end of the primary care record which includes where data is no longer recorded, a patient 
moves to a practice where data is not supplied to SAIL, a patient moves out of Wales or dies). 
 
BLEEDING EVENTS 
Bleeding events were categorised as gastrointestinal (GI), urinary, respiratory, intracranial, 
gynaecological, ocular, or miscellaneous bleeds in other organ systems recorded in either the 
PEDW or WLGP data (see supplementary tables 5.1a & 5.1b for diagnostic codes to define 
bleeding events). Bleeding events that occurred during periods of INR calculation and within 
84 days of the last warfarin prescription were included, and patients were classified as having 
poor or adequate INR control based on the preceding 6-months of INR data.  
 
MEDICAL HISTORY, DEMOGRAPHIC INFORMATION, AND PRESCRIPTIONS 
Demographic and clinical data (chosen to reflect standard stroke and bleeding risk 
classification,21, 22 and comorbidities of major organ systems) prior to the index date for each 
patient were identified. Individual age and deprivation quintile were assigned at the index date. 
The presence of heart failure, hypertension, vascular disease (defined as prior myocardial 
infarction (MI) or peripheral vascular disease (PVD) including peripheral artery disease and 
aortic plaque), prior stroke (including transient ischaemic attack [TIA]), gender, and age were 
used to calculate the individual CHA2DS2-VASc score at index date.21  
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STATISTICAL METHODS 
Baseline variables and characteristics of patients included in the analysis were presented as 
percentages. Characteristics of patients who bled during periods of INR calculation were 
compared to those without bleeding events using chi-squared tests. 
 
We investigated the association between bleeding event outcome and INR control, 
using the NICE, ESC/US and the modified ESC/US definition of adequate or poor INR control. 
Since our data allow us to estimate periods of time for which a patient moves between periods 
of poor and adequate control, it was necessary to treat INR control as a time-dependent variable 
and estimate hazard ratios representing the risk for an individual at any specific time point. In 
the first multivariable-model, we used a Cox regression to estimate the risk of bleed according 
to INR control status, adjusting for the baseline individual CHA2DS2-VASc score and 
deprivation quintile. A second Cox regression model was used to investigate the effect of INR 
control (time-dependent), adjusting for all potential risk factors known to be associated with 
stroke and bleeding, including the individual components of CHA2DS2-VASc score. Analyses 
were performed using IBM SPSS v26 and R version 3.5.3 survival package. 
We calculated the bleeding event rate during the periods of adequate or poor INR 
control using each of the guideline thresholds for INR control. The analyses were repeated 
using secondary outcomes: the most common bleeding events by organ system. 
 
MISSING DATA 
Comparisons were made between those included in the final cohort for analysis and (i) those 
with NVAF prescribed warfarin but with inadequate or no INR test results for analysis, and (ii) 
those with insufficient INR tests recorded in the WLGP to classify INR control prior to a bleed 
(supplementary table 5.2). Finally, within the final cohort for analysis, comparisons were made 
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between those with and without deprivation quintile data available (supplementary table 5.3). 
Differences in these characteristics between groups were again summarised using chi-squared 




Over 4 million patient records were identified in the SAIL Databank during the study period; 
124,324 had a diagnosis of AF and were aged over 18 at the time of diagnosis, of whom a total 
of 35,035 met the final inclusion criteria (figure 5.1). During a mean follow-up time of 4.3 
years per patient, the mean TTR was 71.9; 42.9% of the cohort was female; the mean age was 
73.7 years (standard deviation [SD] = 9.7 years); and the mean CHA2DS2-VASc score was 3.5 
(SD=1.7) (table 5.1). The percentage of time spent in poor INR control using the NICE criteria 
was 34.0%, 40.9% using ESC criteria, and 41.4% using modified ESC criteria. 
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Figure 5.1 Inclusion criteria for study cohort 
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Table 5.1 Cohort baseline characteristics; including pair-wise comparisons of baseline 
characteristics of subgroups with and without bleeding events during follow up.  









 N= 35,035 N= 5,039 N=29,996  
Age    0.001 
 18-64 5,679 (16.2) 725 (14.4) 4,954 (16.5)  
 65-74 11,610 (33.1) 1,703 (33.8) 9,907 (33.0)  
 75+ 17,746 (50.7) 2,611 (51.8) 15,135 (50.5)  
Female 15,041 (42.9) 2,011 (39.9) 13,030 (43.5) <0.001 
Deprivation index 
(quintile) 
   0.009 
1 (most deprived) 5,732 (17.0) 832 (17.1) 4,900 (17.0)  
2 6,573 (19.5) 945 (19.4) 5,628 (19.5)  
3 7,450 (22.1) 1,027 (21.1) 6,423 (22.3)  
4 6,611 (19.6) 915 (18.8) 5,696 (19.8)  
5 (least deprived) 7,296 (21.7) 1,143 (23.5) 6,153 (21.4)  
CHA2DS2-VASc 
score 
   0.001 
 0 and 1 3,971 (11.3) 485 (9.6) 3,486 (11.6)  
 2 6,018 (17.2) 815 (16.2) 5,203 (17.3)  
 3 7,859 (22.4) 1,170 (23.2) 6,689 (22.3)  
 4 7,692 (22.0) 1,128 (22.4) 6,564 (21.9)  
 5 4,999 (14.3) 764 (15.2) 4,235 (14.1)  
 6 2,962 (8.5) 470 (8.9) 2,492 (8.4)  
 ≥7 1,534 (4.4) 240 (4.5) 1,294 (4.4)  
Heart failure 8,283 (23.6) 1,223 (24.3) 7,060 (23.5) 0.256 
Hypertension 23,049 (65.8) 3,558 (67.1) 19,492 (65.6) 0.025 
Diabetes 7,476 (21.3) 1,182 (22.3) 6,294 (21.2) 0.07 
Ischemic stroke 7,291 (20.8) 1,163 (23.1) 6,128 (20.4) <0.001 
Thromboembolism 486 (1.4) 67 (1.3) 419 (1.4) 0.44 
Ischemic heart 
disease 














Liver disease 670 (1.9) 97 (1.9) 573 (1.9) 0.944 
Chronic Kidney 
disease (stage 4+) 
417 (1.2) 65 (1.3) 352 (1.2) 0.48 
Excessive alcohol 
intake 
935 (2.7) 117 (2.3) 818 (2.7) 0.099 
Any prior bleeding 4657 (13.3) 870 (17.3) 3787 (12.6) <0.001 
*Deprivation index was calculated using the Welsh Index of Multiple Deprivation 2011 quintiles. 
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Table 5.2 Multivariable Cox-regression model for hazard of major bleeding events determined by poor INR 
control (according to NICE, ESC/US and a modified-ESC/US criteria). 
Results are adjusted for CHA2DS2-VASc score and deprivation quintiles. Any changes in INR control status for individuals 
over time were included in the model as a time dependent variable. 
 NICE 
HR (95%CI), P value 
ESC/US 
HR (95%CI), P value 
Modified ESC/US 
HR (95%CI), P value 
Poor INR control  1.40 (1.33-1.48), <0.001 1.43 (1.35-1.51), <0.001 1.44 (1.36-1.52), <0.001 
CHA2DS2-VASc score    
 0 &1 Reference Reference Reference 
 2 1.22 (1.09-1.37), <0.001 1.22 (1.09-1.37), <0.001 1.22 (1.09-1.37), <0.001 
 3 1.45 (1.30-1.61), <0.001 1.45 (1.29-1.61), <0.001 1.45 (1.30-1.61), <0.001 
 4 1.54 (1.38-1.72), <0.001 1.54 (1.38-1.72), <0.001 1.54 (1.38-1.72), <0.001 
 5 1.67 (1.48-1.87), <0.001 1.66 (1.48-1.87), <0.001 1.66 (1.48-1.87), <0.001 
 6  1.68 (1.47-1.92), <0.001 1.68 (1.47-1.92), <0.001 1.68 (1.47-1.92), <0.001 
 7 1.99 (1.70-2.34), <0.001 1.98 (1.69-2.33), <0.001 1.98 (1.69-2.33), <0.001 
Deprivation index 
(quintiles)* 
   
1 (most deprived) Reference Reference Reference 
2 0.99 (0.91-1.10), 0.99 0.99 (0.91-1.10), 0.99 1.01 (0.91-1.10), 0.99 
3 0.96 (0.87-1.05), 0.36 0.96 (0.87-1.05), 0.36 0.96 (0.87-1.05), 0.36 
4 0.96 (0.88-1.06), 0.45 0.96 (0.88-1.06), 0.45 0.96 (0.88-1.06), 0.45 
5 (least deprived) 1.00 (0.92-1.10), 0.97 1.00 (0.92-1.09), 0.97 1.00 (0.92-1.10), 0.97 
*Deprivation index was calculated using the Welsh Index of Multiple Deprivation 2011 quintiles. 
 
Across the entire study period, including periods where there were insufficient INR data to 
calculate INR control, a total of 7,220 bleeds occurred in 6,304 patients (supplementary figure 
5.3). During periods of INR calculation, 5,766 bleeds occurred in 5,039 patients (figure 5.2). 
Patients who bled tended to be older, male, have higher CHA2DS2-VASc score, had a higher 
prevalence of hypertension, prior ischemic stroke, ischemic heart disease, and prior bleeding 
events compared to those without a recorded bleeding event (table 5.1). Censoring at the first 
bleed, gastrointestinal bleeding events were the most common, N=2,042 (39.3%), followed by 
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urinary, N=1,344 (25.8%); intracranial, N=527 (10.2%); respiratory, N=488 (9.4%); 
miscellaneous, N=371 (7.2%), gynaecological, N=301 (5.8%), and ocular 119 (2.3%) bleeding 
events. A total of 153 patients had a bleed within multiple organ systems on the same day as 
the first bleed. 
 
Figure 5.2 Number of bleeds by organ system during periods of INR calculation. 
Numbers represent the first documented bleed in patients who had >1 bleed. 153 patients had bleeds in multiple 

















Site of bleed during period of INR calculation
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Table 5.3 Multivariable Cox-regression model for hazard of major bleeding events determined by poor INR 
control (according to NICE, ESC/US and a modified-ESC/US criteria).  
Results are adjusted for individual components of CHA2DS2-VASc score, plus baseline characteristics. Any changes in 
INR control status for individuals over time were included in the model as a time dependent variable. 
 NICE 
HR (95%CI), P value 
ESC/US 
HR (95%CI), P value 
Modified ESC/US 
HR (95%CI), P value 
Poor INR control 1.38 (1.31-1.46), <0.001 1.42 (1.34-1.50), <0.001 1.43 (1.35-1.51), <0.001 
Female  0.85 (0.80-0.90), <0.001 0.85 (0.80-0.90), <0.001 0.85 (0.80-0.90), <0.001 
Age    
 <65  Reference Reference Reference 
 65-74 1.26 (1.16-1.38), <0.001 1.27 (1.16-1.38), <0.001 1.27 (1.16-1.38), <0.001 
 ≥75 1.62 (1.48-1.77), <0.001 1.62 (1.49-1.77), <0.001 1.62 (1.49-1.77), <0.001 
Excessive alcohol 
consumption 
0.96 (0.79-1.17), 0.71 0.96 (0.80-1.16), 0.69 0.96 (0.80 -1.16), 0.69 
Prior bleeding events 1.55 (1.44-1.67), <0.001 1.55 (1.44-1.67), <0.001 1.55 (1.44-1.67), <0.001 
Hypertension 1.05 (0.99-1.12), 0.07 1.05 (0.99-1.12), 0.07 1.05 (0.99-1.12), 0.07 
Liver disease 1.15 (0.94-1.41), 0.19 1.15 (0.93-1.41), 0.19 1.15 (0.93-1.41), 0.19 
Diabetes 1.12 (1.05-1.20), <0.001 1.12 (1.05-1.20), <0.001 1.12 (1.05-1.20), <0.001 
Heart failure 1.08 (1.01-1.15), 0.03 1.08 (1.01-1.15), 0.03 1.08 (1.01-1.15), 0.03 
Ischemic heart disease 1.16 (1.10-1.24), <0.001 1.16 (1.10-1.23), <0.001 1.16 (1.09-1.23), <0.001 
Ischemic stroke 1.10 (1.03-1.17), 0.005 1.10 (1.03-1.17), 0.006 1.10 (1.03-1.17), 0.006 
PVD* 1.11 (0.98-1.24), 0.09 1.11 (0.98-1.24), 0.09 1.11 (0.98-1.24), 0.09 
Thromboembolism 0.93 (0.73-1.20), 0.59 0.93 (0.73-1.20), 0.59 0.93 (0.73-1.20), 0.58 
CKD (stage 4+) 1.45 (1.13-1.85), 0.003 1.44 (1.13-1.85), 0.003 1.44 (1.13-1.85), 0.003 
*PVD indicates Peripheral vascular Disease; CKD indicates Chronic Kidney disease. 
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ESTIMATES OF THE EFFECT OF INR CONTROL ON RISK OF BLEED 
Considering poor INR control as a univariable the hazard ratio (HR) for bleeding using the 
NICE criteria was 1.43 [(95% CI 1.35-1.51), p<0.001], using the ESC/US criteria [HR=1.45 
(95%CI 1.38-1.54), p< 0.001] and the modified ESC/US criteria [HR=1.47 (95%CI 1.39-1.55), 
p<0.001]. 
In the first set of multivariable models, poor INR (defined using either NICE, ESC/US, 
and modified ESC/US criteria for poor INR control) was associated with an increased risk of 
bleeding (table 5.2) after adjustment for CHA2DS2-VASc score and deprivation quintile. 
CHA2DS2-VASc score was also independently associated with bleeding events, after mutual 
adjustment, within each of the three measures of INR control, while there was no significant 
association with deprivation level. 
In the second set of multivariable models, adjustment was made for the full range of 
baseline characteristics. Poor INR control according to NICE, ESC/US and modified ESC/US 
criteria was again associated with bleeding events (table 5.3), independent of other risk factors. 
After mutual adjustment, increasing age was also associated with bleeding events, as was liver 
disease, CKD (stage 4+), heart failure, ischemic heart disease, ischemic stroke, PVD, and 
diabetes. Prior bleeding events were most strongly associated with subsequent bleeding during 
follow-up. Female sex was associated with fewer bleeds. 
Notably, the HR for poor INR control was very stable across all models, for all 
guideline criteria and was very similar in the models containing all available covariates. Indeed, 
the adjusted hazard ratios all remained close to the estimate from the univariable model with 
only poor INR control. 
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BLEEDING EVENT RATE 
The event rate (per 100 patient-years) during periods of INR calculation was 3.9 (95%CI 3.8-
4.0) in the overall population; 3.4 (95% CI, 3.3-3.5) in patients with adequate INR control 
compared to 4.8 (95% CI 4.6-5.0) in those with poor INR control according to NICE criteria 
(supplementary table 5.4). Considering the ESC/US criteria, the event rate was 3.3 (95% CI, 
3.2-3.4) in those with adequate control and 4.7 (95% CI, 4.5-4.9) in those with poor control. 
Finally, the event rate for the modified ESC/US criteria was 3.3 (95% CI, 3.2-3.4) in those with 
adequate control and 4.7 (95% CI, 4.5-4.9) in those with poor control. 
 
BLEEDING RELATED TO INDIVIDUAL ORGAN SYSTEMS 
According to the NICE criteria (table 5.4), poor INR control was associated with 
gastrointestinal, urinary, respiratory, and intracranial bleeds (supplementary tables 5.5-5.6 for 
ESC/US and modified criteria). The strength of association between baseline clinical 
characteristics and bleeding events within these organ systems were similar to those in the 
primary analyses of bleeding at any site. (See supplementary tables 5.7-5.9) for bleeding event 
rate at the individual organ sites).  
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Table 5.4. Multivariable Cox-regression model for hazard of major bleeding events determined by poor INR 
control (according to NICE definition).  
Results are adjusted for individual components of CHA2DS2-VASc score, plus baseline characteristics. Any changes in 
INR control status for individuals over time were included in the model as a time dependent variable. 
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Ischemic heart disease 1.22 (1.12-1.34), 
<0.001 
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DISCUSSION 
This is the first population-level, real-world study that has assessed the association between 
bleeding events and temporal poor INR control in patients prescribed warfarin for NVAF, 
according to clinical guideline criteria produced by NICE and ESC. Evidence of poor INR 
control was present in more than a third of patients when applying these criteria. Bleeding 
events were also common in this cohort, and, although the risk of bleeding was greater during 
periods of poor INR control, most bleeds occurred during periods of therapeutic INR control. 
Importantly, poor INR control by any of the criteria was strongly associated with bleeding risk. 
Increasing stroke risk, assessed by the CHA2DS2-VASc score, was also associated with 
an increased risk of bleeding, as were many individual characteristics commonly associated 
with stroke or bleeding. Increasing age (> 75 years) and prior bleeding events were associated 
with the highest risk of bleeding; both of which have been previously demonstrated to be 
associated with bleeding whilst prescribed warfarin in previous studies.23, 24  
We found that females had a lower likelihood of bleeds, in keeping with previous 
studies.25, 26 Paradoxically, females have a higher risk of poor INR control, as we found in an 
earlier study of this cohort.12 The potential differential in bleeding events by sex could be even 
greater if INR control could be improved in women. 
The overall bleeding event rate in this study was 3.9 bleeds per 100 patient-years. This 
was similar to that recently reported in another real-world study of INR control10, but higher 
than reported in other real-world studies (range 2.5-3.5 bleeds per 100-patients years)27 and 
randomized controlled studies where warfarin was included as a comparator against the 
DOACs (range 3.1-3.4%).28-30  
While the mean TTR in this study was 72% compared to 55-64% in RCTs, the lower 
bleeding event rate observed in the RCTs may be explained by selective patient enrolment and 
enhanced observation of patients compared to real-world studies. Differences in methods of 
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calculating TTR, and the absence of reporting INR control assessed by very low or very high 
individual INRs, limits the comparisons that can be made between studies, and health care 
systems. Lastly, the comparison in bleeding event rate between studies is further limited by the 
lack of consistent reporting of bleeding events and severity. 
Despite a greater proportion of time spent in ‘poor’ INR control with the ESC and 
modified ESC criteria (40.9 and 41.4% respectively) compared to the NICE criteria (34.0%), 
the bleeding event rate and associations between poor INR control and bleeding events were 
very similar between these measures of poor INR control. 
In total there were 20,982 patients prescribed warfarin with NVAF and at least six 
month’s follow-up excluded from the final analyses, of which 18,379 had inadequate numbers 
of INR results to calculate INR control, and a further 2,603 patients that bled during the study 
period but had inadequate number of INR results to assign to either adequate or poor INR 
control (supplementary table 5.2). It cannot be determined why these patients had insufficient 
INR readings recorded. It is likely that these patients were managed in secondary care.  
Notably, these patients had a significantly higher rate of most comorbidities associated with 
greater risk of bleeding. 
In the final cohort, 1,373 patients had a missing deprivation quintile and were therefore 
excluded from the first multivariable analyses (supplementary table 5.3). This group had 
slightly lower prevalence of hypertension and a slightly higher prevalence of heart failure, 
otherwise they had very similar characteristics to the overall cohort. Regardless, all major 
comorbidities were well represented in the multivariable models and the inclusion of this group 
would not be expected to have a significant impact on the observed associations. Surprisingly 
we observed no association between deprivation quintile and INR control (observed in a 
previous study12) or with bleeding in this study. The data for both these studies was obtained 
from patients within the Welsh NHS, where prescriptions and INR monitoring are free to 
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patients at the point of delivery. This potentially mitigates important barriers to healthcare, 
especially in more economically-disadvantaged individuals or populations. This should be an 
important consideration when comparing the findings of our study to other healthcare systems. 
 
We excluded patients with valvular AF and those with a history of DVT or PE. These 
patients may have had “individualised” INR targets, which would not necessarily have been 
identifiable in the SAIL Databank and may potentially have biased the study towards a greater 
number of patients with ‘poor INR control’. Furthermore, our clinical experience suggests that 
these more complex patients are more often managed via specialist, secondary care 
haematology-led anticoagulation services and their INR results may not have been available 
for analysis in this study. 
 
In this study we identified the individual components of the CHA2DS2-VASc score as 
well as risk factors associated with bleeding at the index date of admission into the study. It 
was beyond the scope of this study to recalculate the CHA2DS2-VASc score or identify new 
risk factors/comorbidities dynamically throughout the follow up period. It is unknown whether 
this may have added some incremental benefit or improved the accuracy in the associations 
between these variables and bleeding events. Regardless, the results in this large real-world 
population study are compelling; poor INR control and increasing stroke risk are independent 
markers of increased risk of bleeding events. 
 
The HASBLED score was not calculated in this study for several reasons; poor INR 
control (a component of the HASBLED score) was measured independently; pathology results, 
alcohol and illicit drug use are less robustly documented in the WLGP datasets and aspirin and 
non-steroidal anti-inflammatory are frequently purchased without a prescription in the UK. 
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Finally, the HASBLED score, unlike CHA2DS2-VASc, is at least partially modifiable and 
likely to change throughout the study period.  
 
This study evaluated the impact of multiple clinical and demographic factors as well as 
temporal INR control according to multiple criteria in one of the largest real-world studies of 
INR control in patients with NVAF. The use of a large, data-rich, linked population data source 
is a particular strength. The linked primary and secondary care data held by SAIL enable the 
investigation of a very large cohort of individuals longitudinally over a period of years and 
across multiple data sources, giving a much more complete picture of patient treatment, health, 
and characteristics than previous studies. 
 
The temporal calculation of INR control allowed us to assign patients to adequate or 
poor INR control at each INR result based on the previous 6-months of INR data; periods where 
there were insufficient INR results were excluded from INR calculation but allowed 
determination of outcomes during all periods of exposure when there were sufficient INR 
results to (re)calculate INR control. While this conservative approach had the potential to 
exclude periods of INR calculation in patients who had planned extended periods between INR 
tests, fewer than 1.4% of INR tests had an interval of greater than 84-days. This approach 
provided greater surety that only periods of warfarin administration and monitoring were 
included in the calculation of INR control. Furthermore, the recalculation of INR control and 
assignment to adequate or poor INR control at each INR test allowed us to test the association 
between bleeding events and INR control in the immediate period before the bleed, providing 
an improvement over previous studies that have reported the association between bleeding 
events and mean TTR calculated up to years before an event.8  
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CONCLUSION 
Periods of poor INR control, according to each of the criteria assessed, as well as increasing 
stroke risk and specific comorbidities for stroke and bleeding, were highly associated with 
bleeding events. Reducing bleeding through improvement in INR control at a population level 
is of importance across healthcare systems. At a patient level, detailed individual risk 
assessment, consideration of factors that lead to poor INR control and comorbidities that 
increase bleeding risk remain essential. However, it is clear that improved efforts to optimise 
INR control are likely to be of value in decreasing bleeding events, as are considerations to 
alternative anticoagulation with direct oral anticoagulants (DOACs) when appropriate when 
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SUPPLEMENTARY INFORMATION 
TEMPORAL INR CONTROL  
Our algorithm identifies valid temporal windows to identify sufficient readings to allow us to 
perform TTR calculations. As illustrated in supplementary Figure 1, temporal windows for 
each patient starts from 42-days after the date which marks the earliest point at which a patient 
has both had an INR test and received a prescription for warfarin (this is defined as the study 
start date for the patient). The initial 42-day period is not analysed because the patient’s INR 
is stabilising for this initial period. The existence of records in 6-monthly rolling windows will 
then be checked and we require at least 4 INR readings in each window to then contribute 
toward calculation of TTR for the patient. The final result of this algorithm is then used for 
further analysis to evaluate the bleeding outcomes while taking into the account any changes 
which might happened in the level of controls during the study period. 
 
 
Supplementary figure 5.1 TTR Temporal Window Identification Algorithm 
 
The algorithm starts by identifying all of the INR tests the patient received during the study 
period. If there are 6-months of data present prior to the date of an INR test, the algorithm will 
identify a potential window to analyse the patient’s level of TTR control in the 6-month 
Chapter five 186 
window. The earliest point at which a window can begin is 42-days after the study start date 
for the patient. The algorithm will then perform a series of checks in order to check that the 6-
month window meets the minimum requirements to calculate TTR, which are as follows: 
• The patient must have had at least 4 INR readings in the window. 
• There must be a gap of between 90 to 183 days from the first to the last reading within 
the 6-month period. This ensures we have a sufficient time period to calculate a TTR. 
• There must be a gap of no more than 84-days between each reading and the subsequent 
reading in the sequence. 
A window is excluded if it does not meet these minimum requirements. A window will 
always be exactly 6-months (183-days) long. If a patient does not have at least one valid 
window of data that we can analyse, they are excluded from our analysis. This will produce a 
series of rolling windows which we can use to analyse the patient’s level of control over time. 
EXAMPLES OF EXCLUSION CRITERIA 
Below are a series of examples of valid and invalid temporal windows in the TTR temporal 
window algorithm. 
 
Supplementary figure 5.2a INR inclusion criteria 
This is a valid window of analysis, because the patient has had more than 4 INR tests within 
the period, and there is a gap of more than 90-days from first to last reading: 
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Supplementary figure 5.2b INR exclusion criteria 
This window would be excluded because although there are more than 4 readings within the 
period, the gap between first and last reading is not sufficient to meet our minimum criteria: 
 
 
Supplementary figure 5.2c INR exclusion criteria continued 
This window would be excluded because there are not 4 readings within the period. 
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Supplementary figure 5.2d INR exclusion criteria continued 
This period would be excluded because there are less than 4 readings, and the gap between 
each reading and the subsequent reading is greater than 84-days. 
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Supplementary figure 5.3 Number of bleeds* across the entire study period, including periods 
outside of INR calculation. 
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Supplementary table 5.1a Read codes for bleeding events from WLGP data. 
Bleeding event  Read Code Description  
Gastrointestinal 196B. Painful rectal bleeding 
Gastrointestinal 196C. Painless rectal bleeding 
Gastrointestinal 76191 Gastrot ligate bleed 
Gastrointestinal 77341 Pt int sphincterot for haemorr 
Gastrointestinal 77362 Manual reduct prolapse haemorr 
Gastrointestinal 8512 Rectal packing-haemorr.control 
Gastrointestinal G850. Oesophageal varices + bleeding 
Gastrointestinal G8520 Oesoph.varic.+dis.EC+bleeding 
Gastrointestinal J10y0 Haemorrhage of oesophagus  
Gastrointestinal J1101 Acute GU + haemorrhage 
Gastrointestinal J1111 Chronic GU + haemorrhage 
Gastrointestinal J11y1 Unspec. GU + haemorrhage 
Gastrointestinal J1201 Acute DU + haemorrhage 
Gastrointestinal J1211 Chronic DU + haemorrhage 
Gastrointestinal J12y1 Unspec. DU + haemorrhage 
Gastrointestinal J1301 Acute PU + haemorrhage 
Gastrointestinal J1311 Chronic PU + haemorrhage 
Gastrointestinal J13y1 Unspec. PU + haemorrhage 
Gastrointestinal J1401 Acute GJU + haemorrhage 
Gastrointestinal J1411 Chronic GJU + haemorrhage  
Gastrointestinal J14y1 Unspec. GJU + haemorrhage  
Gastrointestinal J1500 Acute haemorrhagic gastritis  
Gastrointestinal J5109 Bleeding diverticulosis 
Gastrointestinal J573. Haemorrhage of rectum and anus 
Gastrointestinal J5730 Rectal haemorrhage 
Gastrointestinal J5731 Anal haemorrhage 
Gastrointestinal J573z Haemorrhage of rectum/anus NOS 
Gastrointestinal J636. Central haemorrhag necr liver 
Gastrointestinal J6702 Acute haemorrhag.pancreatitis 
Gastrointestinal J68.. Gastrointestinal haemorrhage  
Gastrointestinal J68z. GIT haemorrhage unspecified  
Gastrointestinal J68z0 Gastric haemorrhage NOS 
Gastrointestinal J68z1 Intestinal haemorrhage NOS  
Gastrointestinal J68z2 Upper GI haemorrhage 
Gastrointestinal J68zz GIT haemorrhage NOS  
Gynecological  7F227 Pack to control P/N vag bleed 
Gynecological  8513 Pack non-obst.uterine bleeding  
Gynecological  K5311 Corpus luteum cyst haemorrhage  
Gynecological  K55y3 Haemorrhage of cervix  
Gynecological  K59y3 Intermenstrual bleeding 
Gynecological  K5A1. Postmenopausal bleeding 
Gynecological  K5E.. Oth abnorm uterine vagin bleed  
Gynecological  K5E0. Abn uter bleed unrel menst cyc  
Gynecological  K5E1. Abnorm uterine bleeding, unsp 
Gynecological  K5E2. Abnor vagin bleed, unsp 
Gynecological  K5Ez. Abnor uterine vagin bleed unsp  
Gynecological  Kyu9D [X]O spc abnrm uterin+vg bleed  
Respiratory R0630 [D]Cough with haemorrhage 
Respiratory R0631 [D]Pulmonary haemorrhage NOS  
Respiratory Ryu02 [X]Haemor oth site resp   
Respiratory Ryu07 [X]Haemor from resp uns  
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Supplementary table 5.1a continued. Read codes for bleeding events from WLGP data. 
Bleeding event  Read Code Description  
Ocular 2BB5. O/E – retinal haemorrhages 
Ocular 2BB8. O/E – vitreous haemorrhages  
Ocular F4045 Intra-ocular haemorrhage 
Ocular F4243 Ret.pigm.epith.haemorrh.detach 
Ocular F42y1 Superficial retinal haemorrh.  
Ocular F42y3 Deep retinal haemorrhage 
Ocular F42y4 Subretinal haemorrhage 
Ocular F42y5 Retinal haemorrhage NOS  
Ocular F436. Choroidal haemorrhage/rupture  
Ocular F4360 Choroidal haemorrhage unspec.  
Ocular F4361 Expulsive choroidal haemorrh.  
Ocular F436z Choroidal haemorr./rupture NOS 
Ocular F4372 Haemorrhagic choroidal detach. 
Ocular F4G32 Orbital haemorrhage  
Ocular F4H41 Optic nerve sheath haemorrhage 
Ocular F4K28 Vitreous haemorrhage 
Ocular F4K7. Retrobulbar haemorrhage  
Ocular FyuH4 [X]Vitreous haemorrhage/dis CE 
Urinary K1381 Renal artery haemorrhage 
Urinary K13F. Ureteric haemorrhage 
Urinary K167. Haemorrhage into bladder wall  
Urinary K16y2 Bladder haemorrhage  
Urinary K19y4 Bleeding from urethra  
Urinary K221. Prostatic congestion/haemorrh. 
Urinary K2211 Prostatic haemorrhage  
Urinary K221z Prostatic congest/haemorrh NOS 
Urinary K2752 Corpus cavernosum haemorrhage  
Urinary K2861 Scrotal haemorrhage  
Urinary K2864 Testicular haemorrhage 
Urinary K286w Male genital haemorrhage NOS 
Miscellaneous 7404 Surg arrest bleeding int nose 
Miscellaneous 7404y Surg arrest bleed int nose OS 
Miscellaneous 7404z Surg arrest bleed int nose NOS  
Miscellaneous 74213 Surg arr postop bleed adenoid 
Miscellaneous 75175 Surg arr PO bleed tooth socket  
Miscellaneous 75314 Surg arr PO bleed tonsil bed  
Miscellaneous 77352 Inj sclerosing subst haemorrh 
Miscellaneous 7H022 Reop chest arr PO bleed abd op  
Miscellaneous 7H226 Reop abdo arrest post op bleed  
Miscellaneous 7J013 Reopen cran arrest PO bleeding  
Miscellaneous 7M0U4 Reexplor & arrest PO bleed NOC  
Miscellaneous 851.. Haemorrhage control by packing  
Miscellaneous C063. Thyroid haemorrhage/infarction  
Miscellaneous C0630 Thyroid haemorrhage 
Miscellaneous C063z Thyroid haemorrh/infarct NOS  
Miscellaneous C12y1 Haemorrhage of parathyroid  
Miscellaneous C1542 Adrenal haemorrhage 
Miscellaneous D31X. Haemorrhag condition, unsp  
Miscellaneous D31y. Other haemorrhagic conditions 
Miscellaneous D31yz Other haemorrhagic condit.NOS 
Miscellaneous D31z. Haemorrhagic condition NOS  
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Supplementary table 5.1a continued. Read codes for bleeding events from WLGP data. 
Bleeding event  Read Code Description  
Miscellaneous Dyu34 [X]Haemorrhag condition, unsp 
Miscellaneous J08zD Angina bullosa haemorrhagica  
Miscellaneous R048. [D]Throat haemorrhage 
Miscellaneous Ryu73 [X]Haemorrhage, NEC 
Intracranial 662o. Haemorrhagic stroke monitoring  
Intracranial G60.. Subarachnoid haemorrhage  
Intracranial G60.. Subarachnoid haemorrhage  
Intracranial G600. Ruptured berry aneurysm 
Intracranial G601. Subarac haem/carotd siph+bifur  
Intracranial G602. Subarachd haem/mid cerebrl art  
Intracranial G603. Subarachnd haem/ant commun art  
Intracranial G604. Subarachn haem/post commun art  
Intracranial G605. Subarachnd haem/basilar artery  
Intracranial G606. Subarach haem/vertebral artery  
Intracranial G60X. Subar haem,intracr art,unsp 
Intracranial G60z. Subarachnoid haemorrhage NOS  
Intracranial G60z. Subarachnoid haemorrhage NOS  
Intracranial G61.. Intracerebral haemorrhage 
Intracranial G61.. Intracerebral haemorrhage 
Intracranial G610. Cortical haemorrhage  
Intracranial G610. Cortical haemorrhage  
Intracranial G611. Internal capsule haemorrhage  
Intracranial G611. Internal capsule haemorrhage  
Intracranial G612. Basal nucleus haemorrhage 
Intracranial G612. Basal nucleus haemorrhage 
Intracranial G613. Cerebellar haemorrhage  
Intracranial G613. Cerebellar haemorrhage  
Intracranial G614. Pontine haemorrhage 
Intracranial G614. Pontine haemorrhage 
Intracranial G615. Bulbar haemorrhage  
Intracranial G615. Bulbar haemorrhage  
Intracranial G616. External capsule haemorrhage  
Intracranial G616. External capsule haemorrhage  
Intracranial G617. Intrcereb haem,intraventriculr  
Intracranial G618. Intracerebrl haem,multip local  
Intracranial G619. Lobar cerebral haemorrhage  
Intracranial G619. Lobar cerebral haemorrhage  
Intracranial G61X. Intracer haem hemisph, unsp 
Intracranial G61X0 Left side intracereb haem unsp  
Intracranial G61X1 Right side intracer haem unsp 
Intracranial G61z. Intracerebral haemorrhage NOS 
Intracranial G61z. Intracerebral haemorrhage NOS 
Intracranial G62.. Oth/unspec intracranial bleed 
Intracranial G620. Extradural haemorrh.-nontraum.  
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Supplementary table 5.1a continued. Read codes for bleeding events from WLGP data. 
Bleeding event  Read Code Description  
Intracranial G621. Subdural haemorrhage-nontraum.  
Intracranial G623. Subdural haemorrhage NOS  
Intracranial G62z. Intracranial haemorrhage NOS  
Intracranial G680. Sequel/subarachnoid haemorrhag  
Intracranial G681. Seq/intracerebral haemorrhage 
Intracranial S620. Cls trm subarach haemorrhage  
Intracranial S621. Opn trm subarach haemorrhage  
Intracranial S622. Cls trm subdural haemorrhage  
Intracranial S623. Opn trm subdural haemorrhage  
Intracranial S624. Cls trm extradural haemorrhage  
Intracranial S625. Opn trm extradural haemorrhage  
Intracranial S626. Epidural haemorrhage  
Intracranial S627. Traum subarachnoid haemorrhage  
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Supplementary table 5.1b ICD-10 codes for bleeding events from PEDW. 
Bleeding event  Read Code Description  
Gastrointestinal I850 Oesophageal varices with bleeding  
Gastrointestinal 
I983 
Oesophageal varices with bleeding 





Gastrointestinal K290 Acute haemorrhagic gastritis 
Gastrointestinal 
K762 






Gastrointestinal R041 Haemorrhage from throat  
Gastrointestinal 
R048 








Haemorrhage, not elsewhere 
classified  
Gastrointestinal K921 Melaena  
Gastrointestinal 
K250 












Duodenal ulcerchronic or 
unspecified with haemorrhage  
Gastrointestinal K270 Peptic ulceracute with haemorrhage 
Gastrointestinal 
K280 
Gastrojejunal ulceracute with 
haemorrhage  














Gynecological  N923 Ovulation bleeding  
Gynecological  
N924 
Excessive bleeding in the 
premenopausal period  
Gynecological  
N93 
Other abnormal uterine and vaginal 
bleeding 
Gynecological  N930 Postcoital and contact bleeding 
Gynecological  
N938 
Other specified abnormal uterine 
and vaginal bleeding 
Gynecological  
N939 
Abnormal uterine and vaginal 
bleeding, unspecified  
Gynecological  N950 Postmenopausal bleeding 
Gynecological  N923 Ovulation bleeding  
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Supplementary table 5.1b continued. ICD-10 codes for bleeding events from PEDW. 
Bleeding event  Bleeding event  Bleeding event  
Respiratory R04 
Haemorrhage from respiratory 
passages  
Respiratory J942 Haemothorax  
Respiratory K920 Haematemesis 
Respiratory R042 Haemoptysis  
Respiratory 
R048 
Haemorrhage from other sites in 
respiratory passages 
Ocular H356 Retinal haemorrhage  
Ocular H313 Choroidal haemorrhage and rupture  
Ocular H356 Retinal haemorrhage  
Ocular H431 Vitreous haemorrhage 
Ocular 
H450 
Vitreous haemorrhage in diseases 
classified elsewhere  
Miscellaneous D683 
Haemorrhagic disorder due to 
circulating anticoagulants  
Miscellaneous 
D698 






Miscellaneous S064 Epidural haemorrhage 
Miscellaneous 
T792 




Haemorrhage and haematoma 




Unintentional cut, puncture, 
perforation or haemorrhage during 
surgical and medical care 
Urinary 
N421 








Recurrent and persistent 
haematuriaunspecified  
Urinary R31X Unspecified haematuria  
Intracranial I60 Subarachnoid haemorrhage  
Intracranial 
I600 
Subarachnoid haemorrhage from 
carotid siphon and bifurcation  
Intracranial 
I601 
Subarachnoid haemorrhage from 
middle cerebral artery  
Intracranial 
I602 
Subarachnoid haemorrhage from 
anterior communicating artery 
Intracranial 
I603 
Subarachnoid haemorrhage from 
posterior communicating artery  
Intracranial 
I604 
Subarachnoid haemorrhage from 
basilar artery  
Intracranial 
I605 
Subarachnoid haemorrhage from 
vertebral artery  
Intracranial 
I606 
Subarachnoid haemorrhage from 
other intracranial arteries 
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Supplementary table 5.1b continued. ICD-10 codes for bleeding events from PEDW. 




Intracranial I61 Intracerebral haemorrhage 
Intracranial 
I610 
Intracerebral haemorrhage in 
hemisphere, subcortical  
Intracranial 
I611 




Intracerebral haemorrhage in 
hemisphere, unspecified  
Intracranial 
I613 












Intracerebral haemorrhage, multiple 
localized 




















(nontraumatic), unspecified  
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Supplementary table 5.2 Cohort characteristics and comparisons to patients with inadequate number of INR 
readings to calculate INR control prior to a bleed and those with inadequate number of INR results to calculate 
INR control across any period during the study. 
 Cohort analysed Inadequate number of INR 
results prior to bleed 
Inadequate number of INR 
results to calculate INR 
control at any point 
 N= 35,035 N=2,603 N=18,379 
Mean age at entry into study 73.4 (SD=9.4) 73.7 (SD=9.6), P=0.21 * 
Mean age diagnosis 70.6 (SD=10.6) 71·7 (SD=10·2), P<0·001 70.8 (SD=11.7), P=0.09 
 N (%) N (%) N (%) 
Age category at entry into 
study 
 P=0.36 * 
18-64 5,679 (16.2) 410 (15.8) * 
 65-74 11,610 (33.1) 898 (34.5) * 
 75+ 17,746 (50.7) 1295 (49.8) * 
Female 15,041 (42.9) 1041 (40.0), P=0.003 7858 (42.8), P=0.70 
Deprivation quintile  P=0.005 P<0.001 
1 (most deprived) 5,732 (17.0) 452 (18.0) 2180 (18.5) 
2 6,573 (19.5) 510 (20.3) 2195 (18.7) 
3 7,450 (22.1) 607 (24.2) 2570 (21.8) 
4 6,611 (19.6) 459 )18.3) 2187 (18.6) 
5 (least deprived) 7,296 (21.7) 484 (19.3) 2636(22.4) 
CHA2DS2-VASc (mean) 3.5 (SD=1.69) 3.5 (SD=1.7), P=0.10 3.7 (SD= 1.8), P <0.001 
 N (%) N (%) N (%) 
CHA2DS2-VASc  P= 0.004 P <0.001 
  0 &1 3,971 (11.3) 262 (10.1) 1477 (12.1) 
  2 6,018 (17.2) 495 (19.0) 1702 (13.9) 
  3 7,859 (22.4) 634 (24.4) 2487 (20.3) 
  4 7,692 (22.0) 564 (21.7) 2632 (21.5) 
  5 4,999 (14.3) 352 (13.5) 1907 (15.6) 
  ≥6 4,496 (12.8) 296 (11.4) 2042 (16.7) 
Heart failure 8,283 (23.6) 557 (21.4), P=0.009 6366 (34.6), P<0.001 
Hypertension 23,049 (65.8) 1704 (65.5), P=0.74 11590 (63.1), P <0.001 
Diabetes 7,476 (21.3) 573 (22.0), P=0.42 4643 (25.3), P<0.001 
Ischaemic stroke 7,291 (20.8) 520 (20.0), P=0.31 4220 (23.0), P<0.001 
Ischaemic heart disease 486 (1.4) 872 (33.5), P=0.001 6627 (36.1), P<0.001 
Thromboembolism 10,608 (30.3) 42 (1.6), P=0.34 334 (1.8), P<0.001 
PVD 2139 (6.1) 175 (6.7), P=0.21 1584 (8.6), P<0.001 
Liver disease 670 (1.9) 59 (2.3), P=0.20 727 (4.0), P<0.001 
Chronic kidney disease 
(stage 4+) 
417 (1.2) 42 (1.6), P=0.06 551 (3.0), P<0.001 
Excessive alcohol intake 935 (2.7) 63 (2.4), P=0.45 627 (3.4), P<0.001 
Any prior bleeding 4657 (13.3) 551 (21.2), P<0.001 4188 (22.8), P <0.001 
*Information not entered as this group were not included in the analysis. 
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Supplementary table 5.3. Comparisons between those with deprivation index present and missing from the 
final cohort.  
N= 35,035. 
 Deprivation index present Deprivation index missing 
 N= 33,662 N=1,373 
 Mean (SD) Mean (SD), p 
Mean age  73.6 (9.6) 74.3 (10.2), 0.028 
CHA2DS2-VASc (mean) 3.52 (1.68) 3.53(1.76), 0.71 
 N (%) N (%), p 
Age  P = 0.57 
18-64 5,466 (16.2) 213 (15.5) 
 65-74 11,164 (16.2) 446 (32.5) 
 75+ 17,032 (50.6) 714 (52.0) 
Female 14,473 (43.0) 568(41.4), 0.23 
CHA2DS2-VASc  P= 0.30 
0 &1 3806 (11.3) 165 (12.0) 
2 5777 (17.2) 241 (17.6) 
3 7558 (22.5) 301 (21.9) 
4 7413 (22.0) 279 (20.3) 
5 4811 (14.3) 188 (13.7) 
≥6 4297 (12.8) 199 (14.5) 
Heart failure 7918 (23.5) 365 (26.6), 0.009 
Hypertension 22191 (65.9) 858 (62.5), 0.009 
Diabetes 7195 (21.4) 281 (20.5), 0.42 
Ischaemic stroke 6999 (20.8) 291 (21.3), 0.67 
Ischaemic heart disease 10190 (30.3) 418 (30.4), 0.89 
Thromboembolism 463 (1.4) 23 (1.7), 0.35 
PVD 2058 (6.1) 81 (5.9), 0.75 
Liver disease 640 (1.9) 30 (2.2), 0.45 
Chronic kidney disease 
(stage 4+) 
398 (1.2) 19 (1.4), 0.50 
Excessive alcohol intake 891 (2.6) 44 (3.2), 0.21 
Any prior bleeding 4490 (13.3) 167 (12.2), 0.21 
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Supplementary table 5.4 Bleeding event rate according to INR guideline criteria. 
Guideline criteria INR control Number of bleeds Number of patient 
years 
Event rate per 100 
patient years 
NICE 
 Adequate 2926 85445.3 3.4 
 Poor 2113 44273.7 4.8 
 N/A* 1265 2965.5 42.7 
ESC/US  
 Adequate 2538 765805 3.3 
 Poor 2501 531386 4.7 
 N/A* 1265 2965.5 42.7 
Modified ESC/US 
 Adequate 2503 75993. 3.3 
 Poor 2536 53725.3 4.7 
 N/A* 1265 2965.5 42.7 
*NA indicates bleeds occurring during periods where it was not possible to calculate INR control.  
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SECONDARY ANALYSES: BREAKDOWN BY TYPE OF BLEED 
Supplementary table 5.5 Multivariable Cox-regression model for hazard of bleeding events determined by 
poor INR control (according ESC/US definition of poor INR control (TTR<70%)).  
 GI Urinary Respiratory Intracranial 
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Ischemic heart disease 1.22 (1.12-1.34), 
<0.001 




















Results are adjusted for individual components of CHA2DS2-VASc score, plus baseline characteristics. Any changes in 
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Supplementary table 5.6 Multivariable Cox-regression model for hazard of major bleeding events determined 
by poor INR control (according to the modified ESC/US definition of poor INR control (TTR<70% or low or 
high INRs)).  
 GI Urinary Respiratory Intracranial 
Poor control (TTR 
















Age     
 <65  Reference Reference Reference Reference 












































Ischemic heart disease 1.22 (1.12-1.34), 
<0.001 




















Results are adjusted for individual components of CHA2DS2-VASc score, plus baseline characteristics. Any changes in 
INR control status for individuals over time were included in the model as a time dependent variable. 
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Supplementary table 5.7 Bleeding event rate within organ systems according to periods of NICE guideline 
criteria for INR control. 
Organ system INR control Number of bleeds Number of patient 
years 
Event rate per 100 
patient years 
Gastrointestinal 
 Adequate 1288 89787 1.4 
 Poor 931 44273 2.0 
 N/A* 545 2279 23.9 
Urinary 
 Adequate 888 90434 0.98 
 Poor 597 47404 1.26 
 N/A* 369 2250 16.4 
Intracranial 
 Adequate 327 93106 0.35 
 Poor 262 48883 0.54 
 N/A* 182 2081 8.75 
Respiratory 
 Adequate 270 92766 0.29 
 poor 303 48589 0.62 
 N/A* 142 2033 6.99 
*NA indicates bleeds occurring during periods where it was not possible to calculate INR control.  
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Supplementary table 5.8 Bleeding event rate within organ systems according to periods of ESC/US guideline 
criteria for INR control. 
Organ system INR control Number of bleeds Number of patient 
years 
Event rate per 100 
patient years 
Gastrointestinal 
 Adequate 1113 80460 1.38 
 Poor 1106 56246 1.97 
 N/A* 545 2280 23.9 
Urinary 
 Adequate 787 81044 0.97 
 Poor 698 56794 1.23 
 N/A* 369 2250 16.4 
Intracranial 
 Adequate 276 83437 0.33 
 Poor 313 58550 0.53 
 N/A* 182 2081 8.75 
Respiratory 
 Adequate 234 83150 0.28 
 Poor 339 58204 0.58 
 N/A* 142 2033 6.99 
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Supplementary table 5.9 Bleeding event rate within organ systems according to periods of a modified ESC/US 
guideline criteria INR control. 
Organ system INR control Number of bleeds Number of patient 
years 
Event rate per 100 
patient years 
Gastrointestinal 
 Adequate 1104 79826 1.38 
 Poor 1115 56878 1.96 
 N/A* 545 2280 23.9 
Urinary 
 Adequate 774 80401 0.96 
 Poor 711 57438 1.24 
 N/A* 369 2250 16.4 
Intracranial 
 Adequate 272 82768 0.33 
 Poor 317 59219 0.54 
 N/A* 182 2081 8.75 
Respiratory 
 Adequate 226 82484 0.27 
 Poor 347 58870 0.9 
 N/A* 142 2032 6.99 
*NA indicates bleeds occurring during periods where it was not possible to calculate INR control. 
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CHAPTER 6 
WALES ATRIAL FIBRILLATION AND RECURRENT EVENTS AFTER PCI 
(WARP) 
A REAL-WORLD ANALYSIS OF BLEEDING AND THROMBOTIC OUTCOMES 
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INTRODUCTION 
Antithrombotic prescribing in patients undergoing percutaneous coronary intervention (PCI) 
complicated by atrial fibrillation (AF) represents a clinical dilemma. Dual antiplatelet therapy 
(DAPT), a combination of aspirin and P2Y12 antagonist is recommended to prevent in stent 
thrombosis and coronary artery occlusion in patients undergoing PCI for both acute coronary 
syndrome (ACS) and elective stenting.1-3 In patients with AF, oral anticoagulation (OAC) has 
been shown to be superior to the combination of aspirin and clopidogrel in preventing vascular 
events (stroke, systemic embolism, myocardial infarction(MI) and death). 4 
In patients undergoing PCI who also have AF, guidelines recommend a tailored 
approach based on stroke risk, bleeding risk and concerns regarding ischaemic risk.1, 5, 6 The 
use of the combination DAPT+OAC, triple antithrombotic therapy (TAT) is an option for 
patients at high risk of coronary events also at high risk of stroke, however, this approach is 
often limited by concerns over excess bleeding risks.7 As such, the optimal antithrombotic 
regimen remains uncertain in this population; the need to protect coronary arteries from 
thrombosis, prevent stroke and minimise bleeding events that may trigger prothrombotic 
processes or result in the cessation of antithrombotic therapy represents competing risks.  
Recent medium sized randomised control trials (RCTs) have examined bleeding 
outcomes for a range of Direct Oral Anticoagulants (DOACs) and Vitamin-K antagonists 
(VKA) based antithrombotic strategies.8-11 However, real world data are limited, have focused 
on short-term outcomes12 and the association between bleeding and ischaemic outcomes has 
not been fully evaluated.  
Our objectives were to analyse the rate of hospitalisation for major cardiovascular 
events, haemorrhage and mortality in patients with AF in the first year after successful PCI, 
accounting for risk factors and antithrombotic regimen.   
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METHOD 
We undertook a retrospective observational cohort study using linked anonymised healthcare 
data for patients undergoing PCI in Wales from January 2011 to December 2018 using the 
Secure Anonymised Information Linkage (SAIL) Databank.13, 14 SAIL is part of the National 
e-health records research infrastructure for Wales (holding > 4million linked patient records 
across primary and secondary care). The study population included patients discharged from 
hospital following PCI with a prior or new diagnosis of AF. Follow up was for twelve months 
post discharge. Patients who also underwent Coronary artery bypass graft surgery during the 
index admission were excluded.  
The following datasets held within SAIL were linked at patient level: the Patient 
Episode Database for Wales (PEDW),15 which records hospital admission and discharge dates, 
diagnoses and operational procedures, demographic data, and date of death where applicable 
for the population of Wales; the Welsh Longitudinal General Practice (WLGP) dataset16 
containing demographic, clinical and prescribing data for approximately 80% of primary care 
practices across Wales; the Welsh Demographic (WDS) dataset,17 which contains basic 
demographic information and history of individuals’ residence in Wales and registration with 
GP practices; and the Welsh Index of Multiple Deprivation (WIMD) 201118, an area-based 
deprivation measure and the date of death, where relevant, was identified from the Annual 
District Death Extract (ADDE).17 
MEDICAL HISTORY, DEMOGRAPHIC INFORMATION AND PRESCRIPTIONS 
The PEDW data was used to identify patients undergoing PCI during the study period. The 
first PCI during the study period was classified as the index admission with the date of 
admission and discharge identified either side of the index PCI. PEDW was also used to 
identify whether the index PCI was for an acute coronary syndrome (ACS) or stable disease, 
prior hospital admissions for major bleeding events, prior coronary revascularisation (either 
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PCI or coronary artery bypass graph [CABG]) and exclude patients who had undergone CABG 
during the index admission. 
Both PEDW and WLGP data were searched for prior history or contemporary diagnosis 
of vascular disease (peripheral artery disease or aortic plaque), AF/flutter, MI, Ischemic stroke, 
arterial thromboembolism, heart failure and diabetes.  
Hypertension, ischemic heart disease (IHD), chronic kidney disease CKD (stage 4+), 
chronic liver disease (including cirrhosis, fibrosis, chronic hepatitis and chronic active 
hepatitis, fatty liver, sclerosis of the liver, unspecified alcoholic liver damage, hepatic failure), 
age and sex was identified from the WLGP. Prescriptions for antithrombotic therapy issued 
within 90 days prior to the index admission date were also documented. 
The presence of heart failure, hypertension, vascular disease (defined as prior 
myocardial infarction (MI) or peripheral vascular disease (PVD) including peripheral artery 
disease and aortic plaque), prior stroke (including TIA), gender and age were used to calculate 
the individual CHA2DS2-VASc score at the time of the index PCI.19 
ANTITHROMBOTIC PRESCRIBING AND CLASSIFICATION 
Prescriptions for antithrombotic therapy including aspirin, P2Y12 inhibitors (including 
clopidogrel, prasugrel or ticagrelor), and anticoagulants: either warfarin or DOAC (including 
apixaban, dabigatran, edoxaban or rivaroxaban) recorded in the WLGP during the first 90 days 
post discharge were documented. Antithrombotic prescriptions were then classified as DAPT 
(aspirin plus P2Y12 antagonist), TAT (DAPT + anticoagulant) or OAC plus single AP (aspirin 
or P2Y12) [OAC+AP]. Other combinations of an antithrombotic therapy were excluded from 
the final analyses. 
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STATISTICAL ANALYSES 
Baseline variables and patient characteristics including demographics, lifestyle behaviours and 
medical history were presented as percentages and means with standard deviations. Differences 
in the baseline characteristics between those prescribed DAPT, OAC+AP and TAT (and those 
prescribed other antithrombotic regimens not included in the final analysis) were compared 
using ANOVA. 
 
PRIMARY END POINTS 
The Kaplan-Meier method was used to estimate the rate of hospitalisation during follow up for 
(i) ischaemic stroke (including transient ischemic attacks (TIA); (ii) ACS (including unstable 
angina, acute ischaemic heart disease and myocardial infarction); and (iii) death (by any cause), 
(iv) the combination of death or hospital admission for stroke or ACS, and (v) hospitalisations 
for bleeding events (including respiratory tract, intracranial, gastrointestinal, and urinary tract 
bleeds) (see supplementary table 6.1 for ICD-10 codes for all outcomes). All models were 
presented by stroke risk according to CHA2DS2-VASc score (grouped as CHA2DS2-VASc 
score 1-3 and ≥4) and antithrombotic regimen. The log rank test was used to report difference 
in survival functions (Kaplan-Meier) between groups. 
Cox-proportional hazard models were used to determine predictors associated with the 
endpoints measured in the Kaplan-Meier analyses, with bleeding during follow up modelled as 
a time dependent covariate in the first 4 models. In the fifth model (major bleeding event during 
follow up) and prior hospitalisation for bleeding was included as an independent variable. 
All models were run in SPSS version 26.0. The final multivariable Cox model was 
selected by minimising the Bayesian Information Criterion (BIC).   
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RESULTS 
A total of 25,690 patients were identified who had undergone PCI during the study period 
(figure 6.1). After excluding those without linked health data (prior to PCI) and/or those who 
underwent CABG during the index admission, 2,097 (11.2%) had a new or pre-existing 
diagnosis of AF. 18,674 patients survived the index admission and had post discharge linked 
data of which 1960 (10.8%) had a diagnosis of AF, of these 1,613 patients were identified as 
being prescribed DAPT, TAT or OAC +AP (figure 6.1) (see supplementary table 6.2 for details 
of antithrombotic regimens). Of these patients 1,111 (69%) underwent PCI for ACS and 1,170 
had a diagnosis of AF prior to the index admission (table 6.1). 
 
Patients prescribed TAT or OAC+AP compared to those prescribed DAPT were older, 
had a higher CHA2DS2-VASc score, higher rates of obesity, diabetes, hypertension, heart 
failure and prior ischaemic strokes and more likely to have been prescribed oral anticoagulation 
prior to the index admission. Those prescribed DAPT were more likely to have presented with 
an ACS during the index admission and had a higher rate of new AF diagnosis compared to 
other regimens.  
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Figure 6.1 Study population cohort selection.  
*See supplement for detail of antithrombotic regimens. 
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Table 6.1 Baseline characteristics of cohort by antithrombotic regimen 









Mean age, y (SD) 71.8 (10.2) 74.4 (8.2) 72.9 (8.5) <0.001 
Characteristic, n(%)     
Male 591 (70.9) 244 (69.3) 334 (78.2) 0.007 
Deprivation index    0.91 
  1 151 (18.1) 71 (20.2) 79 (18.5)  
  2 163 (19.5) 65 (18.5) 84 (19.7)  
  3 167 (20.2) 77 (21.8) 88 (20.6)  
  4 163 (19.5) 50 (14.2) 71 (16.6)  
  5 169 (20.2) 81 (23.0) 88 (20.6)  
Medical history, n(%)  
Hypertension 427 (51.2) 215 (61.1) 241 (56.4) 0.005 
Diabetes  225 (27.0) 106 (30.1) 157 (36.8) 0.002 
CKD stage 4+ 28 (3.4) 6 (1.7) 13 (3.0) 0.30 
Chronic liver disease 9 (1.1) 0 (0) <5* (<1.2) 0.14 
Prior IHD 498 (59.7) 199 (56.5) 263 (61.6) 0.35 
Prior MI 236 (28.3) 92 (26.1) 115 (26.9) 0.93 
Prior revascularisation 173 (20.7) 76 (21.6) 69 (16.2) 0.006 
ACS during index 
admission 
612 (73.4) 224 (63.6) 275 (64.4) <0.001 
Diagnosis of AF before 
the index admission  
533 (63.9) 297 (84.4) 340 (79.6) <0.001 
Prior bleeding event 121 (14.5) 62 (17.6) 81 (19.0) 0.099 
Heart Failure 259 (31.1) 145 (41.2) 189 (43.6) <0.001 
Thromboembolism 20 (2.4) 11(3.1) 7 (1.6) 0.39 
Ischaemic stroke 93 (11.2) 70 (19.9) 77 (18.0) <0.001 
PVD 93 (11.2) 54 (15.3) 42 (9.8) 0.045 
CHA2DS2-VASc score, 
n (%) 
   <0.001 
  1-3 362 (43.4) 99 (28.1) 147 (34.4)  
  4+ 472 (56.6) 253 (71.9) 280 (65.6)  
     
Mean CHA2DS2-VASc 
score (SD) 
3.8 (1.6) 4.5 (1.6) 4.3 (1.7) <0.001 
Prior prescriptions, n(%) 
  Antiplatelet (aspirin 
and/or P2Y12 
antagonist) 
489 (58.6) 115 (32.7) 140 (32.7) <0.001 
    Aspirin 448 (53.7) 81 (23.0) 121 (28.3) <0.001 
    P2Y12 antagonist 148 (17.7) 43 (12.2) 32 (7.5) <0.001 
    Oral AC 81 (9.7) 254 (72.1) 278 (65.1) <0.001 
    VKA 72 (8.6) 225 (63.9) 233 (54.6) <0.001 
    DOAC 9(1.1) 31 (8.8) 45 (10.5) <0.001 
ACS indicates acute coronary syndrome; IHD: Ischaemic heart disease; CKD: Chronic kidney disease; MI: myocardial infarction; PVD: 
peripheral vascular disease; VKA: vitamin K antagonist; DOAC: direct oral anticoagulant; AC: anticoagulant (VKA and/or DOAC); 
DAPT: dual antiplatelet therapy (combination of aspirin + P2Y12 antagonist); OAC+AP: combination of oral anticoagulant (either 
warfarin or DOAC) + antiplatelet therapy (aspirin or P2Y12 antagonist); TAT: combination of oral anticoagulant (either VKA or DOAC) 
+ DAPT; AF: atrial fibrillation.. * Numbers <5 are suppressed due to governance restrictions with the SAIL databank. 
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During the one year follow up period, 48 (3.0%) patients had been readmitted for an 
ischaemic stroke, 189 (11.7%) for an ACS, and 124 (7.7%) had died. A total of 315 (19.5%) 
patients had either been readmitted for an ischaemic stroke or ACS or had died (supplementary 
table 6.3). During the same period 142 (8.8%) patients had been readmitted for a bleed. The 
event rate (per 100 patient years) for ischaemic stroke, ACS and death was 3.21 (95%CI 2.75-
3.67), 13.47 (95%CI 12.50-14.46) and 8.16 (95%CI 7.43-8.90), respectively (combined 
outcome rate 22.71 (95%CI 21.4-23.99). The event rate for bleeding was 9.82 (95%CI, 8.99-
10.64).  
Nine patients experienced both a bleed and a stroke, of whom six had that bleed during 
the hospital admission for the stroke; in two patients the bleed occurred in a hospital admission 
prior to that of the stroke, and one patient the bleed occurred in an admission after the stroke. 
Twenty-four patients bled and had a hospital admission for an ACS, of whom eleven suffered 
both events during the same hospital admission; in three the bleed was documented during a 
prior hospital admission to that of the ACS and in ten the bleed was documented in an 
admission after the ACS. Twenty-three patients bled then died, 2 on the same date. The event 
rates (per 100 patient years) for stroke, ACS, death and the combination of these events were 
substantially higher amongst patients that bled (table 6.2). 
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Table 6.2 Adverse event rates during the first year follow up post-PCI 
 Event rate per 100 patient-years (95% confidence Interval) 
  Overall Event rate amongst 
patients who did not 
bleed* 
Event rate amongst 
patients who bled 
Stroke 3.21 (2.75-3.67) 2.72 (2.29-3.16) 13.45 (8.96-17.93) 
ACS 13.47 (12.50-14.46) 12.30 (11.34-13.26) 39.34 (31.31-47.37) 
Death 8.16 (7.43-8.90) 7.25 (6.53-7.97) 32.78 (25.95-39.62) 
Combined stroke, ACS 
or death 
22.71 (21.4-23.99) 20.09 (18.86-21.32) 83.76 (71.67-95.86) 
Bleeding 9.82 (8.99-10.64) NA NA 
*Censoring occurred at time of stroke/ACS/death. 
 
RELATIONSHIPS BETWEEN THROMBOEMBOLIC RISK AND ADVERSE OUTCOMES 
Kaplan-Meier analyses showed that patients with a CHA2DS2-VASc score ≥4 (compared to 
those ≤3) were more likely to have a stroke (p<0.001), die (p<0.001) or bleed (<0.001), but 
the difference in the rate of ACS was not statistically different (p=0.055). 
 
RELATIONSHIPS BETWEEN ANTITHROMBOTIC REGIMEN, THROMBOEMBOLIC RISK AND 
ADVERSE OUTCOMES 
In the Kaplan-Meier analyses, antithrombotic strategy had no association with stroke (p=0.99), 
ACS (p=0.26), death (p=0.65), or the combination of these events (p=0.38) in those with a 
CHA2DS2-VASc ≤3 and ≥4 (supplementary figure 6.1a-e shows Kaplan-Meier analyses 
according to antithrombotic strategy in those with a CHA2DS2-VASc score ≤3 and ≥4). 
However antithrombotic regimen was associated with hospitalisation for bleeding events 
(p=0.002) with lowest bleeding risk seen in those on DAPT in both groups with CHA2DS2-
VASc ≤3 and ≥4 (figures 6.1a-6e and supplementary figures 6.1a-i & supplementary table 6.3).  
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Figure 6.2 Kaplan-Meier estimate of the risk of (a) stroke, (b) ACS, (c) death and (d) combined 
outcome of stroke, ACS or death, and (e) bleeding event during the first 365 days post 
discharge, stratified by antithrombotic regimen.  
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Table 6.3 Multivariable Cox-proportional hazard models of characteristics associated with adverse outcomes 
Variable* Stroke 
 
HR (95%CI), P 
ACS  
 
HR (95%CI), P 
Death 
 
HR (95%CI), P 
Stroke/ACS/ 
Death 
HR (95%CI), P 
Bleed during 
follow up  
HR (95%CI), P 
Bleed during 













- - - - - 
   Dapt  - - - - Reference, 0.011 
   OAC+AP - - - - 1.71 (1.13-2.59)  
   TAT - - - - 1.68 (1.14-2.49) 






Gender  - - - - - 
Hypertension - - - - - 
Diabetes mellitus - - - - 1.66 (1.19-2.32), 
0.003 




- - - - - 
Heart failure 2.30 (1.28-4.13), 
0.005 













- - - - 
Systemic 
thromboembolism 







- - - 
Previous 
revascularisation 
- - - - - 
Prior bleeding 
events 
NA NA NA NA 1.52 (1.04-2.22), 
0.03 
*Only variables selected in the final model are presented.  
ACS indicates acute coronary syndrome; PVD: peripheral vascular disease; CKD :Chronic kidney disease; DAPT: dual antiplatelet 
therapy (combination of aspirin + P2Y12 antagonist); OAC+AP: combination of oral anticoagulant (either warfarin or DOAC) + 
antiplatelet therapy (aspirin or P2Y12 antagonist); TAT: combination of oral anticoagulant (either VKA or DOAC) + DAPT 
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MULTIVARIABLE MODELLING  
In multivariable Cox-proportional hazard models, bleeding during follow up was significantly 
associated with death [HR= 3.43, 95%CI (2.16-5.46), P<0.001], hospitalisations for stroke 
[HR=4.40 (2.01-9.64), <0.001] and ACS [HR= 2.73 (1.57-4.77), <0.001], and the combined 
outcome of stroke, ACS or death [HR=3.22 (2.26-4.59), <0.001] (table 6.3). After mutual 
adjustment antithrombotic therapy had no association with these outcomes. However, 
compared to DAPT, both OAC+AP [HR= 1.71 (1.13-2.59), 0.01] and TAT [1.68 (1.14-2.49), 
0.01] were associated with bleeding risk. 
AIC model selection resulted in selecting only one more variable for stroke and death, 
three more variable for ACS and the combined outcome of stroke, ACS and death and an exact 
match for bleeding. (supplementary tables 6.4 and 6.5). 
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DISCUSSION 
In this real-world population-level study of patients with AF undergoing PCI, ischaemic events, 
hospitalisation for bleeding and all-cause mortality were common. Approximately one in five 
patients experienced a stroke, ACS or died during the first-year post-discharge. Bleeding events 
were also common. Notably, the rate of hospitalisation for stroke was almost five times greater, 
the rate of ACS over three times greater and death was more than four times greater amongst 
those who bled compared to those who didn’t. 
Hospitalisation for bleeding events during follow-up, modelled as a time dependent 
variable was strongly associated with stroke, ACS and death. In patients who had a 
combination of bleed and stroke or bleed and ACS, we note the bleeding event frequently 
occurred during that hospital admission for stroke and/or ACS. Bleeding is a recognised 
adverse consequence of antithrombotic therapy and is associated with a greater incidence of 
death and ischaemic events. 20, 21 Due to the nature of this real-world data it was not possible 
to determine the exact sequence of these haemorrhagic and ischemic events during follow up. 
The triggering of pro-thrombotic and pro-inflammatory responses following a bleed, with or 
without discontinuation of antithrombotic therapy, in addition to anaemia and/or shock in the 
case of more severe bleeds, may have led to a rebound increased risk of ischaemic events. 
Likewise, it is possible that administration of thrombolytic and/or antithrombotic therapy for 
the management of the stroke and/or ACS may have triggered the haemorrhagic event during 
that admission.  
Patients prescribed OAC+AP or TAT were more likely to experience a bleed compared 
to those prescribed DAPT as were those with CKD stage 4+ and those with a history of prior 
bleeding events. Notably, adverse outcomes were predominantly driven by ACS and death with 
comparatively far fewer strokes, particularly in those with a CHA2DS2-VASc score of 1-3. 
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While there was a numerical decrease in ACS and death amongst those prescribed OAC+AP 
or TAT compared to DAPT there was no significant association. 
Surprisingly we found no association between antithrombotic regimen and risk of 
stroke. However, this may be explained by differences in patient characteristics between 
antithrombotic treatment groups. Patients prescribed OAC+AP or TAT had higher CHA2DS2-
VASc score including greater prevalence of the individual risk factors than DAPT; markers 
not just for increased stroke risk but also for increased risk of bleeding.22 Notably, stroke 
outcomes were still similar on Kaplan-Meier analysis even when analyses were restricted to 
those with highest stroke risk (CHA2DS2-VASc ≥4, supplementary figure 6.1b). 
Patients prescribed DAPT were marginally younger, were more likely to have presented 
with an ACS for the index PCI and were marginally less likely to have had a diagnosis of AF 
prior to the index admission. It is therefore possible that they had lower AF burden, but this is 
not possible to assess in this study. 
In conducting the Cox-regressions we adjusted for antithrombotic regimen, risk factors 
and comorbidities. However, due to the nature of this type of analysis, unknown/unrecorded 
variables may influence these associations between treatment groups, stroke risk and outcomes.  
During this study period we identified 25,690 patient who had undergone PCI from a 
population of Wales of ~3.1M, equating to a PCI rate of ~ 1,023/Million population, consistent 
with UK practice.23 The proportion of patients undergoing PCI for an ACS indication (69%) is 
also consistent with contemporary UK practice. The prevalence of AF in the cohort undergoing 
PCI (11.2 % during the index admission and 10.8% of those discharged) is consistent with 
other reports.24-26 The high prescription rate for DAPT is also consistent with previous reports25 
but not with guidelines; possibly reflecting the lack of definitive evidence on antithrombotic 
approach to this high risk cohort.  
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There are a number of limitations with the assigning of patients to antithrombotic 
regimens. It was not possible to determine the intended discharge antithrombotic regimen from 
hospital, therefore, antithrombotic regimens were therefore identified from prescriptions issued 
in the first 90 days post discharge from the index PCI (a period long enough to account for 
hospital discharge supply to have expired and a new prescription to be issued from primary 
care). As we did not apply a censoring period, adverse events occurring in the first 90 days 
may have resulted in amendment of the initial antithrombotic regimen. It was not possible to 
account for changes to the antithrombotic regimen or patient compliance during the follow-up 
period. Lastly, there was insufficient data to categorise by DOAC or Vitamin-K antagonist 
strategy or by aspirin/P2Y12 antagonist combination.  
We excluded 347 patients from the final analysis who we could not identify being 
prescribed DAPT, OAC+AP or TAT. The majority of these patients were prescribed single 
OAC or AP and 96 where we couldn’t identify any antithrombotic therapy (of which almost 
half had died within 90 days, therefore lacking follow data to assign antithrombotic therapy). 
Notably this group was less likely to have undergone prior revascularisation and less likely to 
have undergone the index PCI for an ACS (supplementary table 6.6). Inclusion of small 
individual treatment groups with heterogenous clinical factors would have likely of had limited 
validity and wider applicability to the general population. 
Patients were grouped according to a CHA2DS2-VASc score of 1-3 and ≥4 to provide 
a balance between those with lower to intermediate risk of stroke to those with higher risk. Due 
to governance restrictions with the SAIL databank on reporting patient numbers <5, it would 
have not been possible to report outcomes in smaller groups, particularly where both death and 
stroke events were already low in CHA2DS2-VASc score<3 group and most notably in the 
small group with a CHA2DS2-VASc <2. 
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The HASBLED score was not calculated in this study for several reasons; INR results 
were not available (and INR control would not have applied to those prescribed DAPT only or 
DOAC based regimens); pathology results, alcohol and illicit drug use are less robustly 
documented in the WLGP datasets and non-steroidal anti-inflammatory are frequently 
purchased without a prescription in the UK. Finally, the HASBLED score, unlike CHA2DS2-
VASc, is at least partially modifiable and likely to change throughout the study period. 
However, risk factors associated with increased risk of bleeding (present at or before the index 
PCI) were adjusted for in the multivariable analyses.  
We documented hospitalisation for gastrointestinal bleeds; intracranial bleeds, urinary 
tract bleeds and airway bleeds in order to be consistent with previous studies,27 but bleeding 
events occurring in other organ systems or bleeding events not resulting in hospitalisation may 
have had major clinical outcomes. The lack of an accepted standard for defining relevant 
bleeding events and defining their severity in real-world studies is a recognised limitation. 
Similarly, there has been a lack of standardisation of bleeding definitions amongst the 
major RCTs that have investigated DOAC versus Vitamin K antagonist based TAT and 
OAC+AP strategies in patients with AF undergoing PCI or with a recent ACS.8-11 The primary 
end-point in the AUGUSTUS trial8 included major or ‘clinically relevant bleeds’; in the 
PIONEER AF-PCI trial primary end point was a composite of major or minor bleeding 
according to the Thrombolysis in Myocardial Infarction (TIMI) criteria or ‘bleeding requiring 
medical attention’10, and in the RE-DUAL PCI trial and ENTRUST-AF PCI trials the endpoint 
was major or ‘clinically nonmajor bleeding’. 9, 11 
The rate of bleeding events in these trials ranged from 10.5% to 17% with DOACs, and 
14.7% to 26.7% with vitamin K antagonist treatment. In our study we observed a much lower 
overall bleed rate (8.8%) although we only considered hospitalisation for bleeding in order to 
focus on more clinically severe bleeds which would not have been possible with the further 
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inclusion of primary care documented bleeding outcomes. It is therefore uncertain how the 
addition of potentially less severe bleeding events to the analysis would have influenced the 
association between bleeding and stroke/ACS events or mortality, and beyond the scope of this 
study. 
Despite the large numbers recruited to RCT’s and included in previous real-word 
studies28 they have remained underpowered to detect differences in ischaemic or 
thromboembolic outcomes or mortality between treatment strategies, as is the case with this 
study. Indeed, it was our main intention to review how these patients were being treated and 
document their clinical outcomes in relation to treatment strategy and key risk factors in order 
to understand the key determinants of adverse outcomes in routine clinical practice and to raise 
the profile of these issues and stimulate debate amongst the clinical community.  
It is critical to note that a significant proportion of these patients bled, which was 
associated with a very high rate of cardiovascular events and death. Our data emphasises the 
critical importance of considering the expected incremental prognostic impact of PCI on 
ischaemic outcomes over conservative medical management in patients with AF, before 
committing them to an antithrombotic regimen that is not only associated with a high bleeding 
risk but with greatly increased risk of ischaemic events (eg stent thrombosis) if needing to be 
discontinued due to bleeding, which we observe is not uncommon and an important outcome. 
In this study just under a third of patients underwent the index PCI for stable disease,  
which does not improve clinical outcomes for the majority of clinical indications.29, 30 
Furthermore, trials investigating PCI versus optimal medical therapy have not stratified results 
by AF or have actively excluded patients with indications for OAC.31 In contemporary 
interventional practice, clinicians therefore have to consider the relative safety and efficacy of 
combination anti-platelet and anticoagulant regimens on the basis of ischaemic and bleeding 
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risk without definitive RCT evidence for guidance in both the acute and elective. PCI setting 
for each individual patient  
To the best of our knowledge this is the first study that has looked at event rates 
stratified by stroke risk, antithrombotic therapy and evaluating the impact of bleeding events 
on stroke, ACS and death. The use of a large, data-rich, linked population data source is a 
particular strength. The linked primary and secondary care data held by SAIL enabled the 
investigation of a large cohort if individuals across multiple data sources giving a much more 
complete picture of patient treatment, risk factors and events over a 1-year period after PCI.  
 
CONCLUSION 
In this real-world study of a national cohort of patients with AF who had undergone PCI, 
adverse events in the year post discharge were common. Approximately one in five patients 
experienced a stroke, ACS or died during the first-year post-discharge. Bleeding events were 
also common and were associated with a five, three and four-fold increase risk of stroke, ACS 
and death. These data emphasise the importance of careful consideration of ischaemic and 
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SUPPLEMENTARY MATERIAL  
Supplementary table 6.1 ICD10 codes for major adverse outcomes 
Diagnosis Code Description 
ACS I210 Acute transmural myocardial infarction of anterior wall 
ACS I211 Acute transmural myocardial infarction of inferior wall 
ACS I214 Acute subendocardial myocardial infarction 
ACS I213 Acute transmural myocardial infarction of unspecified site 
ACS I219 Acute myocardial infarctionunspecified 
ACS I212 Acute transmural myocardial infarction of other sites 
ACS I221 Subsequent myocardial infarction of inferior wall 
ACS I228 Subsequent myocardial infarction of other sites 
ACS I220 Subsequent myocardial infarction of anterior wall 
ACS I229 Subsequent myocardial infarction of unspecified site 
ACS I249 Acute ischaemic heart diseaseunspecified 
ACS I200 Unstable angina 
Stroke I630 Cerebral infarct due to thrombosis of precerebral arteries 
Stroke I633 Cerebral infarction due to thrombosis of cerebral arteries 
Stroke I638 Other cerebral infarction 
Stroke I634 Cerebral infarction due to embolism of cerebral arteries 
Stroke I632 Cereb infarct due unsp occlusion or stenos precerebrl arts 
Stroke I636 Cereb infarct due cerebral venous thrombosisnonpyogenic 
Stroke 
G458 
Other transient cerebral ischaemic attacks and related 
synd 
Stroke G459 Transient cerebral ischaemic attackunspecified 
Stroke I635 Cerebrl infarct due unspec occlusion or stenos cerebrl arts 
Stroke I639 Cerebral infarctionunspecified 
Stroke 
I631 
Cerebral infarction due to embolism of precerebral 
arteries 
Stroke I653 Occlusion and stenosis of multip and bilat precerebrl arts 
Stroke I652 Occlusion and stenosis of carotid artery 
Stroke I658 Occlusion and stenosis of other precerebral artery 
Stroke I651 Occlusion and stenosis of basilar artery 
Stroke I650 Occlusion and stenosis of vertebral artery 
Stroke I659 Occlusion and stenosis of unspecified precerebral artery 
Stroke I64X Strokenot specified as haemorrhage or infarction 
Stroke I661 Occlusion and stenosis of anterior cerebral artery 
Stroke I660 Occlusion and stenosis of middle cerebral artery 
Stroke I668 Occlusion and stenosis of other cerebral artery 
Stroke I662 Occlusion and stenosis of posterior cerebral artery 
Stroke I669 Occlusion and stenosis of unspecified cerebral artery 
Stroke I663 Occlusion and stenosis of cerebellar arteries 
Stroke I664 Occlusion and stenosis of multiple and bilat cerebrl arts 
Haemorrhage R31X Unspecified haematuria 
Haemorrhage K270 Peptic ulceracute with haemorrhage 
Haemorrhage K254 Gastric ulcerchronic or unspecified with haemorrhage 
Haemorrhage K280 Gastrojejunal ulceracute with haemorrhage 
Haemorrhage K250 Gastric ulceracute with haemorrhage 
Haemorrhage R049 Haemorrhage from respiratory passagesunspecified 
Haemorrhage N028 Recurrent and persistent haematuriaother 
Haemorrhage R042 Haemoptysis 
Haemorrhage R040 Epistaxis 
Haemorrhage R041 Haemorrhage from throat 
Haemorrhage J942 Haemothorax 
Haemorrhage N029 Recurrent and persistent haematuriaunspecified 
Haemorrhage R048 Haemorrhage from other sites in respiratory passages 
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Haemorrhage K264 Duodenal ulcerchronic or unspecified with haemorrhage 
Haemorrhage K260 Duodenal ulceracute with haemorrhage 
Haemorrhage K920 Haematemesis 
Haemorrhage K922 Gastrointestinal haemorrhageunspecified 
Haemorrhage K921 Melaena 
Haemorrhage I690 Sequelae of subarachnoid haemorrhage 
Haemorrhage I691 Sequelae of intracerebral haemorrhage 
Haemorrhage I692 Sequelae of other nontraumatic intracranial haemorrhage 
Haemorrhage 
I602 
Subarachnoid haemorrhage from anterior communicating 
artery 
Haemorrhage I604 Subarachnoid haemorrhage from basilar artery 
Haemorrhage 
I603 
Subarachnoid haemorrhage from posterior communicating 
artery 
Haemorrhage I608 Other subarachnoid haemorrhage 
Haemorrhage I605 Subarachnoid haemorrhage from vertebral artery 
Haemorrhage I629 Intracranial haemorrhage (nontraumatic)unspecified 
Haemorrhage I607 Subarachnoid haemorrhage from intracranial arteryunspec 
Haemorrhage 
I600 
Subarachnoid haemorrhage from carotid siphon and 
bifurcation 
Haemorrhage I609 Subarachnoid haemorrhage unspecified 
Haemorrhage 
I606 
Subarachnoid haemorrhage from other intracranial 
arteries 
Haemorrhage I601 Subarachnoid haemorrhage from middle cerebral artery 
Haemorrhage I611 Intracerebral haemorrhage in hemispherecortical 
Haemorrhage I616 Intracerebral haemorrhagemultiple localized 
Haemorrhage I612 Intracerebral haemorrhage in hemisphereunspecified 
Haemorrhage I610 Intracerebral haemorrhage in hemispheresubcortical 
Haemorrhage I619 Intracerebral haemorrhageunspecified 
Haemorrhage I613 Intracerebral haemorrhage in brain stem 
Haemorrhage I615 Intracerebral haemorrhageintraventricular 
Haemorrhage I618 Other intracerebral haemorrhage 
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Supplementary table 6.2 Combinations of antithrombotic therapy. 
DAPT ,  
N=834 
Aspirin + Clopidogrel N= 704 
Aspirin + Prasugrel N=52 
Aspirin + Ticagrelor M= 78 
OAC+AP, 
N = 353 
VKA+ Aspirin N= 88 
VKA + Clopidogrel N=199 
VKA + Ticagrelor N=5 
DOAC+ Aspirin N=16 






DOAC+Aspirin+ P2Y12 antagonist*=89 
Other antithrombotic regimens that were excluded  
N= 347 
DOAC only= 20 
VKA only=65 
Aspirin only = 106 
P2Y12 antagonist only* = 59 
No antithrombotic therapy = 96 
*Clopidogrel and ticagrelor numbers have been grouped due to restrictions in SAIL that suppress numbers <5. 
 




















1-3 DAPT 362 5 (1.4) 40 (11.0) * 51 (14.1) 11 (3.0) 
1-3 OAC+AP 99 0 (0) 7 (7.1) * 10 ( 10.1) 7 (7.1) 
1-3 TAT 147 0 (0) 13 (8.8) * 16 (10.9) 10 (6.8) 
1-3 Overall  608 5(1.4) 60 (9.9) 18 (3.0) 77 (12.7) 28 (4.6) 
        
≥4 DAPT 472 20 (4.2) 68 (14.4) 55 (11.7) 122 (25.8) 42 (8.9) 
≥4 OAC+AP 253 10 (4.0) 31 (12.3) 26 (10.3) 57 (22.5) 33 (13.0) 
≥4 TAT 280 13 (4.6) 30 (10.7) 25 (8.9) 59 (21.1) 39 (13.9) 
≥4 Overall 1005 43 (4.3) 129 (12.8) 106 (10.5) 238 (23.7) 114 (11.3) 
        
All patients Total 1613 48 (3.0) 189 (11.7) 124 (7.7) 315 (19.5) 142 (8.8) 
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Supplementary table 6.4 Multivariable Cox-proportional hazard models of characteristics associated with 
adverse outcomes. Models selected using AIC. 
Variable* Stroke 
 
HR (95%CI), P 
ACS  
 
HR (95%CI), P 
Death 
 
HR (95%CI), P 
Stroke/ACS/ 
Death 
HR (95%CI), P 
Bleed during 
follow up  
HR (95%CI), P 
Bleed during 













- - - - - 
   Dapt  - - - Reference, 0.033 Reference, 0.011 


















Gender  - - - - - 
Hypertension - - - - - 
Diabetes mellitus - - - - 1.66 (1.19-2.32), 
0.003 
CKD stage 4+ - 1.81 (0.97-3.36), 
0.06 




- - - - - 
Heart failure 2.09 (1.16-3.77), 
0.015 
































 1.49 (1.07-2.07), 
0.018 
   
Prior bleeding 
events 
NA NA NA NA 1.52 (1.04-2.22), 
0.03 
*Only variables selected in the final model using the AIC are presented. 
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Supplementary table 6.5 Comparison of BIC and AIC selection criteria for multivariable Cox regression 














follow up  
 
 BIC AIC BIC AIC BIC AIC BIC AIC BIC AIC 
Bleed during 
follow up (time 
dependent) 
Ö Ö Ö Ö Ö Ö Ö Ö NA NA 
Antithrombotic 
regimen 
       Ö Ö Ö 
Age  Ö  Ö Ö Ö Ö Ö Ö Ö 
Gender            
Hypertension           
Diabetes mellitus         Ö Ö 
CKD stage 4+ Ö Ö  Ö     Ö Ö 
Chronic liver 
disease 
          
Heart failure     Ö Ö Ö Ö Ö Ö 
PVD      Ö Ö Ö   
Prior ischaemic 
stroke 
Ö Ö      Ö   
Systemic 
thromboembolism 
          
Presenting with 
ACS 
  Ö Ö    Ö   
Previous 
revascularisation 
   Ö       
Prior bleeding 
events 
NA NA NA NA NA NA NA NA Ö Ö 
Match between 
BIC and AIC 
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Supplementary table 6.6 Cohort characteristics between those included prescribed DAPT, OAC+AP or TAT 
and those not included prescribed other antithrombotic regimens 


















      
Age. Mean (SD), p 71.8 (10.2) 74.4 (8.2) 72.9 (8.5) 75 (10.0) <0.001 
Gender (M) 591 (70.9) 244 (69.3) 334 (78.2) 234 (67.4) 0.004 
Deprivation index     0.849 
  1 151 (18.6) 71 (20.6) 79 (19.3) 62 (17.9)  
  2 163 (20.0) 65 (18.9) 84 (20.5) 59 (17.0)  
  3 167 (20.5) 77 (22.4) 88 (21.5) 69 (19.9)  
  4 163 (20.0) 50 914.5) 71 (17.3) 67 (19.3)  
  5 169 (20.8) 81 (23.5) 88 (21.5) 74 (21.3)  
Obese 230 (27.6) 121 (34.4) 156 (36.5) 90 (25.9) <0.001 
Hypertension 427 (51.2) 215 (61.1) 241 (56.4) 178 (51.3) 0.008 
Diabetes  225 (27.0) 106 (30.1) 157 (36.8) 106 (30.5) 0.005 
CKD stage 4+ 28 (3.4) 6 (1.7) 13 (3.0) 15 (4.3) 0.252 
Prior IHD 498 (59.7) 199 (56.5) 263 (61.6) 115 (33.1) 0.036 
Prior MI 236 (28.3) 92 (26.1) 115 (26.9) 56 (16.1) 0.002 
Prior 
revascularisation 
173 (20.7) 76 (21.6) 69 (16.2) 46 (13.3) 0.005 
ACS during index 
admission 
612 (73.4) 224 (63.6) 275 (64.4) 130 (37.5) <0.001 
Diagnosis of AF 
before index 
admission 
533 (63.9) 297 (84.4) 340 (79.6) 274 (79.0) <0.001 
Prior bleeding event 121 (14.5) 62 (17.6) 81 (19.0) 81 (23.3) 0.003 
Heart Failure 259 (31.1) 145 (41.2) 189 (43.6) 129 (37.2) <0.001 
Thromboembolism 20 (2.4) 11(3.1) 7 (1.6) 5 (1.4) 0.375 
Ischaemic stroke 93 (11.2) 70 (19.9) 77 (18.0) 60 (17.3) <0.001 
Vascular disease 93 (11.2) 54 (15.3) 42 (9.8) 40 (11.5) 0.102 
CHA2DS2-VASc 
score mean (SD) 
3.8 (1.6) 4.5 (1.6) 4.3 (1.7) 4.3 (1.6) <0.001 
CHA2DS2-VASc 
score  
    <0.001 
  1-3 362 (43.4) 99 (28.1) 147 (34.4) 104 (30.0)  
  4+ 472 (56.6) 253 (71.9) 280 (65.6) 243 (70.0)  
Prior prescriptions      
  Aspirin 448 (53.7) 81 (23.0) 121 (28.3) 117 (33.7) <0.001 
  P2Y12 148 (17.7) 43 (12.2) 32 (7.5) 43 (12.4) <0.001 
  Antiplatelet  489 (58.6) 115 (32.7) 140 (32.7) 144 (41.5) <0.001 
  VKA 72 (8.6) 225 (63.9) 233 (54.6) 98 (28.2) <0.001 
  Oral AC 81 (9.7) 254 (72.1) 278 (65.1) 6 (1.7) <0.001 











CHA2DS2-VASc score ≤3 
CHA2DS2-VASc score ≤3 
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Supplementary figure 6.1 Kaplan-Meier estimates of the risk of (a&b) stroke, (c&d) ACS, 
(e&f) death and (g&h) combnined outcome of stroke, ACS or death, and (i&j) bleeding event 
during the first 365 days post discharge, stratified by antithrombotic regimen and CHA2DS2-
VASc score 
G H
II JCHA2DS2-VASc score ≤3 
CHA2DS2-VASc score ≤3 CHA2DS2-VASc score ≥4
CHA2DS2-VASc score ≥4
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CHAPTER 7. 
CONCLUDING REMARKS  
Within this thesis I have identified gaps in the provision of evidenced based medicine and 
described the adverse outcomes amongst patients with IHD and AF. The use of large, data-
rich, individually linked datasets, spanning multiple data sources, has provided a detailed and 
more complete picture of patient characteristics and treatment than many previous studies. 
In this thesis I described the rate and adverse consequences of discontinuation of P2Y12 
antagonists in a post PCI population. The incorporation of the cardiac intervention dataset and 
discharge prescribing datasets into the core SAIL datasets allowed us to identify intended 
duration of treatment. The ~ 6% rate of discontinuation was much lower than previously 
presented in the literature (~50%) where intended treatment duration was not known. This 
study refines our understanding of post PCI antiplatelet discontinuation. Identifying the 
intended duration of treatment at discharge allowed me to identify patients who had truly 
discontinued therapy, and accurately describe both patient characteristics and the adverse 
consequences of early discontinuation.  
The inclusion of bleeding as a time dependent variable in the investigation of adverse 
outcomes with discontinuation P2Y12 antagonists post-PCI and amongst patients with AF who 
had undergone PCI was an important and novel element to these studies. In both studies, 
bleeding was independently and highly associated with adverse CV outcomes and death.  
Assessing the prescribing of LLT and achievement of 2016 and the updated 2019 
ESC/EAS guideline lipid targets provided a useful ‘barometer’ of post-PCI CVD risk 
management and described the implications at a population level in meeting updated targets. 
With just under half of patients meeting the 2016 guideline target LDL-C levels and fewer than 
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a quarter were below 2019 targets, we have demonstrated the gap between guideline 
recommendations and real-world management.  
The SAIL Warfarin Out of Range Descriptors Study (SWORDS) study was the first 
publication to assess INR control according to NICE consensus defined poor INR control at a 
population level. This study showed that poor INR control was common with 43% of patients 
having at least one marker of poor INR control, and amongst those with an acceptable TTR 
(>65%) one quarter still had unacceptably low or high INR levels according to NICE criteria. 
This highlighted both the importance of identifying variability of INR control as well as TTR 
control when using the NICE guideline definition of poor INR control and the extent of poor 
INR control in the population.  
The SAIL AF Bleeding Risk Evaluation (SABRE) study improved our understanding 
of the association between poor INR control and bleeding events. In this study assessing the 
temporal presence of poor INR control on bleeding events using NICE and ESC definitions of 
poor INR control, the percentage of time spent in poor control was 34.0% and 40.9% 
respectively. Periods of poor INR control according to NICE (HR=1.38 [1.31-1.46], <0.001) 
and ESC (HR=1.42 [1.34-1.50], <0.001) were independently associated with an increased 
bleeding risk. 
Both SWORDS and SABRE were developed from a large national cohort with 
extensive longitudinal follow up and are amongst the largest studies of INR control. However, 
the robustness of these studies and the novel addition to the existing literature lies in both the 
methodology as well as the population size. The testing of temporal INR control and allowing 
patients to “move between” poor and adequate INR control during the prospective analysis, 
coupled with a conservative approach to excluding periods where there was insufficient INR 
data allowed us to test the association between INR control immediately before a bleed. This 
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provided an important improvement over previous studies that reported associations between 
bleeding events and historic INR control, often calculated years before an event.  
At the time of submission of this Ph.D. thesis, the analyses within the SABRE study 
were being updated to include the investigation of the association between INR control and 
stroke and systemic embolism. Pending reviewer’s response to SABRE these data may be 
combined into one publication. 
The published data from both SWORDS (full manuscript) and SABRE (presented as 
an abstract at time of thesis submission) have been used to support the work of the Welsh ‘Stop 
a Stroke Campaign’, and work undertaken by the Welsh the Cardiac Network on stroke 
prevention. This work has also informed the cross-party coalition on stroke prevention within 
Welsh Government. For the issue of posterity, it is worth noting that SWORDS was published 
in November 2019 and SABRE was first presented in abstract form to the European Society of 
Cardiology Heart and Stroke conference in January 2020. Shortly after this the COVID-19 
pandemic was upon us. In the last few months (time of writing July 2020) we have seen large 
numbers of patients who were previously prescribed warfarin being switched to DOACs in 
order to reduce patient contact and opportunity for transmission of the virus. At a local level at 
least, data from these publications has supported clinical pathway development for 
identification and prioritising of patients who should be considered for alternative therapy.  
The final results chapter in this thesis addressed the question of clinical outcomes in 
relation to antithrombotic management in patients with AF undergoing PCI for treatment of 
both acute and chronic coronary syndromes. With limited publications and the focus of 
research and discussion limited to the use of DOAC vs VKA based antithrombotic regimens, 
our data provides a valuable addition to this field. This study highlighted the far higher rate of 
adverse outcomes in this group and in particular the higher rate amongst patients who bled. 
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This emphasises the importance of assessing bleeding risk and careful balance of bleeding risk 
vs potential therapeutic benefit before undertaking PCI and committing patients to an 
antithrombotic regimen that is not only associated with a high risk of bleeding but with an 
increased risk of ischaemic events if needing to be discontinued due to bleeding. 
I have endeavoured to present the relevant limitations with the respective chapters. 
However, an issue not addressed so far is that of veracity of clinical coding and data linkage 
within SAIL. As mentioned in the introduction, ICD-10 and OPCS-4 codes are entered by 
clinical coders from information contained in the medical record. Less than 1% of medical 
records are externally audited, although there is a high rate of internal audit and validation. 
This is a universal limitation for all real-world research that relies on the use of data that has 
been collected for clinical and administrative purposes. While it was not possible to validate 
hospital clinical coding, it was reassuring that all patients who we identified in the cardiac 
intervention database were coded as having undergone PCI during the same admission within 
the SAIL PEDW datasets. Fewer than 1% of patients did not have a matched record within 
SAIL and these were largely accounted for due to a lack of NHS registered number, and/or 
were domicile outside of Wales. 
Throughout this thesis I have detailed the patient characteristics of those most likely to 
experience adverse events and those least likely to be adhering to guidelines or targets. These 
data presented within this thesis can potentially be used to aid improvement at both individual 
and population level. For example, in the post PCI cohort (chapter two), adverse events were 
highest amongst those who discontinued antithrombotic therapy and/or bled. Notably those 
most likely to discontinue were those individuals who had previously undergone 
revascularisation; possibly describing a ‘revolving door’ of poor adherence and repeated 
revascularisation and worse overall outcomes. 
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Post-PCI prescribing of high intensity statin and adjuvant lipid lowering therapy was 
poor, as were achievement of guideline lipid targets. Female patients and those who had 
undergone elective PCI were less likely to have lipids checked and when checked were less 
likely be at target. Furthermore, while diabetics were more likely to have achieved guideline 
LDL-C they were less likely to achieve non-HDL-C targets, highlighting the importance of this 
measure amongst the diabetic population.  
SWORDS and SABRE demonstrated the paradox of those at the highest risk of stroke 
a priori being most likely to have poor INR control and were also the most likely to bleed.  
These data presented within this thesis can be used to identify individuals or groups 
that may benefit from closer monitoring or consideration of alternative treatment strategies. At 
a population level our data demonstrates the potential for improvement of patient care and 
outcomes. These findings have identified the potential to improve patient outcomes and are 
already being used to that effect. 
  
